CN1840178A - Tumour-specific animal proteins - Google Patents

Abstract

CASB7439 polypeptides and polynucleotides, immunogenic compositions comprising them and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing CASB7439 polypeptides and polynucleotides in diagnostics, and vaccines for prophylactic and therapeutic treatment of cancers, particularly colorectal cancers, autoimmune diseases, and related conditions.

Description

Tumour-specific animal proteins

The application is dividing an application of following application: the applying date: February 16 calendar year 2001; Application number: 01808411.7 (PCT/EP01/01779); Denomination of invention: " tumour-specific animal proteins ".

Invention field

The present invention relates to be used to induce Pharmaceutical composition and method at the immunne response of tumor associated antigen.More particularly, the present invention relates to polynucleotide (this paper is called the CASB7439 polynucleotide), by their encoded polypeptides (this paper is called the CASB7439 polypeptide), be used to produce their recombined material and method.On the other hand, the present invention relates to the using method of such polypeptide and polynucleotide, comprise treatment cancer, the therapy of colorectal carcinoma and autoimmune disease and other associated conditions more especially.On the other hand, the present invention relates to contain CASB7439 polypeptide and polynucleotide Pharmaceutical composition, relate to this composition manufacturing method and in the application of field of medicaments.Again on the one hand, the present invention relates to identify the method for agonist and antagonist/inhibitor and the method for the treatment of the disease uneven relevant with institute's compounds identified with the CASB7439 polypeptide with material provided by the invention.Another aspect the present invention relates to be used to detect the diagnostic analysis of the disease relevant with inappropriate CASB7439 polypeptide active or level.

Background technology

Polypeptide of the present invention and polynucleotide are considered to the important immunogen of or therapeutic immunization preventative at the specificity of tumor, because compare with the expression in normal cell, they are specific expressed or height overexpression in tumor, therefore can by antigen specific immune mechanism targeting they, cause destroying tumor cell.They can also be used for the existence of diagnosing tumour cell.In addition, their unsuitable in some cases expression can cause induce autoimmune, be unsuitable immunne response, by with described polypeptide or polynucleotide suitably vaccination may correct described unsuitable immunne response.In this respect, for our purpose, most important biological activity is the antigen active and the immunogenicity activity of polypeptide of the present invention.A peptide species of the present invention also may show at least a other biological activity of a kind of CASB7439 polypeptide, and it may be counted as the therapeutic that is different from therapeutic relevant with described immunne response or preventative interference or the target of preventative interference.

Summary of the invention

First aspect the present invention relates to the CASB7439 polypeptide.This peptide comprises isolating polypeptide, one section aminoacid sequence that described polypeptide comprises is at SEQ ID NO:2, SEQ ID NO:3, SEQID NO:7, SEQ ID NO:10, SEQ ID NO:11, on the total length of SEQ ID NO:12 or SEQ IDNO:14 respectively with SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:10, SEQ ID NO:11, the aminoacid sequence of SEQ ID NO:12 or SEQ ID NO:14 has at least 70% homogeneity, preferred at least 80% homogeneity, more preferably at least 90% homogeneity, more preferably at least 95% homogeneity again, 97-99% homogeneity at least most preferably, prerequisite is that described isolating polypeptide is not SEQ ID NO:2, SEQ ID NO:12 or SEQ IDNO:14.This peptide species comprises the amino acid whose polypeptide that contains SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:10 and SEQ ID NO:11.

Other peptide of the present invention comprises isolating polypeptide, wherein said aminoacid sequence is at SEQ IDNO:2, SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:10, SEQ ID NO:11, on the total length of SEQ ID NO:12 or SEQ ID NO:14 respectively with SEQ ID NO:2, SEQ IDNO:3, SEQ ID NO:7, SEQ ID NO:10, SEQ ID NO:11, the aminoacid sequence of SEQ ID NO:12 or SEQ ID NO:14 has at least 70% homogeneity, preferred at least 80% homogeneity, more preferably at least 90% homogeneity, more preferably at least 95% homogeneity again, 97-99% homogeneity at least most preferably, prerequisite is that described isolating polypeptide is not SEQ ID NO:2, SEQID NO:12 or SEQ ID NO:14.This peptide species comprises the polypeptide of SEQ ID NO:3, SEQ IDNO:7, SEQ ID NO:10 and SEQ ID NO:11.

Preferred aforementioned polypeptides produces by reorganization.Be purified most preferably, and be substantially free of the material in any other albumen or contaminative host source according to polypeptide of the present invention.

Other peptide of the present invention comprises by the isolating polypeptide that is included in the polynucleotide encoding of contained sequence among the SEQ ID NO:1.

The present invention also provides the immunogenic fragments of CASB7439 polypeptide, be a continuous part of CASB7439 polypeptide, described immunogenic fragments has and the same or analogous immunogenicity characteristic of polypeptide that comprises following aminoacid sequence: SEQ ID NO:2, SEQ ID NO:3, SEQID NO:7, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12 or SEQ IDNO:14.That is to say that described fragment (if necessary, with the carrier coupling or as the part than larger fusion protein) can produce the immunne response of the described CASB7439 polypeptide of identification.Such immunogenic fragments can comprise and for example lacks the CASB7439 polypeptide that the terminal targeting sequencing of N-, membrane spaning domain or C-end anchors domain.One preferred aspect, comprise whole basically ectodomain of polypeptide according to CASB7439 immunogenic fragments of the present invention, described polypeptide is at SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:10, SEQ ID NO:11, on the total length of SEQ ID NO:12 or SEQ ID NO:14 respectively with SEQID NO:2, SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:10, SEQ ID NO:11, the aminoacid sequence of SEQ ID NO:12 or SEQ ID NO:14 has at least 70% homogeneity, preferred at least 80% homogeneity, more preferably at least 90% homogeneity, more preferably at least 95% homogeneity again, 97-99% homogeneity at least most preferably.Preferably comprise at least one epi-position according to immunogenic fragments of the present invention.

The fragments of peptides that mixes the CASB7439 epi-position comprises at least 7, preferred 9 or 10 continuous amino acids that derive from SEQ ID NO:2 usually.Preferred epi-position is shown among SEQ ID NO:16 to the SEQ ID NO:33.

The peptide that mixes these epi-positions constitutes a preferred aspect of the present invention.The mimic epitope (mimotope) identical with the feature of these epi-positions and comprise these mimic epitopes, produce and the epi-position in CASB7439 branch subenvironment has the immunogen of the immunne response of cross reaction also constitutes a part of the present invention.

Therefore, the present invention includes the isolating peptide that comprises these epi-positions itself and any mimic epitope thereof.That the implication of mimic epitope is defined as is enough similar to natural CASB7439 epi-position, so that can be identified the entity of the antibody recognition of described natural molecule; (Gheysen, H.M. etc., 1986, Synthetic peptides as antigens.Wiley, Chichester, Ciba foundationsymposium 119, the 130-149 pages or leaves; Gheysen, H.M., 1986, MolecularImmunology, 23,7,709-715); Perhaps can produce the entity of antibody when with the suitable carrier coupling, wherein said antibody and described natural molecule have cross reaction.

The peptide mimic epitope of the above epi-position of identifying can be designed to use for specific purpose by adding, lack or replacing selected aminoacid.Thereby, can modify peptide of the present invention, put together with protein carrier being convenient to.For example, for some chemically conjugated method, may it is desirable to described epi-position and comprise a terminal cysteine.In addition,, may it is desirable to comprise a terminal hydrophobicity end of puting together, so that described peptide free unconjugated terminal keeps and the surface association of described carrier protein away from described peptide for the peptide of puting together with protein carrier.This has reduced the conformational freedom of described peptide, thus increased with the most similar conformation probability of presenting described peptide of the peptide conformation that under the situation of described complete molecule, exists.For example, described peptide can be changed and become to have a N-end cysteine and a C-end hydrophobic amide tail.On the other hand, can carry out the interpolation or the replacement of one or more described amino acid whose D-stereoisomer forms,, for example strengthen the stability of described peptide to produce useful derivant.Those of skill in the art will recognize that this modified peptide or mimic epitope can be all or part of non-peptide mimic epitopes, wherein said composition residue not necessarily is limited to 20 kinds of naturally occurring aminoacid.In addition, can be by technology known in the art with its cyclisation, described peptide is limited in the conformation of the shape in complete minute subenvironment of similar described peptide sequence closely.A method for optimizing of peptide cyclisation is comprised a pair of cysteine residues of interpolation, to allow to form a disulphide bridges.

In addition, those of skill in the art will recognize that mimic epitope of the present invention or immunogen can be bigger than the epi-position of above-mentioned evaluation, therefore can comprise sequence disclosed herein.Therefore, mimic epitope of the present invention can be included in the terminal N that adds many other natural residue of an end or two and/C holds extension.Described peptide mimic epitope also can be the antitone sequence (retrosequence) of native sequences, because described sequence direction is opposite; Perhaps described sequence can be all or is made of D-stereoisomer aminoacid (inversion sequence (inverso sequence)) to small part.In addition, described peptide sequence can be (retro-inverso) of anti--inversion on feature, because described sequence direction is opposite, and described aminoacid is the D-stereoisomer form.The advantage right and wrong self of anti--inversion peptide like this, therefore can overcome the problem of the self-tolerance in the immune system.

On the other hand, adopt multiple technologies, use and himself can identify the peptide mimic epitope with the bonded antibody of epi-position of the present invention such as display technique of bacteriophage (EP 0 552 267 B1).This technology produces the peptide sequence of a large amount of simulation native peptides structures, therefore can with anti-native peptides antibodies, but not necessarily self and the shared significant sequence homology of described native peptides.This method may be very favorable, because make and to identify the enhanced peptide of immunogenicity characteristic, perhaps can overcome any potential autoantigen tolerance problem that may be relevant with the described native sequence polypeptide of application, in addition, in view of it has shared chemical characteristic in institute's identification polypeptide mimic epitope sequence, this technology makes it possible to identify the recognition mode of various native peptides.

Can make described peptide and immunogenic carrier carry out covalent coupling with method well-known in the art.Therefore, for example,, might utilize carbodiimide, glutaraldehyde or (N-[γ-dimaleoyl imino butyryl acyloxy] succinimide ester, utilize common commercially available Heterobifunctional joint for example CDAP and SPDP (adopting manufacturer's explanation)) for direct covalent coupling.After coupling reaction, described immunogen can easily be separated and purification by dialysis, gel filtration, fractionated method etc.

Used bearer type is that those skilled in the art know easily in the immunogen of the present invention.It is auxiliary that the function of described carrier provides cytokine, so that help to induce the immunne response at described peptide.The non-property the exhausted catalog that can be used for carrier of the present invention comprises: keyhole  hemocyanin (KLH), serum albumin be the purfied protein derivative (PPD) of bovine serum albumin (BSA), deactivation bacteriotoxin (for example tetanus toxin or diphtheria toxin, diphtherotoxin (TT and DT)) or its recombinant fragment (for example, the domain 1 of the fragment C of TT or the translocation domain of DT) or tuberculin for example.On the other hand, described mimic epitope or epi-position can be directly and liposome vectors put together, described liposome vectors comprises in addition can provide the T-cell auxiliary immunogen.Mimic epitope preferably is about 1: 1 to 20: 1 with the ratio of carrier, and each carrier preferably should carry 3-15 peptide.

In one embodiment of the invention, a kind of preferred carrier is the D albumen (EP 0 594 610 B1) of Haemophilus influenzae (Haemophilus influenzae).D albumen is that a kind of IgD that derives from Haemophilus influenzae is conjugated protein, and Forsgren (WO 91/18926, Granted publication number (granted) EP 0 594 610 B1) power has patented.In some cases, for example in the former expression system of recombinant immune, may preferably utilize the proteic fragment of D, for example D proteic 1/3rd (comprising terminal 100-110 the aminoacid (GB 9717953.5) of D albumen N-).

Another preferable methods of presenting peptide of the present invention is to present in the environment of recombinant fusion molecule.For example, EP 0 421 635 B have described using chimeric hepadnavirus core antigen particles and have presented exogenous peptide sequence in the virus-like particle.Therefore, immunogen of the present invention can be included in the peptide of presenting in the chimeric granule that is made of hepatitis B core antigen.In addition, described recombination fusion protein can comprise mimic epitope of the present invention and a kind of carrier protein, for example NS1 of influenza virus.For any recombinant expressed albumen that constitutes the present invention's part, the described immunogenic nucleic acid of encoding also constitutes one aspect of the present invention.

Peptide used among the present invention can be easily synthetic by solid phase method well-known in the art.Suitable synthetic can being undertaken by utilizing " T-boc " or " F-moc " method.Cyclic peptide can utilize the polyamide in well-known " F-moc " method and the full-automatic device to synthesize by solid phase method.Perhaps, one skilled in the art will recognize that and manually carry out the essential laboratory method of described method.The technology of solid phase synthesis and method be described in E.Atherton and R.C.Sheppard's " Solid Phase Peptide Synthesis:A Practieal Approach ", the IRL of OxfordUniversity Press publishes (1989).Perhaps, described peptide can produce by recombination method, is included in the nucleic acid molecules of expressing the described mimic epitope of coding in antibacterial or the mammal cell line, then the expressed mimic epitope of purification.Peptide and proteic recombination and expression techniques are known in the art, and are described in Maniatis, T., Fritsch, E.F. and Sambrook etc., Molecular cloning, a laboratory manual, second edition; Cold Spring HarborLaboratory Press, Cold Spring Harbor, New York (1989).

The preparation method of polypeptide described herein is provided in an embodiment more of the present invention.Method of the present invention can be undertaken by conventional recombinant technique, and described conventional recombinant technique for example is described in Maniatis etc., Molecular Cloning-A Laboratory Manual; Among the Cold SpringHarbor (1982-1989).Therefore, provide the method for preparation according to polypeptide of the present invention, described method is included under the condition that is enough to produce described polypeptide and cultivates host cell, reclaims described polypeptide from described culture medium.Specifically, method of the present invention may preferably include the following step:

I) preparation can be in host cell the replication form or the integrated expression vector of expressible dna polymer, described DNA polymer comprises the nucleotide sequence of encoding said proteins or its immunogenic derivatives;

Ii) use described carrier transformed host cell;

Iii) under the condition that allows the described DNA polymer of expression, cultivate described transformed host cells, to produce described albumen; With

Iv) reclaim described albumen.

Polypeptide of the present invention or immunogenic fragments can be " maturation " albumen forms, perhaps can be the parts of bigger albumen such as precursor protein or fusion rotein.Comprise that the additional amino acid sequence that comprises following sequence is normally favourable: secretion sequence or targeting sequencing, former sequence (pro-sequences), the sequence that helps purification such as polyhistidine residue or in the recombinant production process, help stability other sequence.In addition, also consider to add allogenic polypeptide or lipid tail or polynucleotide sequence, to increase the immunogenic potential of final molecule.

On the one hand, the present invention relates to the genetic engineering soluble fusion protein, described fusion rotein comprises polypeptide of the present invention or its fragment, and the different piece of the constant region of the immunoglobulin of different subclass (IgG, IgM, IgA, IgE) heavy chain or light chain.As immunoglobulin, preferably the constant portion of the heavy chain of IgG (particularly IgG1) wherein merges at hinge region.In a particular, can just can remove the Fc part by the cutting sequence that adds available factor Xa excision.In addition, the present invention relates to prepare the method for these fusion rotein by genetic engineering, and the application of these fusion rotein in drug screening, diagnosis and treatment.A particularly preferred aspect of the present invention relates to the application polypeptide or the treatment of polynucleotide production immunotherapeutical suffers from or the patient's of easy cancer stricken, especially colon cancer or other colon dependency tumor or disease vaccine.The polynucleotide that also relate to the such fusion rotein of coding more on the one hand of the present invention.In international patent application no WO94/29458 and WO94/22914, can find the example of fusion protein technology.

Described albumen can be chemically conjugated or as fusion protein expression, so that compare with the albumen that does not merge, the level that produces in expression system improves.Described fusion partner can assist to provide t helper cell epi-position (Immune Fusion gametophyte), the t helper cell epi-position of preferably being discerned by the mankind, and perhaps described fusion partner helps to express described albumen (expression enhancer) than natural recombiant protein higher yield.Best described fusion partner is the Immune Fusion gametophyte, is again to express to strengthen gametophyte.

Fusion partner comprises the D albumen of Haemophilus influenzae B and the non-structural protein NS 1 (hemagglutinin) of influenza virus.Another kind of Immune Fusion gametophyte is the albumen that is called LYTA.Preferably use the C-end portion of described molecule.Lyta derives from streptococcus pneumoniae (Streptococcuspneumoniae), it synthesizes N-acetyl-L-ala amide enzyme-amidase LYTA (by lytA gene code { Gene, 43 (1986) 265-272 pages or leaves }), i.e. the autolysin of some key in the specificity degraded Peptidoglycan skeleton.The affinity to choline or some cholinomimetics such as DEAE is responsible in the proteic C-end structure of LYTA territory.Utilized this feature development to can be used for the escherichia coli C-LYTA expression plasmid of expressed fusion protein.Described at its aminoterminal and comprised the proteic purification of the segmental hybrid of C-LYTA { Biotechnology:10, (1992) 795-798 pages or leaves }.Can utilize the repetitive sequence part that originates in residue 178 that is present in Lyta molecule C-end, for example residue 188-305.

The present invention also comprises the xenogenesis form (being also referred to as directly to the congener form) of aforementioned polypeptide, described xenogenesis form is meant with human antigen (being also referred to as autoantigen) to have the roughly antigen of sequence homogeneity, and described antigen is as the reference antigen that derives from different non-human species.Aspect this, described roughly homogeneity is meant the concordance of an aminoacid sequence and another aminoacid sequence or a polynucleotide sequence and another polynucleotide sequence when arranging with the optimal sequence comparison in sequence any in numerous sequence alignment albumen known in the art.So-called roughly homogeneity is meant that the sequence homogeneity between the comparative sequences is at least 70-95%, preferably 85-95%, 90-95% at least most preferably at least.Therefore, according to the present invention, xenogenesis CASB7439 polypeptide will be to be xenogeneic CASB7439 polypeptide for people CASB7439, and in other words, xenogenesis CASB7439 polypeptide is separated from inhuman species.In a preferred embodiment, described polypeptide separates from mice, rat, pig or Rhesus Macacus, most preferably separates from mice or rat.Therefore, the present invention also is provided at the method for inducing in the human body at the immunne response of people CASB7439, described method comprises the compositions of the xenogenesis form that comprises described as described herein people CASB7439 that gives described curee's effective dose, and the aminoacid sequence of described people CASB7439 is shown in the arbitrary sequence among sequence SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:7, SEQID NO:10 or the SEQ ID NO:11.Embodiment preferred is to use from mice, rat, pig or Rhesus Macacus isolating xenogenesis CASB7439 to induce method at the immunne response of people CASB7439.Another kind of method for optimizing according to induce immune response of the present invention is to use the antigen composition that comprises the live virus expression system of expressing described heteroantigen.The sequence of preferred xenogenesis CASB7439 polypeptide is shown among SEQ ID NO:12 (mice) or the SEQ ID NO:14 (rat).

Isolating xenogenesis CASB7439 polypeptide is usually shared roughly sequence similarity, comprises on the total length that is included in SEQ ID NO:12 or SEQ ID NO:14 that aminoacid sequence with SEQ ID NO:12 or SEQID NO:14 has at least 70% homogeneity, preferred at least 80% homogeneity, more preferably at least 90% homogeneity, more preferably at least 95% homogeneity, the isolated polypeptide of the aminoacid sequence of 97-99% homogeneity at least most preferably again.Therefore, described xenogenesis polypeptide comprises the immunogenic fragments of the polypeptide of SEQ IDNO:12 or SEQ ID NO:14, and the immunogenicity activity of the wherein said immunogenic fragments polypeptide with SEQ ID NO:12 or SEQ ID NO:14 basically is identical.In addition, described xenogenesis CASB7439 polypeptide can be such fragment: be selected from the aminoacid sequence shown in SEQ IDNO:12 or the SEQ ID NO:14 at least about 20 continuous amino acids, preferred about 30, more preferably from about 50, more preferably from about 100,150 continuous amino acids most preferably from about again.More particularly, xenogenesis CASB7439 fragment can keep more macromolecular some functional characteristic shown in SEQ ID NO:12 or the SEQ ID NO:14, immunocompetence preferably, and can be used in the method as herein described (for example can be used for Pharmaceutical composition or vaccine combination, the diagnostics is medium).Specifically, described fragment can cause the immunne response at human homologue, for example produces the cross reacting antibody with self the human CASB7439 form reaction shown in arbitrary SEQ ID NO:2.In a specific embodiment, xenogenesis polypeptide of the present invention can be the part of big fusions, and described fusions comprises xenogenesis CASB7439 polypeptide or its fragment and aforesaid heterologous protein or protein part as fusion partner.

The present invention also comprises the variant of aforementioned polypeptide, is replaced and the polypeptide different with reference substance by the residue that another has similar characteristic thereby promptly replace a residue by conserved amino acid.Usually such replacement occurs between Ala, Val, Leu and the Ile; Between Ser and the Thr; Between acidic residues Asp and the Glu; Between Asn and the Gln; And between alkaline residue Lys and the Arg; Or between aromatic residue Phe and the Tyr.Preferred especially wherein several, 5-10,1-5,1-3,1-2 or 1 variant that aminoacid replaces, lacks or add with any combination.

Can prepare polypeptide of the present invention in any suitable manner.Such polypeptide comprises polypeptide, synthetic polypeptide that produces that isolating naturally occurring polypeptide, reorganization produce or the polypeptide that passes through the combination results of these methods.The method that is used to prepare such polypeptide is well-known in the art.

On the other hand, the present invention relates to the CASB7439 polynucleotide.Such polynucleotide comprise the isolating polynucleotide of the nucleotide sequence that contains coded polypeptide, and described polypeptide has at least 70% homogeneity, preferably at least 80% homogeneity, more preferably at least 90% homogeneity, more preferably at least 95% homogeneity again with the aminoacid sequence of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:7, SEQ IDNO:10 or SEQ ID NO:11 respectively on the total length of SEQ IDNO:2, SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:10 or SEQ ID NO:11.At this on the one hand, highly preferably have the coded polypeptide of at least 97% homogeneity, and more highly preferably have the coded polypeptide of 98-99% homogeneity at least, topnotch preferably has the coded polypeptide of at least 99% homogeneity.

Other polynucleotide of the present invention comprise isolating polynucleotide, and one section nucleotides sequence that described polynucleotide comprise is listed on the complete coding region nucleotide sequence with the polypeptide of coding SEQ ID NO:2, SEQ IDNO:3, SEQ ID NO:7, SEQ ID NO:10 or SEQ ID NO:11 and has at least 70% homogeneity, preferably at least 80% homogeneity, more preferably at least 90% homogeneity, more preferably at least 95% homogeneity again.At this on the one hand, highly preferably have the polynucleotide of at least 97% homogeneity, and more highly preferably have the polynucleotide of 98-99% homogeneity at least, topnotch preferably has the polynucleotide of at least 99% homogeneity.

Other polynucleotide of the present invention comprise isolating polynucleotide, and one section nucleotides sequence that described polynucleotide comprise is listed on the total length of described sequence and SEQ ID NO:1, SEQ IDNO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:8 or SEQ ID NO:9 or at SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, on the total length of the described coded sequence of SEQ ID NO:8 or SEQ ID NO:9 with SEQ IDNO:1, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, the coded sequence of SEQ ID NO:8 or SEQ ID NO:9 has at least 70% homogeneity, preferred at least 80% homogeneity, more preferably at least 90% homogeneity, more preferably at least 95% homogeneity again.At this on the one hand, highly preferably have the polynucleotide of at least 97% homogeneity, and more highly preferably have the polynucleotide of 98-99% homogeneity at least, topnotch preferably has the polynucleotide of at least 99% homogeneity.Such polynucleotide comprise and contain SEQ ID NO:1, SEQ ID NO:4, SEQ IDNO:5, SEQ ID NO:6, the polynucleotide of SEQ ID NO:8 or SEQ ID NO:9 polynucleotide and SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:8, the polynucleotide of SEQ ID NO:9 or SEQ ID NO:1, SEQ IDNO:4, SEQ ID NO:5, SEQ ID NO:6, the coding region of SEQ ID NO:8 or SEQ ID NO:9.

The present invention also provides the nucleic acid of coding aforementioned foreign protein of the present invention and in the application of field of medicaments.In a preferred embodiment, the sequence that is used for the xenogenesis CASB7439 polynucleotide of Pharmaceutical composition is shown in SEQ ID NO:13 (mice) or SEQ ID NO:15 (rat).According to isolating xenogenesis CASB7439 polynucleotide of the present invention can be strand (coding strand or antisense strand) or two strands, and can be dna molecular (genome molecule, cDNA molecule or synthetic molecules) or RNA molecule.Other coded sequence or non-coding sequence can but not necessarily be present in the polynucleotide of the present invention.In other related embodiment, the invention provides the polynucleotide variant, sequence disclosed herein has roughly homogeneity among described polynucleotide variant and SEQ ID NO:13 or the SEQ ID NO:15, for example adopts the method as herein described BLAST of canonical parameter (for example use analyze) to compare with polynucleotide sequence of the present invention to comprise at least 70% sequence homogeneity, preferred at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% or the polynucleotide variant of higher sequence homogeneity.In a related embodiment, isolating xenogenesis polynucleotide of the present invention comprise on the total length that is coded in SEQ ID NO:12 or SEQID NO:14 aminoacid sequence with SEQ ID NO:12 or SEQ ID NO:14 have at least 90%, preferably 95% and the nucleotide sequence of the polypeptide of 95% above homogeneity or with the complementary nucleotide sequence of described isolating polynucleotide.

The present invention also provides and the complementary polynucleotide of all above-mentioned polynucleotide.

In the recombinant microorganism that described polynucleotide can be inserted into suitable plasmid, recombinant microorganism carrier or live, and can use for immunity inoculation (referring to for example Wolff etc., Science247:1465-1468 (1990); Corr etc., J.Exp.Med.184:1555-1560 (1996); Doe etc., Proc.Natl.Acad.Sci.93:8578-8583 (1996)).Therefore, the invention provides expression vector that comprises described polynucleotide as defined above or the recombinant microorganism of living.

The present invention also provides the fragment of CASB7439 polynucleotide, and wherein described segmental immunogenicity characteristic is identical with the immunogenicity characteristic of following polynucleotide when giving the curee: SEQ ID NO:1, SBQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ IDNO:8, SEQ ID NO:9, SEQ ID NO:13 or SEQ ID NO:15.

The present invention also provides the segmental polynucleotide of immunity of coding as previously defined CASB7439 polypeptide.

Described segmental immunogenicity activity level is SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:10 or SEQ ID NO:11, peptide sequence shown in SEQ ID NO:12 or the SEQID NO:14 or by SEQ ID NO:1, SEQ ID NO:4, SEQID NO:5, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9, the immunogenicity activity level of the peptide sequence of the polynucleotide sequence coding shown in SEQ ID NO:13 or the SEQ ID NO:15 at least about 50%, preferably at least about 70%, more preferably at least about 90%.

Preferably comprise at least about 5 according to polypeptide fragment of the present invention, 10,15,20,25,50 or 100 continuous amino acids or the continuous amino acid more than 100, the peptide composition shown in this article that comprises all length placed in the middle, SEQ ID NO:2 for example, SEQID NO:3, SEQ ID NO:7, SEQ ID NO:10, SEQ ID NO:11, peptide composition shown in SEQ ID NO:12 or the SEQ ID NO:14 is perhaps by SEQ ID NO:1, SEQ IDNO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9, the peptide composition of the polynucleotide sequence coding shown in the sequence of SEQ ID NO:13 or SEQ ID NO:15.

The nucleotide sequence of SEQ ID NO:1 is the cDNA sequence of the polypeptid coding sequence (nucleotide 545-1126) that to comprise 193 amino acid whose polypeptide of coding be the polypeptide of SEQ ID NO:2.The nucleotide sequence of the polypeptide of coding SEQ ID NO:2 can be identical with polypeptid coding sequence contained in SEQ ID NO:1, perhaps it can be the sequence that is different from polypeptid coding sequence contained in SEQ ID NO:1, the polypeptide of SEQ ID NO:2 because the Feng Yuxing (degeneracy) of genetic code, described nucleotide sequence also encode.The polypeptide of SEQ ID NO:2 structurally other albumen with achaete scute family is relevant, and also called after " people Achaete Scute congener 2 " (HASH2) (registration number NP_005161 and AAB86993).

People Achaete Scute congener 2 (HASH2) gene-definite designation behaviour ASCL2 (Achaete Scute complex sample 2) is the congener of Drosophila (Drosophila) Achaete and Scute gene.People ASCL2 only expresses in the fine hair (extravillustrophoblast) outside the trophoderm of developmental Placenta Hominis, and maps to upward close IGF2 of chromosome 11p15 and H19.Mice achaete-scute homologue-2 gene (MASH2) is coded in the transcription factor that works in the trophoblastic growth.The Mash2 gene is paternal inheritance in mice, and lacks the expression of people ASCL2 in non-pernicious blister shape (gynogenesis (andorgenetic)) mole, shows also heredity in the mankind of people Ascl2.

The Ascl2 gene is the member of alkaline helix-loop-helix (BHLH) family of transcription factor.They are by combining and activated transcription with E frame (5 '-CANNTG-3 ').It is Dimerized with other BHLH albumen that to be that effective dna combines required.They are at Drosophila melanogaster (Drosophilamelanogaster) and may participate in unify neuron precursor among the central nervous system of decision peripheral nervous system in mammal.

The complementary strand of SEQ ID NO:1 nucleotide sequence is the polynucleotide sequence of SEQ ID NO:6.This chain also comprises two kinds of other polypeptid coding sequences.The first peptide species coded sequence (the nucleotide 1184-399 of SEQ IDNO:1, the nucleotide 608-1393 of SEQ ID NO:6) coding a kind of 262 amino acid whose polypeptide, the i.e. polypeptide of SEQ ID NO:3.The second peptide species coded sequence (the nucleotide 840-262 of SEQ ID NO:1, the nucleotide 952-1530 of SEQ ID NO:6) coding a kind of 193 amino acid whose polypeptide, the i.e. polypeptide of SEQ ID NO:11.The nucleotide sequence of coding SEQ IDNO:3 and the polypeptide of SEQ ID NO:11 can be identical with polypeptid coding sequence contained in SEQ ID NO:6, perhaps it can be the sequence that is different from polypeptid coding sequence contained in SEQ ID NO:6, the polypeptide of SEQ ID NO:3 and SEQ ID NO:11 because the Feng Yuxing (degeneracy) of genetic code, described nucleotide sequence also encode.The polypeptide of SEQ IDNO:3 structurally other albumen with montage coactivator family is relevant, has homology and/or structural similarity with people (Homo sapiens) montage coactivator subunit srm300 (Genbank registration number AAF21439).The polypeptide of SEQ ID NO:11 is uncorrelated with any known protein.Polynucleotide sequence shown in peptide sequence shown in SEQ ID NO:3 and the SEQ ID NO:11 and the SEQ ID NO:6 is new sequence, and also constitutes a part of the present invention.

Expect preferred polypeptide of the present invention and polynucleotide inter alia, similar to the biological function/characteristic of its homeopeptide and polynucleotide.In addition, the preferred polypeptide of the present invention, immunity fragment and polynucleotide have the suitable at least a activity of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 or SEQ ID NO:11.

The invention still further relates to part or other incomplete polynucleotide sequence and peptide sequence, described sequence is at first to identify before the corresponding full length sequence of measuring SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ IDNO:11.

Therefore, on the one hand, the invention provides isolating polynucleotide, described polynucleotide again:

(a) be included on the total length of SEQ ID NO:4 and SEQ ID NO:5 with SEQ ID NO:4 and SEQ ID NO:5 and have at least 70% homogeneity, preferred at least 80% homogeneity, more preferably at least 90% homogeneity, more preferably at least 95% homogeneity even the more preferably nucleotide sequence of 97-99% homogeneity at least again;

(b) have on the total length of SEQ ID NO:4 and SEQ ID NO:5 respectively with SEQ IDNO:1 or SEQ ID NO:6 and have at least 70% homogeneity, preferred at least 80% homogeneity, more preferably at least 90% homogeneity, more preferably at least 95% homogeneity even the more preferably nucleotide sequence of 97-99% homogeneity at least again;

(c) polynucleotide of SEQ ID NO:4 and SEQ ID NO:5; Or

(d) polynucleotide of the nucleotide sequence of coded polypeptide and SEQ ID NO:4 and SEQ ID NO:5, described polypeptide have at least 70% homogeneity, preferably at least 80% homogeneity, more preferably at least 90% homogeneity, more preferably at least 95% homogeneity even more preferably 97-99% homogeneity at least again with the aminoacid sequence of SEQ ID NO:2 and SEQ ID NO:7 respectively on the total length of SEQ ID NO:2 and SEQ ID NO:7.

The present invention also provides such polypeptide, described polypeptide:

(a) be included on the total length of SEQ ID NO:2 or SEQ ID NO:7 aminoacid sequence with SEQ ID NO:2 and SEQ ID NO:7 and have at least 70% homogeneity, preferred at least 80% homogeneity, more preferably at least 90% homogeneity, more preferably at least 95% homogeneity, the aminoacid sequence of 97-99% homogeneity at least most preferably again;

(b) have on the total length of SEQ ID NO:2 or SEQ ID NO:7 aminoacid sequence with SEQ ID NO:2 or SEQ ID NO:7 and have at least 70% homogeneity, preferred at least 80% homogeneity, more preferably at least 90% homogeneity, more preferably at least 95% homogeneity, the aminoacid sequence of 97-99% homogeneity at least most preferably again;

(c) comprise the aminoacid of SEQ ID NO:2 or SEQ ID NO:7; With

(d) be the polypeptide of SEQ ID NO:7;

And the present invention also provides the polypeptide by the polynucleotide encoding that is included in sequence contained among SEQ ID NO:4 and the SEQ ID NO:5.

Can the employing standard clone and triage techniques, obtain polynucleotide of the present invention in the deutero-cDNA of mRNA from the human colon cancer cell library, (Sambrook etc. for example, MolecularCloning:A Laboratory Manual, second edition, Cold Spring Harbor LaboratoryPress, Cold Spring Harbor, N.Y. (1989)).Polynucleotide of the present invention also can derive from the natural origin such as genome dna library, perhaps can adopt well-knownly to synthesize in commercially available technology.

When with polynucleotide recombinant production of the present invention polypeptide of the present invention, described polynucleotide can comprise the coded sequence of mature polypeptide itself; Or in frame, also has for example the encode sequence of targeting sequencing or secretion sequence, preceding albumen (pre-protein) sequence or former albumen (pro-protein) sequence or preceding former albumen (prepro-protein) sequence or other fusogenic peptide part of the coded sequence of the mature polypeptide of other coded sequence, described other coded sequence.For example, can encode and help the labelled sequence of the polypeptide that purification merges.In the present invention's some embodiment preferred aspect this, described labelled sequence is at pQE carrier (Qiagen, Inc.) provide in and at Gentz etc., the six histidine peptides of describing among Proc Natl Acad Sci USA (1989) 86:821-824, or HA labelling.Described polynucleotide also can contain 5 ' and 3 ' non-coding sequence, for example transcribe but the sequence of sequence, splicing signal and polyadenylation signal, ribosome binding site and the stable mRNA do not translated.

Other embodiment of the present invention comprises the polynucleotide of coded polypeptide variant, described polypeptide variants comprises the aminoacid sequence of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:7, SEQ IDNO:11, SEQ ID NO:13 or SEQ ID NO:15, wherein several, for example 5-10,1-5,1-3,1-2 or 1 aminoacid replaces, lacks or add with any combination.

The polynucleotide identical or enough identical with nucleotide sequence contained among SEQ ID NO:1 or the SEQ ID NO:6 can be used as the hybridization probe of cDNA and genomic DNA or be used as the primer of nucleic acid amplification (PCR), separating the full-length cDNA and the genomic clone of code book invention polypeptide, and separation and SEQ ID NO:1 or SEQ ID NO:6 have the cDNA and the genomic clone of other gene (comprising that coding derives from people's symbiosis congener and derives from the straight gene to congener and symbiosis congener that removes the species the mankind) of height sequence similarity.Usually, these nucleotide sequences and the sequence of reference substance have 70% identical, preferred 80% identical, more preferably 90% identical, most preferably 95% identical.Described probe or primer generally comprise at least 15 nucleotide, at least 30 nucleotide preferably, and can have at least 50 nucleotide.Particularly preferred probe has 30-50 nucleotide.Particularly preferred primer has 20-25 nucleotide.Specifically, the polypeptide or the polynucleotide that come source sequence to obtain from allogenic animal can be used as immunogen, to obtain to have with people's gene the immunne response of cross reaction.

Code book invention polypeptide comprises the polynucleotide from the homologue of the species except that the people, can obtain by such method: described method is included under the stringent hybridization condition, with the sequence with SEQ ID NO:1 or SEQ ID NO:6 or its segmental label probe, screen suitable library; And the step of separating the full-length cDNA and the genomic clone that contain described polynucleotide sequence.Such hybridization technique is that those skilled in the art are well-known.Preferred stringent hybridization condition is included in the solution that comprises following component in 42 ℃ of incubated overnight: the salmon sperm DNA that 50% Methanamide, 5x SSC (150mM NaCl, 15mM trisodium citrate), 50mM sodium phosphate (pH7.6), 5x DenhardtShi solution, 10% dextran sulfate and 20 micrograms/ml degeneration is sheared; In 0.1x SSC, wash filter membrane down then at about 65 ℃.Therefore, the present invention is also included within the stringent hybridization condition, with sequence or its segmental label probe with SEQ ID NO:1 or SEQ ID NO:6, by screening the obtainable polynucleotide in suitable library.

The technical staff knows that in many cases, isolating cDNA sequence is incomplete, because the coding region of described polypeptide is shorter at the 5 ' end of described cDNA.

To those skilled in the art, the methods that have several to obtain full-length cDNAs or extend short cDNA can be utilized and be well-known, for example based on those methods of terminal rapid amplifying (RACE) method of cDNA (referring to for example Frohman etc., PNAS USA 85,8998-9002,1988).For example with Marathon ^TMTechnology (Clontech Laboratories Inc.) has been simplified search to longer cDNA greatly for up-to-date improved this technology of example.At Marathon ^TMIn the technology, use the mRNA that from selected tissue, extracts to prepare cDNA, and " joint " sequence is connected to each end.Use the combination of gene specific oligonucleotide primers and joint specific oligonucleotide primer then, carry out nucleic acid amplification (PCR), with described cDNA " disappearance " 5 ' end that increases.Use " nested " primer to repeat described PCR reaction then, " nested " primer promptly be design in the product that is increased annealed primer (by be 3 ' farther in the joint sequence annealed joint Auele Specific Primer and in known gene order farther 5 ' the annealed gene-specific primer).Can analyze the product of this reaction then by dna sequencing, produce complete sequence by making described product be directly connected to existing cDNA subsequently, perhaps use new sequence information design 5 ' primer to carry out an independently total length PCR, make up full-length cDNA.

By method well-known in the art, can prepare recombinant polypeptide of the present invention with the genetically engineered host cell that comprises expression system.Therefore, more on the one hand, the present invention relates to comprise the expression system of polynucleotide of the present invention, relate to, also relate to by recombinant technique and produce polypeptide of the present invention with the genetically engineered host cell of such expression system.Also can adopt RNA, use the such protein of cell free translation system production derived from DNA construct of the present invention.

For recombinant production, can expression system or its part of genetically engineered host cell to mix polynucleotide of the present invention.Can adopt the method for introducing in many standard laboratory handbooks, realization imports host cell with polynucleotide, described laboratory manual is Davis etc. for example, Basic Methods in Molecular Biology (1986) and Sambrook etc., MolecularCloning:A Laboratory Manual, second edition, Cold Spring Harbor LaboratoryPress, Cold Spring Harbor, N.Y. (1989).Preferred these class methods comprise that transfection, transposition, microinjection, the transfection of cation lipid mediation, electroporation, transduction, scratch application of sample (scrape loading), the particle gun of for example calcium phosphate transfection, the mediation of DEAE-glucosan introduce (ballisticintroduction) or infect.

Best and trans thioredoxin (TIT) coexpression of albumen of the present invention.Preferably trans and cis thioredoxin coexpression does not have thioredoxin to keep antigen, and does not need protease.The thioredoxin coexpression makes albumen of the present invention be easy to dissolving.The thioredoxin coexpression is also to the protein purification yield, produce appreciable impact to the dissolubility of purifying protein and quality.

The representative example of suitable host comprises bacterial cell, as streptococcus (Streptococci), staphylococcus (Staphylococci), escherichia coli, streptomyces (Streptomyces) and bacillus subtilis (Bacillus subtilis) cell; Fungal cell, for example cell of yeast cells and aspergillus (Aspergillus); Insect cell, for example Drosophila (Drosophila) S2 cell and greedy noctuid (Spodoptera) Sf9 cell; Zooblast, for example CHO, COS, HeLa, C127,3T3, BHK, HEK 293 and Bowes melanoma cells; And plant cell.

Can use various expression systems, the for example deutero-system of chromosome, the deutero-system of episome and viral deutero-system are for example derived from following carrier: bacterial plasmid, phage, transposon, yeast episome, insertion element, yeast chromosomal element; Carrier derived from following virus: baculovirus, papovavirus (as SV40), vaccinia virus, adenovirus, fowlpox virus, pseudorabies virus and retrovirus retrovirus; And derived from the carrier of its combination, for example derived from those carriers of plasmid and phage genetic elements, such as cosmid and phasmid.Described expression system can comprise regulates and produces the control zone of expressing.Generally speaking, can use and in the host, to keep, breed or express polynucleotide to produce any system or the carrier of polypeptide.Can be by in the multiple well-known routine techniques any, suitable nucleotide sequence is inserted in the expression system, described routine techniques is Sambrook etc. for example, the technology that Molecular Cloning:A Laboratory Manual (referring to above) is introduced.In order to allow the protein excretion of translating in endoplasmic, periplasmic space or born of the same parents' external environment, suitable secretion signal can be incorporated in the required polypeptide.These signals can be endogenous for described polypeptide, and perhaps they can be the allos signals.

Described expression system also can be the recombinant microorganism of living, for example virus or antibacterial.Interested gene can be inserted in the genome of recombinant virus alive or antibacterial.With infecting in inoculation of the carrier of this work and the body, will make described antigen express also induce immune response in vivo.

Therefore, in certain embodiments, adopt numerous knownly, the polynucleotide of code book invention immunogenic polypeptide are imported the suitable mammalian host cell that is used for expressing based on the arbitrary system in the system of virus.In an illustrative embodiment, retrovirus retrovirus is provided for the convenient effective platform of gene delivery system.Adopt technology known in the art, the selected nucleotide sequence of code book invention polypeptide can be inserted in the carrier, then at the counter-transcription-ing virus particle intermediate package.Can separate described recombinant virus then, give the curee it.(for example United States Patent (USP) the 5th, 219, No. 740 for the existing introduction of many illustrative retrovirus retrovirus systems; Miller and Rosman (1989) BioTechniques 7:980-990; Miller, A.D. (1990) Human Gene Therapy 1:5-14; Scarpa etc. (1991) Virology 180:849-852; Burns etc. (1993) Proc.Natl.Acad.Sci.USA 90:8033-8037; With Boris-Lawrie and Temin (1993) Cur.Opin.Genet.Develop.3:102-109).

In addition, also there is introduction in many illustrative systems based on adenovirus.Different with the retrovirus retrovirus in being incorporated into host genome, adenovirus is positioned at outside the chromosome always, thereby the danger relevant with inserting mutation is reduced to minimum (Haj-Ahmad and Graham (1986) J.Virol.57:267-274; Bett etc. (1993) J.Virol.67:5911-5921; Mittereder etc. (1994) Human Gene Therapy 5:717-729; Seth etc. (1994) J.Virol.68:933-940; Barr etc. (1994) Gene Therapy 1:51-58; Berkner, K.L. (1988) BioTechniques6:616-629; With (1993) Human Gene Therapy 4:461-476 such as Rich).

Also develop various adeno associated viruss (AAV) carrier system in order to transmit polynucleotide.Adopt technology well-known in the art, can easily make up the AAV carrier.Referring to, for example, United States Patent (USP) the 5th, 173, No. 414 and the 5th, 139, No. 941; International publication number WO 92/01070 and WO 93/03769; Lebkowski etc. (1988) Molec.Cell.Biol.8:3988-3996; Vincent etc. (1990) Vaccines 90 (Cold Spring Harbor Laboratory Press); Carter, B.J. (1992) Current Opinion in Biotechnology 3:533-539; Muzyczka, N. (1992) Current Topics in Microbiol.and Immunol.158:97-129; Kotin, R.M. (1994) Human Gene Therapy 5:793-801; Shelling and Smith (1994) Gene Therapy 1:165-169; With (1994) J.Exp.Med.179:1867-1875 such as Zhou.

Can be used for passing other viral vector move the nucleic acid molecules that transmits code book invention polypeptide and comprise viral vector derived from Poxviridae (for example vaccinia virus and fowlpox virus) by gene.As an example, vaccinia virus recombinant that can the described recruit of following construction expression.At first the DNA with coded polypeptide is inserted in the suitable carriers, makes it in abutting connection with a vaccinia virus promoter and flank vaccinia virus DNA sequence, the sequence of thymidine kinase (TK) that for example encode.Use the cell of vaccinia virus infection then simultaneously with this carrier transfection.Homologous recombination makes the vaccinia virus promoter add that the gene of the interested polypeptide of coding is inserted in the viral genome.By leave cultured cell down at 5-bromouracil deoxyribose, choose the resistance virus plaque then, can select TK.sup. (-) recombinant that is produced.

Can use induction type transient expression or coexpression that one or more polypeptide as herein described are provided in the host cell of a certain biology based on the infection/transfection system of vaccinia virus easily.In this particular system, at first at the vaccinia virus recombinant infection cell of external use coding phage t7 RNA polymerase.This polymerase shows sensitive specificity, because it only transcribes the template that has the T7 promoter.After the infection, cell one or more interested polynucleotide transfections by the T7 promoters driven.The polymerase of expressing in kytoplasm from the vaccinia virus recombinant is transcribed into RNA with the DNA of transfection, by host's machine translator it is translated into polypeptide then.Described method is available for high level, instantaneous, a large amount of RNA and the translation products thereof of the interior production of kytoplasm.Referring to, for example, Elroy-Stein and Moss, Proc.Natl.Acad.Sci.USA (1990) 87:6743-6747; Fuerst etc., Proc.Natl.Acad.Sci.USA (1986) 83:8122-8126.

Perhaps, also available fowlpox virus (avipoxvirus) such as fowlpox virus (fowlpox virus) and canary pox virus transmits interested coded sequence.The immunogenic recombinant fowlpox virus (avipox virus) that known expression derives from the mammal pathogen provides protective immunity when giving non-avian species.It is ideal especially using the fowlpox virus carrier in people and other mammalian species, and this is because the member of Avipoxvirus only can duplicate to productivity in the avian species of susceptible, so they do not have appeal in mammalian cell.The method for preparing recombinant fowlpox virus is known in this area, and uses aforesaid genetic recombination about the preparation vaccinia virus.Referring to, for example, WO 91/12882; WO 89/03429 and WO92/03545.

Can also transmit polynucleotide compositions of the present invention with in numerous Alphavirus carriers any, for example at U.S. Patent number 5,843, those carriers of introducing in 723,6,015,686,6,008,035 and 6,015,694.Also can use some carrier based on Venezuelan equine encephalitis (VEE) virus, its illustrative example can be at United States Patent (USP) the 5th, 505, No. 947 and the 5th, 643, finds in No. 576.

In addition, can also use the molecule of introducing among Proc.Natl.Acad.Sci.USA (1992) 89:6099-6103 such as J.Biol.Chem. (1993) 268:6866-6869 such as Michael and Wagner to put together carrier and carry out gene transmission of the present invention such as the adenovirus chimeric vector.

Other accountability information of relevant these and other known transmission system based on virus can find in following document: Fisher-Hoch etc. for example, Proc.Natl.Acad.Sci.USA86:317-321,1989; Flexner etc., Ann.N.Y. Acad.Sci.569:86-103,1989; Flexner etc., Vaccine 8:17-21,1990; U.S. Patent number 4,603,112,4,769,330 and 5,017,487; WO 89/01973; U.S. Patent number 4,777,127; GB 2,200, and 651; EP0,345,242; WO 91/02805; Berkner, Biotechniques 6:616-627,1988; Rosenfeld etc., Science 252:431-434,1991; Kolls etc., Proc.Natl.Acad.Sci.USA 91:215-219,1994; Kass-Eisler etc., Proc.Natl.Acad.Sci.USA90:11498-11502,1993; Guzman etc., Circulation 88:2838-2848,1993; With Guzman etc., Cir.Res.73:1202-1207,1993.

The recombinant microorganism of above-mentioned work can have virulence, or in every way attenuation to obtain live vaccine.Such live vaccine also constitutes a part of the present invention.

In certain embodiments, polynucleotide can be incorporated in the genome of target cell.This integration can be carried out (gene substitution) with specific direction by homologous recombination at ad-hoc location, perhaps it can at random, integrate (gene amplification) in the nonspecific position.In the other embodiment, described polynucleotide can be in cell stably keep as additive type DNA section independently.The sequence of such polynucleotide section or " episome " coding is enough to allow its maintenance and is independent of that the host cell cycle duplicates or duplicates with the host cell cycle synchronisation.Mode and described polynucleotide that expression construct is passed to cell remain on the type that used expression construct is depended in described intracellular position.

In another embodiment of the present invention, for example as at Ulmer etc., Science259:1745-1749, description and Cohen in 1993, Science 259:1691-1692,1993 summary, polynucleotide give/transmit as " naked " DNA.By naked DNA bag quilt to quilt effectively on the biodegradable microballon in the transporte to cells, can be increased the absorption of described DNA.

In an embodiment again, compositions of the present invention can be transmitted by the particle bombardment method, and wherein many methods are existing to be introduced.In an illustrative embodiment, use such as PowderjectPharmaceuticals PLC (Oxford, UK) and Powderject Vaccines Inc. (Madison, WI) device of Sheng Chaning can realize that pneumatic particle quickens, wherein some embodiment is described in U.S. Patent number 5,846, and 796,6,010,478,5,865,796,5,584,807 and european patent number 0500799.This method provides a kind of needleless transmission method, and wherein the particulate dry powder preparation such as polynucleotide or polypeptide particle is accelerated at a high speed in the helium injection stream that is produced by hand held deviee, promotes described particle and arrives interested target tissue.

In a related embodiment, other apparatus and method that can be used for the pneumatic Needleless injection present composition comprise Bioject, Inc. (Portland, the apparatus and method that OR) provide, wherein some embodiment is described in U.S. Patent number 4,790, and 824,5,064,413,5,312,335,5,383,851,5,399,163,5,520,639 and 5,993,412.

By well-known method, can reclaim from the reconstitution cell culture and purification polypeptide of the present invention, described method comprises ammonium sulfate precipitation or ethanol precipitation, acid extraction, anion-exchange chromatography or cation-exchange chromatography, cellulose phosphate chromatography, hydrophobic interaction chromatography, affinity chromatograph, hydroxyapatite chromatography and agglutinin chromatography.Most preferably use ionic metal affinity chromatograph (IMAC) to carry out purification.When described polypeptide is synthetic in born of the same parents, in separation and/or the purge process during degeneration, can use the refolding albumen technology of knowing to rebuild activity conformation.

Another importance of the present invention relates to the method for inducing, strengthening or regulate immunne response in the mammalian body, described method comprises with being enough to produce of the present invention complete polypeptide or polynucleotide or its fragment seeded with mammalian of antibody and/or T cellullar immunologic response, is used for immunoprophylaxis or being used for the treatment of property treatment cancer, more especially colorectal carcinoma and autoimmune disease and associated conditions.The method of inducing, strengthening or regulate immunne response in the mammalian body that relates in one aspect to again of the present invention, described method comprises by instructing the carrier or the cell of expressing described polynucleotide and coding said polypeptide to transmit polypeptide of the present invention in vivo, so that induce such immunne response, to produce prevention or to treat described animal exempt from the to take a disease immunne response of disease.

Of the present inventionly relate in one aspect to immune formulation/bacterin preparation (compositions) again and in the application of field of medicaments.After described compositions is introduced into mammalian hosts, in this mammalian body, induce, reinforcement or metering needle be to the immunne response of polypeptide of the present invention, wherein said compositions comprises polypeptide of the present invention or polynucleotide or its immunology fragment that is limited as this paper front.More particularly, comprise CASB7439 polypeptide or its immunogenic fragments of safe and effective amount according to immunogenic composition of the present invention, wherein said CASB7439 polypeptide is selected from SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:10, SEQ ID NO:11, SEQ IDNO:12 or SEQ ID NO:14.In another embodiment, described immunogenic composition comprises polynucleotide or its fragment of the coding CASB7439 of safe and effective amount, and the polynucleotide of wherein said coding CASB7439 are selected from SEQ ID NO:1, SEQ ID NO:4, SEQ IDNO:5, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:13 or SEQ ID NO:15.

Can also comprise a kind of suitable carriers according to bacterin preparation of the present invention, promptly pharmaceutically acceptable carrier.Because polypeptide may decompose under one's belt, thus they preferably parenteral give (for example subcutaneous injection, intramuscular injection, intravenous injection or intradermal injection).The preparation that is suitable for parenteral comprises aqueous and non-water aseptic parenteral solution, and described injection can comprise antioxidant, buffer agent, antibacterial and make described preparation and the isoosmotic solute of receptor blood; And the aqueous and the non-water sterile suspensions that can comprise suspending agent or thickening agent.Described preparation can be contained in unit-dose container or the multi-dose container (for example sealed ampoule and phial), and can preserve under lyophilisation condition, only need get final product facing with preceding adding sterile liquid carrier.

The cell that relates in one aspect to employing from immune system more of the present invention,, and these activating immune cells are fed back to described mammal with the treatment disease at complete polypeptide of the present invention or polynucleotide or its segmental immunne response or at the immunne response of the molecule that comprises polypeptide of the present invention or polynucleotide external evoked.By with complete polypeptide of the present invention or polynucleotide or the molecule that comprises polypeptide of the present invention or polynucleotide having or not having external hatching under the situation of various immune modulatory molecules, reach activation from described immune described cell.Of the present invention relating in one aspect to again by giving antigen-presenting cell immunity mammal, described antigen-presenting cell is by in external loading complete polypeptide of the present invention or its part or comprise the molecule of polypeptide of the present invention and modified, then in the immunogenicity mode with in the described antigen-presenting cell donor.Perhaps, can be with containing complete polynucleotide of the present invention or its fragment or comprising the carrier of the molecule of polynucleotide of the present invention, the in-vitro transfection antigen-presenting cell, for example to express corresponding polypeptide, then in the immunogenicity mode with in the described antigen-presenting cell donor.Therefore, Pharmaceutical composition of the present invention comprises the antigen-presenting cell of effective dose and effective carrier pharmaceutically, and described antigen-presenting cell is by being modified at external loading CASB7439 polypeptide or at the external genetically modified CASB7439 of expression polypeptide.

According to another embodiment, except that immunogenicity polynucleotide of the present invention, polypeptide, antibody, T cell and/antigen-presenting cell (APC) compositions, Pharmaceutical composition/immunogenic composition as herein described also comprises one or more immunostimulant.Therefore, this paper provides the method for producing described immunogenic composition, and described method comprises mixes the polynucleotide of CASB7439 polypeptide or coding CASB7439 with suitable adjuvant/immunostimulant, diluent or other pharmaceutically acceptable carrier.Immunostimulant is meant any material that improves or strengthen exogenous antigenic immunne response (antibody and/cell-mediated) in fact.A kind of immunostimulant of preferred type comprises adjuvant.Many adjuvants contain design week exempts from quick decomposition with protection antigen material; for example aluminium hydroxide or mineral oil; and the stimulant that contains immunne response; for example lipid A, Bordetella pertussis (Bortadella pertussis) or mycobacterium tuberculosis (Mycobacterium tuberculosis) endogenous binding protein.Some adjuvant is commercially available, for example incomplete Freund and Freund's complete adjuvant (Dffco Laboratories, Detroit, MI); The Merck adjuvant 65 (Merck and Company, Inc., Rahway, NJ); AS-2 (SmithKlineBeecham, Philadelphia, PA); Aluminum salt such as gel aluminum hydroxide (Alumen) or aluminum phosphate; Calcium salt, iron salt or zinc salt; The insoluble suspending agent of acidylate tyrosine; Acidylate sugar; The polysaccharide of cation or anionic derivativeization; Polyphosphazene; Biodegradable microsphere; Single phosphatidyl lipid A and quil A.Cytokine and other similar somatomedin such as GM-CSF, interleukin-2, interleukin-7, il-1 2 also can be used as adjuvant.

In certain embodiments of the invention, described adjunvant composition is preferably mainly induced the adjunvant composition of Th1 type immunne response.High-caliber Th1 cytokines (for example IFN-γ, TNF α, IL-2 and IL-12) often promotes to induce at the antigenic cell-mediated immune responses of give.On the contrary, high-caliber Th2 cytokines (for example IL-4, IL-5, IL-6 and IL-10) often promotes to induce humoral immunoresponse(HI).After using vaccine provided herein, the patient will support to comprise the immunne response that Th1 type and Th2 type are replied.In replying a preferred embodiment that is mainly the Th1 type, the level of Th1 cytokines is bigger than the degree of the level increase of Th2 cytokines.Adopt standard test can easily estimate the level of these cytokines.The summary of cells involved factor family sees also Mosmann and Coffman, Ann.Rev.Immunol.7:145-173,1989.

For induce be mainly some preferred adjuvant that the Th1 type replys comprise for example single phosphatidyl lipid A, preferably 3-take off-the single phosphatidyl lipid A of O-acidylate is with the combination of aluminum salt.MPL ^Adjuvant can derive from Corixa Corporation (Seattle, WA; Referring to, for example, U.S. Patent number 4,436,727,4,877,611,4,866,034 and 4,912,094).The oligonucleotide (wherein the CpG dinucleotide is not methylated) that contains CpG is also induced and is mainly replying of Th1 type.Such oligonucleotide is well-known, is described in for example WO 96/02555, WO99/33488 and U.S. Patent number 6,008,200 and 5,856,642.The immunostimulation DNA sequence also is described in for example Sato etc., Science 273:352,1996.Another preferred adjuvants comprises the saponin or derivatives thereof such as Quil A, comprise QS21 and QS7 (Aquila Biopharmaceuticals Inc., Framingham, MA); Aescine; Digitonin; Or chalk-plant (Gypsophila) or Chenopodium quinoa saponin.In adjuvant of the present invention combination, other preferred preparation comprises more than one saponin, for example below at least two kinds combination: QS21, QS7, QuilA, β-aescine or digitonin.

Perhaps, can with the saponin preparation with by chitosan or other polycationic polymer, polyactide and polylactide-co-glycolide copolymer pellet, mix based on the polymeric matrix of poly-n-acetyl glycosamine, the vaccine carrier formed by polysaccharide or the granule of forming through the polysaccharide of chemical modification, liposome and granule of forming based on the granule of lipid, by monoglyceride etc.Saponin also can be prepared in the presence of cholesterol, to form graininess structure, for example liposome or ISCOM.In addition, saponin can be with polyoxyethylene ether or ester at non-particulate property solution or suspension or prepare in the graininess structure such as paucilamelar liposome or ISCOM.Saponin also can with such as Carbopol ^RExcipient prepare together, to increase viscosity, perhaps can prepare with powdery excipient with dry powder form such as lactose.

In a preferred embodiment, described adjuvant system comprises the combination of single phosphatidyl lipid A and saponin derivative, for example QS21 and the 3D-MPL that describes in WO 94/00153 ^The combination of adjuvant or the wherein QS21 that in WO 96/33739, the describes lower compositions of reactionogenicity of cholesterol quencher.Other preferred preparation comprises oil in water emulsion and tocopherol.Use QS21,3D-MPL have been described among the WO 95/17210 ^The particularly preferred adjuvant formulation of another of the oil in water emulsion of adjuvant and tocopherol.

Another enhanced adjuvant system comprises the combination of disclosed CpG and QS21 among combination, the especially WO 00/09159 that contains CpG oligonucleotide and saponin derivative.Described preparation preferably comprises oil in water emulsion and tocopherol in addition.

Other illustrative adjuvant that is available in the Pharmaceutical composition of the present invention comprises MontanideISA 720 (Seppic, France), SAF (Chiron, Califomia, the U.S.), the adjuvant of ISCOMS (CSL), MF-59 (Chiron), SBAS series (for example SBAS-2 or SBAS-4, can derive from SmithKline Beecham, Rixensart, Belgium), Detox (Enhanzyn ^) (Corixa, Hamilton, MT), RC-529 (Corixa, Hamilton, MT) and other aminoalkyl glucosaminide 4-phosphate ester (AGP), for example the U.S. Patent application serial number 08/853,826 and 09/074 of pending trial, adjuvant (disclosure of described patent application all is attached to herein by reference) and the polyoxyethylene ether adjuvant described in 720, for example adjuvant of describing among the WO 99/52549A1.

Other preferred adjuvants comprises the adjuvant molecule of general formula (I):

HO(CH ₂CH ₂O) _n-A-R

Wherein n is 1-50, A be a key or-C (O)-, R is C _1-50Alkyl or phenyl C _1-50Alkyl.

One embodiment of the invention comprise the bacterin preparation of the polyoxyethylene ether that contains general formula (I), and wherein n is 1-50, is preferably 4-24, most preferably is 9; The R component is C _1-50Alkyl, be preferably C _4-20Alkyl, most preferably be C ₁₂Alkyl; A is a key.The concentration range of polyoxyethylene ether should be for 0.1-20%, be preferably 0.1-10%, most preferably be 0.1-1%.Preferred polyoxyethylene ether is selected from following group: polyoxyethylene 9-lauryl ether, polyoxyethylene-9-stearyl ether, polyoxyethylene-8-stearyl ether, polyoxyethylene-4-lauryl ether, polyoxyethylene-35-lauryl ether and polyoxyethylene-23-lauryl ether.Polyoxyethylene ether such as polyoxyethylene lauryl ether has description in Merck index (the 12nd edition: entry 7717).These adjuvant molecules have description in WO 99/52549.

If desired, the polyoxyethylene ether according to above-mentioned general formula (I) can make up with another adjuvant.The combination of for example a kind of preferred adjuvants preferably with the UK Patent Application GB 9820956.2 of pending trial in the CpG combination described.

According to preferably also there being a kind of carrier in the vaccine combination of the present invention.Described carrier can be an oil in water emulsion, or a kind of aluminum salt, for example aluminum phosphate or aluminium hydroxide.

Preferred oil in water emulsion comprises a kind of metabolizable oil, for example Squalene, alpha-tocopherol and Tween 80.One particularly preferred aspect, mix with QS21 and 3D-MPL in this Emulsion according to the antigen in the vaccine combination of the present invention.In addition, described oil in water emulsion can contain span 85 and/or lecithin and/or tricaprylin.

During administration of human, usually QS21 in the vaccine and 3D-MPL content range are every dose 1 μ g-200 μ g, for example 10 μ g-100 μ g, 10 μ g-50 μ g preferably.And oil in water emulsion comprises 2-10% Squalene, 2-10% alpha-tocopherol and 0.3-3% Tween 80 usually.Squalene: the ratio of alpha-tocopherol preferably is equal to or less than 1, because such ratio provides more stable Emulsion.The content of Span 85 also can be 1%.In some cases, to contain a kind of stabilizing agent in addition may be favourable to vaccine of the present invention.

Nontoxic oil in water emulsion is preferably in and contains a kind of nontoxic oil for example squalane or Squalene in the aqueous carrier, and a kind of emulsifying agent Tween 80 for example.Described aqueous carrier can be a phosphate buffered saline(PBS) for example.

Described a kind of especially effectively adjuvant formulation among the WO 95/17210, said preparation is the oil in water emulsion that comprises QS21,3D-MPL and tocopherol.

The present invention also provides multivalent vaccine composition, and described multivalent vaccine composition comprises bacterin preparation of the present invention and other antigen, is particularly useful for treating cancer, the antigen of colorectal carcinoma, autoimmune disease and associated conditions more especially.Such multivalent vaccine composition can comprise TH-1 inducing adjuvant as indicated above.

According to another embodiment of the invention, immunogenic composition as herein described is passed to the host by antigen-presenting cell (APC), and described antigen-presenting cell (APC) for example dendritic cell, macrophage, B cell, mononuclear cell and other can be by engineered to become the cell of effective APC.This class cell can but not necessarily by genetic modification, with the ability, the activation and/or the maintenance that improve t cell response that increase antigen-presenting, itself have Graft Versus Tumor and/or with receptor be compatible (promptly mating the HLA haplotype) on immunology.APC generally can separate from any of various biological fluids or organ (comprising tumor and tumor surrounding tissue), maybe can be autogenous cell, homogeneous variant cell, homogenic cell of the same race or heterogenous cell.

Some embodiment preferred of the present invention uses dendritic cell or its CFU-GM as antigen-presenting cell.Dendritic cell are very effective APC (Banchereau and Steinman, Nature392:245-251,1998), and shown that as inducing physiology adjuvant preventative or that therapeutic anti-tumour is immune be effectively (referring to Timmerman and Levy, Ann.Rev.Med.50:507-529,1999).Generally speaking, dendritic cell may according to its typical shape (original position is starlike, external visible significantly cytoplasmic process (dendron)), its absorption, projection and with the ability of high efficiency antigen-presenting with and activate originally the ability of t cell response and identify.Certainly, can carry out engineeredly to dendritic cell, to express usually in vivo or non-existent specific cell surface receptor or part on the stripped dendritic cell, the present invention has considered the modified dendritic cell of this class.As the substitute of dendritic cell, in vaccine, can use to load the antigenic dendritic cell of secreting type vesicle (being called allochthon) (referring to Zitvogel etc., Nature Med 4.594-600,1998).

Dendritic cell and CFU-GM can be soaked into cell, lymph node, spleen, skin, Cord blood or any other suitable tissue or body fluid acquisition from peripheral blood, bone marrow, tumor-infiltrated cell, tumor surrounding tissue.For example, can by with cytokine for example the combination of GM-CSF, IL-4, IL-13 and/or TNF α be added to from the monocyte cultures of peripheral blood results, make the dendritic cell ex vivo differentiation.Perhaps, can make from the CD34 positive cell of peripheral blood, Cord blood or bone marrow results and be divided into dendritic cell by inducing the chemical compound of dendritic cell differentiation, maturation and propagation to join in the described culture medium GM-CSF, IL-3, TNF α, CD40 part, LPS, flt3 part and/or other.

The dendritic cell routine is divided into " immaturity " cell and " maturation " cell, and available simple mode makes a distinction two kinds of phenotypes that fully characterize.Yet this name should not be interpreted as getting rid of all possible middle differential period.The antigen relevant with the mannose receptor high expressed with Fc γ receptor that is characterized as of immaturity dendritic cell is taken in and the high APC of working ability.Ripe phenotype is common is characterised in that the expression of these labellings is lower, but is responsible for the expression height of cell surface molecule (for example I class MHC and II class MHC), adhesion molecule (for example CD54 and CD11) and the co stimulatory molecule (for example CD40, CD80, CD86 and 4-1BB) of T cell activation.

Generally can make encoded polypeptide or its immunogenicity part at described cell surface expression with polynucleotide of the present invention (or its part or other variant) transfection APC.Can exsomatize and carry out such transfection, the Pharmaceutical composition that comprises such transfectional cell then can be used for therapeutic purposes as herein described.Perhaps, can give the patient, cause taking place in vivo transfection the gene delivery vector of targeting dendritic cell or other antigen-presenting cell.Generally speaking, adopt any method known in the art, for example method of introducing among the WO 97/24447 or Mahvi etc., Immunology and cell Biology 75:456-460, the 1997 particle gun methods of introducing can be carried out for example interior and stripped transfection of body of dendritic cell.By dendritic cell or CFU-GM are hatched with oncopeptide, DNA (naked DNA or the DNA in plasmid vector) or RNA; Perhaps hatch with the recombinant bacteria or the virus (for example vaccinia virus, fowlpox virus, adenovirus or lentivirus carrier) of antigen expressed, the antigen that can reach dendritic cell loads.Before loading, can and provide the auxiliary immune gametophyte of T cell (for example carrier molecule) covalency to put together with polypeptide.Perhaps, dendritic cell can be individually or in the presence of described polypeptide with unconjugated immune gametophyte burst process.

Can use under the situation of any suitable carrier well known by persons skilled in the art in Pharmaceutical composition of the present invention, bearer type becomes with mode of administration usually.Compositions of the present invention can be prepared and be used for any suitable administering mode, comprises for example local, oral, nasal cavity, mucosa, intravenous, intracranial, intraperitoneal, subcutaneous and intramuscular administration.

The carrier that uses for this class Pharmaceutical composition is biocompatible, and also biodegradable.In certain embodiments, described preparation preferably provides with relative constant level and discharges effective ingredient.Yet, in other embodiments, may after administration, discharge effective ingredient immediately with the speed of more accelerating.Adopting known technology to prepare this based composition is in those skilled in the art's the ken.The illustrative carrier that can be used for this aspect comprises microgranule of polylactide-co-glycolide copolymer, polyacrylate, latex, starch, cellulose, glucosan etc.The carrier that other illustrative postpones to discharge comprises the supermolecule bio-carrier, it comprises immobilising hydrophilic core (for example cross-linked polysaccharides or oligosaccharide) and the optional skin that comprises amphipathic compound (for example phospholipid) (referring to for example, United States Patent (USP) the 5th, 151, No. 254 and PCT application WO 94/20078, WO 94/23701 and WO 96/06638).The amount of contained reactive compound depends on speed and the expected duration and the disease character to be treated or prevention of implant site, release in slow releasing preparation.

In another illustrative embodiment, biodegradable microsphere (for example poly-lactic acid ester polyglycolic acid ester) is as the carrier of the present composition.Suitable biodegradable microsphere is disclosed in for example U.S. Patent number 4,897,268; 5,075,109; 5,928,647; 5,811,128; 5,820,883; 5,853,763; 5,814,344,5,407,609 and 5,942,252.Modified HBc protein carrier system, for example the carrier system of describing in WO/99 40934 and the list of references wherein quoted also can be used in many application.Another illustrative carrier/transmission system uses the carrier that comprises the graininess albumen composition, for example at United States Patent (USP) the 5th, 928, and the carrier of describing in No. 647, described carrier can induce the cytotoxic T lymphocyte of I class restriction to reply in host.

Pharmaceutical composition of the present invention also comprises one or more buffer agents (for example neutral buffered saline solution or phosphate buffered saline(PBS)) usually; saccharide (glucose for example; mannose; sucrose or glucosan); mannitol; protein; polypeptide or aminoacid (for example glycine); antioxidant; antibacterial; chelating agen (for example EDTA) or glutathion; adjuvant (for example aluminium hydroxide); blood that makes preparation and receptor etc. oozes; the solute that hypotonic or weak height oozes; suspending agent; thickening agent and/or antiseptic.Perhaps, the present composition can be formulated as lyophilized formulations.

Pharmaceutical composition as herein described can be contained in unit-dose container or the multi-dose container (for example sealed ampoule or phial).The common sealing means of this class container makes and keeps described preparation aseptic and stable before using.Generally speaking, preparation can be used as suspensoid, solution or the Emulsion preservation in oiliness or the aqueous vehicles.Perhaps, Pharmaceutical composition can be preserved under the freeze-dried condition, only need get final product facing with preceding adding sterile liquid carrier.

For for using particular composition as herein described in the various therapeutic schemes, the exploitation of suitable dosage regimen and therapeutic scheme (comprising for example oral, parenteral, intravenous, intranasal and intramuscular administration and used preparation) is well-known in the art, in order to illustrate, hereinafter will discuss some scheme wherein in a capsule.

In some applications, Pharmaceutical composition disclosed herein can be passed to animal by oral administration.Therefore, these compositionss can be prepared with inert diluent or with absorbable edible carrier, perhaps they can be encapsulated in duricrust gelatine capsule or the soft shell gelatin capsules, and perhaps they can be squeezed into tablet, and perhaps they can directly be incorporated in the food of meals.

Described reactive compound even may mix with excipient, with edible tablet, buccal tablet, lozenge, capsule, elixir, suspensoid, syrup, wafer form etc. use (referring to, for example, Mathiowitz etc., Nature on March 27th, 1997; 386 (6623): 410-4; Hwang etc., Crit Rev Tjer Drug Carrier Syst 1998; 15 (3): 243-84; United States Patent (USP) 5,641,515; United States Patent (USP) 5,580,579 and United States Patent (USP) 5,792,451).Tablet, lozenge, pill, capsule etc. also can contain any in many additional component, can add for example binding agent, for example tragakanta, Radix Acaciae senegalis, corn starch or gelatin; Excipient, for example dicalcium phosphate; Disintegrating agent, for example corn starch, potato starch, alginic acid etc.; Lubricant, for example magnesium stearate; And sweeting agent, for example sucrose, lactose or glucide or correctives, for example Herba Menthae, wintergreen oil or cherry are chosen correctives.When dosage unit form was capsule, it can also contain liquid-carrier except that the above-mentioned type material.Various other materials may exist as coating materials, perhaps improve the physical form of dosage unit in others.For example, tablet, pill or capsule can or be used Lac and sweet tablet simultaneously with Lac, sugar.Certainly, used any material all should be that pharmacy is pure and be nontoxic basically in employed amount in any dosage unit form of preparation.In addition, described reactive compound can be incorporated in the slow releasing preparation.

Usually, these preparations contain at least about 0.1% reactive compound or the reactive compound of high dose more, although the percentage rate of effective ingredient can change certainly, may conventionally be total weight of formulation or body knit about 1% or 2% to about 60% or 70% or higher.Certainly, in every kind of treatment that may prepare in the effective composition mode of the consumption of reactive compound make any given unit dose with described chemical compound obtain proper dosage.When this pharmaceutical formulation of preparation, all multifactor and other pharmacology that those skilled in the art will consider such as dissolubility, bioavailability, biological halflife, route of administration, goods storage periods considers that therefore various dosage and therapeutic scheme may all be ideal.

On the other hand, for oral administration, compositions of the present invention can be mixed one or more excipient in mouth-wash, dentifrice, buccal tablet, oral spray or Sublingual oral Preparation form.Perhaps, described effective ingredient can be incorporated in the oral administration solution that oral administration solution for example contains sodium borate, glycerol and sodium bicarbonate, perhaps in dentifrice, disperse, or join in the compositions that may comprise water, binding agent, abrasive, correctives, foaming agent and wetting agent with the treatment effective dose.Perhaps, described compositions can be finish-machined to and can put into the Sublingual or in the tablet or the solution form of dissolved in oral cavity.

In some cases, it is desirable to parenteral, intravenous, intramuscular or even intraperitoneal give Pharmaceutical composition disclosed herein.Such method is well known to those skilled in the art, and wherein some method is further described in for example United States Patent (USP) 5,543,158; United States Patent (USP) 5,641,515 and United States Patent (USP) 5,399,363.In certain embodiments, in water, suitably mix, can prepare described reactive compound is gone up acceptable salt as free alkali or pharmacology solution with surfactant (for example hydroxypropyl cellulose).Also can prepare dispersant at glycerol, liquid macrogol and composition thereof with in oil.Under common storage and service condition, these preparations generally contain antiseptic, to prevent microbial growth.

The illustrative medicine that is suitable for injection forms and comprises aseptic aqueous solution or dispersant and be used for the aseptic injection of interim preparation or the sterilized powder (for example, referring to United States Patent (USP) 5,466,468) of dispersion liquid.In all cases,, described form must be aseptic and must be liquid being easy to aspect the injection.Produce and the condition of storage under it must be stable and must prevent the contamination of microorganism (for example antibacterial and fungus).Described carrier can be solvent or contain for example water, ethanol, polyhydric alcohol (for example glycerol, propylene glycol and liquid macrogol etc.), their suitable mixture and/or the disperse medium of vegetable oil.For example, under dispersive situation,, can keep suitable flowability by keeping required granular size and/or utilizing surfactant by utilizing coating materials such as lecithin.Can utilize various antibacterial agents or antifungal agent (for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal etc.) to prevent action of microorganisms.In many cases, preferably include isotonic agent, for example sugar or sodium chloride.The prolongation of injectable composition absorbs can be by using the medicament that postpones absorption in compositions, for example aluminum monostearate and gelatin are realized.

In one embodiment, give aqueous solution for parenteral, described in case of necessity solution should suitably cushion, described liquid diluent at first with the saline of capacity or glucose make its etc. ooze.These specific water solublity are particularly suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration.At this on the one hand, according to disclosure of the present invention, operable sterile aqueous media is known for those skilled in the art.For example, a dosage can be dissolved in the 1ml isotonic sodium chlorrde solution, then or join the subcutaneous perfusion of 1000ml with liquid or in the infusion site injection of suggestion (referring to for example, " Remington ' s Pharmaceutical Sciences ", the 15th edition, 1035-1038 page or leaf and 1570-1580 page or leaf).According to curee's to be treated disease, some variation of dosage is essential.In addition, for human administration, certainly preparation preferably meets aseptic, apyrogeneity and according to desired general safety of FDA Office of Biologics standard and purity rubric.

In another embodiment of the invention, compositions disclosed herein can be mixed with neutral form or salt form.Illustrative pharmaceutically acceptable salt comprises acid-addition salts (generating with proteinic free amine group), and with the mineral acid of all example hydrochloric acids or phosphoric acid or the acid-addition salts that generates with organic acid such as acetic acid, oxalic acid, tartaric acid, mandelic acid etc.The salt that forms with free carboxy also can be derived from inorganic base, for example sodium hydroxide, potassium hydroxide, ammonium hydroxide, calcium hydroxide or hydrated ferric oxide.; And organic base, for example 2-aminopropane., triethylamine, histidine, procaine etc.When preparation, the mode that solution gives needs compatible with drug-delivery preparation, and the dosage that gives is the treatment effective dose.

Described carrier can also comprise any He all solvents, disperse medium, solvent, coating materials, diluent, antibacterial agent and antifungal agent, isotonic agent and absorption delay agent, buffer agent, carrier solution, suspensoid, colloid etc.This class medium and medicament that the hyoscine active substance uses are well-known in the art.Except that any conventional media and medicament and the inconsistent situation of effective ingredient, consider its application in therapeutic combination.Also the effective ingredient that replenishes can be incorporated in the described compositions.Phrase " pharmaceutically acceptable " is meant molecular entity and the compositions that does not produce allergy or similar undesired reaction when the administration of human time-like.

In certain embodiments, described Pharmaceutical composition can be sprayed, suck and/or other aerosol is transmitted carrier and transmits by intranasal.Gene, nucleic acid and peptide combinations are described in for example United States Patent (USP) 5,756,353 and United States Patent (USP) 5,804,212 by the method that the nose aerosol spray directly gives pulmonary.Equally, adopt intranasal finely divided resin (Takenaga etc., J Controlled Release1998 March 2; 52 (1-2): also be that pharmaceutical field is well-known 81-7) with lysophosphatidyl glycerol chemical compound (United States Patent (USP) 5,725,871) administration.Equally, the illustrative mucosal of politef support skeleton form is at United States Patent (USP) 5,780, description arranged in 045.

In some embodiment, use liposome, nanocapsule, microgranule, lipid granule, vesicle etc. that compositions of the present invention is introduced in proper host cell/biology.Specifically, compositions of the present invention can be mixed with and be used in encapsulation transmission such as lipid granule, liposome, vesicle, nanosphere or nanoparticles.Perhaps, compositions of the present invention can with such carrier surface or covalent bond or non-covalent combination.

Liposome and liposome sample preparation as the preparation of potential drug carrier and use generally be for those skilled in the art known (referring to for example, Lasic, Trends Biotechnol in July, 1998; 16 (7): 307-21; Takakura, Nippon Rinsho in March, 1998; 56 (3): 691-5; Chandran etc., Indian J Exp Biol.1997 August; 35 (8): 801-9; Margalit, CritRev Ther Drug Carrier Syst.1995; 12 (2-3): 233-61; United States Patent (USP) 5,567,434; United States Patent (USP) 5,552,157; United States Patent (USP) 5,565,213; United States Patent (USP) 5,738,868 and United States Patent (USP) 5,795,587; Each document all is attached to herein particularly by reference).

Liposome successfully uses by other method cells transfected type with many being difficult to usually, comprises T cell suspensoid, primary hepatocyte culture and PC 12 cells (Renneisen etc., J Biol Chem.1990 JIUYUE 25 days; 265 (27) .16337-42; Muller etc., DNA Cell Biol.1990 April; 9 (3): 221-9).In addition, liposome is not based on DNA length restriction common in the viral drug-supplying system.Liposome is used for gene, various medicine, radiotherapy medicine, enzyme, virus, transcription factor, allosteric effect agent etc. are imported in various cultured cell systems and the animal effectively.In addition, it seems that the application of liposome and the back autoimmunity that is administered systemically are replied or unacceptable toxicity is irrelevant.

In certain embodiments, liposome forms and forms automatically the double-deck vesicle (being also referred to as multilamellar liposome (MLV)) of multilayer concentric by dispersive phospholipid in aqueous medium.

On the other hand, in other embodiments, the invention provides the pharmaceutically acceptable nanocapsule preparation of the present composition.Nanocapsule generally can with stable and reproducible mode encapsulation compound (referring to, for example, Quintanar-Guerrero etc., Drug Dev Ind Pharm.1998 December; 24 (12): 1113-28).For fear of because the intracellular polymer side effect that overloads and cause, such ultramicro powder (the about 0.1 μ m of size) can adopt can vivo degradation polymer design.Such granule can be prepared by following document is described: Couvreur etc. for example, Crit Rev Ther Drug Carrier Syst.1988; 5 (1): 1-20; Zur Muhlen etc., Eur JPharm Biopharm.1998 March; 45 (2): 149-55; Zambaux etc., J ControlledRelease.1998 January 2; 50 (1-3): 31-40; With United States Patent (USP) 5,145,684.

The present invention also relates to derive from the polynucleotide of primer form of polynucleotide of the present invention and specificity at the polypeptide of the antibody of polypeptide of the present invention or reagent form purposes as diagnostic reagent.

Evaluation can detect in the carcinogenesis approach genetic marker or biochemical marker in extremely early stage blood that changes or the tissue, will help to be identified for patient's best therapy.Can use the alternative tumor marker of expressing, diagnose multi-form and cancer stadium such as polynucleotide.The evaluation of polynucleotide expression of the present invention both be can be used for the stadium classification of Cancerous disease, can be used for the character classification of cancerous tissue again.The progress of stadium sorting technique monitoring cancer, and according in the biopsy district, whether existing malignant tumor tissue to determine.Polynucleotide of the present invention can help to be tested and appraised the labelling of cancer attack, for example described stadium sorting technique is improved in the existence in the body different parts.How similar closely the hierarchical description tumor of cancer is to the normal structure of its same type, and estimate by its cellular morphology and other differentiation marker.Polynucleotide of the present invention can be used for determining the tumor rank, because they have the differentiation state that helps determine tumor cell.

By comprise the unusual minimizing of determining to derive from polypeptide in curee's sample or mRNA level or be increased in method diagnose, described diagnostic analysis provides a kind of and is used for cancer diagnosis, autoimmune disease and associated conditions or determines method to the susceptibility of described disease.This diagnostic method is called differential expression.The relatively expression of specific gene in illing tissue and the normal structure.Difference described in two kinds of tissues of this that is compared between polynucleotide related gene, mRNA or the albumen, the difference aspect molecular weight, aminoacid sequence or nucleotide sequence or relative abundance for example shows at gene described in the tissue of suspecting ill people or regulates the variation of its gene.

Can on rna level, measure minimizing or the increase expressed.At first from these two kinds of tissues, isolate PolyA RNA, can detect by the following method by detection then corresponding to the mRNA of the gene code of the polynucleotide of the present invention of differential expression: for example the in situ hybridization of tissue slice, reverse transcription-PCR, use RNA trace or any other direct or indirect RNA detection method of containing PolyA+mRNA.Compare increase or minimizing that given RNA expresses with normal structure in illing tissue, point out described transcript and/or expressed albumen in described disease, to work.Therefore, it is more high or low than normal level to detect the mRNA level that corresponds to SEQ ID NO:1, shows that described patient suffers from cancer.

MRNA expression in the sample can be determined by the library that produces expressed sequence tag (EST) from described sample.Can use the relative expressivity of EST in described library, estimate the relative expressivity of described genetic transcription thing in primary sample.The EST of described test can be analyzed EST with the reference sample then and analyze and compare, thereby measure relative expression's level of interested polynucleotide.

Can adopt successive analysis (SAGE) method (Velculescu etc. of gene expression, Science (1995) 270:484), (for example, US 5,776 for the mRNA differential display mRNA method, 683) or depend on the nucleotide narrow spectrum hybridization analysis that interacts, carry out other mRNA and analyze.

On the other hand, can on protein level, compare.Use antibody test from the polypeptide in the Western blotting of the protein extract in described two kinds of tissues, can the protein size in two kinds of tissues be compared.Use the antibody of anti-corresponding protein, can also on immunology, detect expression and Subcellular Localization.Can be used for measuring other analytical technology of the protein level (polypeptide level for example of the present invention) in the host-derived sample, know to those skilled in the art.The expression of polypeptides level is compared with same protein expression in the normal structure and is raise or reduction in illing tissue, shows that expressed albumen may be relevant with described disease.

In mensuration of the present invention,, can determine described diagnosis by detecting expression by the gene outcome of at least a sequential coding shown in the SEQ ID NO:1.Also can follow the tracks of advancing of disease or alleviation with the mRNA level in illing tissue and the normal structure or the comparison of protein level.

Adopt the polynucleotide array, the many polynucleotide sequences in can analytic sample.These polynucleotide can be used for detecting the differential expression of gene, thereby determine the function of gene.For example, can determine any whether variant expression between normal cell and cancer cell of described polynucleotide with the array of polynucleotide sequence SEQ ID NO:1.In one embodiment of the invention, can make up an array that comprises SEQ ID NO:1 nucleotide sequence or its segmental oligonucleotide probe, to carry out for example effective screening of genetic mutation.The array technique method is well-known and has general applicability, can be with the various problems that solve the molecular genetics aspect, comprise that gene expression, genetic linkage and hereditary variability are (referring to for example: M.Chee etc., Science, the 274th volume, 610-613 page or leaf (1996)).

" diagnosis " used herein comprise determine the curee to the susceptibility of disease, determine whether the curee suffers from described disease at present, can also do prognosis to the curee who is subjected to described sickness influence.

The invention still further relates to the diagnostic kit that is used to carry out diagnostic analysis, described test kit comprises:

(a) a kind of polynucleotide of the present invention or its fragment, described polynucleotide are the nucleotide sequence of SEQID NO:1 preferably;

(b) a kind of and the complementary nucleotide sequence of nucleotide sequence (a), the preferably nucleotide sequence of SEQ IDNO:6;

(c) a kind of polypeptide of the present invention or its fragment, described polypeptide be the polypeptide of SEQ ID NO:2 or SEQ ID NO:3 preferably; Or

(d) a kind of antibody of anti-polypeptide of the present invention, the antibody of preferably anti-SEQ ID NO:2 or SEQ IDNO:3 polypeptide.

For chromosome mapping, nucleotide sequence of the present invention also is valuable.Ad-hoc location on the described sequence-specific ground targeting people individual chromosome, and can with its hybridization.According to the present invention relevant sequence being mapped to chromosome, is the important first step making those sequences and gene-correlation disease in getting in touch.In case, physical location and the gene mapping data of described sequence on described chromosome are interrelated with map exact position to chromosome of sequence.Such data can be at for example V.McKusick, finds among the Mendelian Inheritance inMan (can by online the obtaining of Johns Hopkins University Welch Medical Library).Identify by linkage analysis (the common heredity of physically adjacent gene) then and mapped to the gene of same chromosomal region and the relation between the disease.Also can determine cDNA sequence between affected individuals and the uninfluenced individuality or the difference in the genome sequence.

Polypeptide of the present invention or its fragment or its analog or the cell of expressing them can also be used as immunogen, to produce the immune specificity antibody of anti-polypeptide of the present invention.Term " immune specificity " is meant that described antibody is more much higher to the affinity of other related polypeptide in the prior art than them to the affinity of polypeptide of the present invention.

Again on the one hand, immune specificity antibody or its immunology fragment that the invention provides as mentioned to be limited according to polypeptide of the present invention.Described antibody is monoclonal antibody preferably.

Adopt conventional method,, can obtain the antibody that produces at polypeptide of the present invention by described polypeptide or the fragment, analog or the cell that carry epi-position being given animal, non-human animal preferably.In order to prepare monoclonal antibody, can use any technology that the antibody of being produced by the continuous cell line culture is provided.Example comprises hybridoma technology (Kohler, G. and Milstein, C., Nature (1975) 256:495-497), trioma technology-human B cell hybridoma technology (Kozbor etc., Immunology Today (1983) 4:72) and EBV hybridoma technology (Cole etc., MonoclonalAntibodies and Cancer Therapy, 77-96, Alan R.Liss, Inc., 1985).

Produce the technology of single-chain antibody, for example at United States Patent (USP) the 4th, 946, the technology of describing in No. 778 may also be applicable to the single-chain antibody that produces anti-polypeptide of the present invention.In addition, can express humanized antibody with transgenic mice or other biology (comprising other mammal).

Can use the clone of above-mentioned antibody separation or the described polypeptide of evaluation expression or pass through the described polypeptide of affinitive layer purification.Also can use antibody prevention of the present invention or treatment cancer, especially colorectal carcinoma, autoimmune disease and associated conditions.

Another aspect of the present invention relates to the method for inducing or regulating immunne response in the mammalian body; described method comprises with the described mammal of peptide vaccination of the present invention that is enough to produce antibody and/or T cellullar immunologic response, to protect or to improve the symptom or the process of described disease.The method of inducing or regulating immunne response in the mammalian body that relates in one aspect to again of the present invention; described method comprises by instructing the carrier transfer polypeptide of the present invention of expressing described polynucleotide and coding said polypeptide in vivo; so that induce this immunne response that produces antibody, thereby protect described animal to exempt from the disease that takes a disease.

Therefore people will appreciate that, the invention provides existence, the overexpression of treatment and CASB7439 polypeptide active or express for example method of cancer and autoimmune disease, especially colorectal carcinoma of the relevant unusual disease of deficiency.Other unusual disease relevant with the CASB7439 expression that the present invention attempts to treat is chronic lymphocytic leukemia and germ cell tumor.

The present invention also provides SCREENED COMPOUND to identify the method that stimulates or suppress those chemical compounds of CASB7439 polypeptide function.Generally speaking, for this class disease of above being mentioned, in order to treat and to prevent purpose can use agonist or antagonist.Can be from various sources for example the mixture of cell, acellular prepared product, chemical library and natural product come authenticating compound.As the case may be, natural or the modified substrate that this excitomotor, antagonist or the inhibitor of identifying like this can be described polypeptide, part, receptor, enzyme etc., perhaps also can be they the structural simulation thing or the functional simulation thing (referring to Coligan etc., Current Protocols inImmunology 1 (2): the 5th chapter (1991)).Screening technique is well known by persons skilled in the art.Other screening technique can also be at for example D.Bennett etc., J Mol Recognition, 8:52-58 (1995); With K.Johanson etc., J Mol Biol, 270 (16): find in 9459-9471 (1995) and the list of references wherein.

Therefore, the invention provides and identify the screening technique that stimulates or suppress the chemical compound of polypeptide function of the present invention, described method comprises a kind of following method that is selected from:

(a) utilize directly or indirectly in conjunction with the labelling of candidate compound, measure described candidate compound and described polypeptide (or with cell that carries described polypeptide or cell membrane) or with the combining of its fusion rotein;

(b) in the presence of labelling competition thing, measure candidate compound and described polypeptide (or with cell that carries described polypeptide or cell membrane) or with the combining of its fusion rotein;

(c) use the detection system of cell or the cell membrane be suitable for carrying described polypeptide, test the signal whether described candidate compound causes that activation or inhibition owing to described polypeptide produce;

(d) require the solution of 1 polypeptide to mix with containing right candidate compound, form mixture, measure the activity of polypeptide described in the described mixture then, and the activity of described mixture and the activity of standard substance are compared; Or

(e) for example adopt ELISA to measure, detect the influence of candidate compound the generation of the mRNA of coding said polypeptide in cell and described polypeptide.

By standard receptors bind technology known in the art, polypeptide of the present invention also can be used to identify membrane-bound receptor or soluble recepter (if any).Can also identify and agonist and the antagonist (if any) of polypeptide competition of the present invention with well-known screening technique with the polypeptide of the present invention of its receptors bind.

Therefore, on the other hand, the present invention relates to be used to identify agonist, antagonist, part, receptor, substrate, enzyme of polypeptide of the present invention etc.; Perhaps reduce or increase the screening reagent box of the chemical compound of this class polypeptide generation, described test kit comprises:

(a) a kind of polypeptide of the present invention;

(b) a kind of reconstitution cell of expressing polypeptide of the present invention;

(c) a kind of cell membrane of expressing polypeptide of the present invention; Or

(d) antibody of anti-polypeptide of the present invention;

Described polypeptide is the polypeptide of SEQ ID NO:2 or SEQ ID NO:3 preferably.

Those skilled in the art can recognize easily that polypeptide of the present invention can also be used for the method based on the agonist of the described polypeptide of structural design, antagonist or inhibitor, and using method comprises:

(a) three dimensional structure of at first definite described polypeptide;

(b) the possible active site of derivation agonist, antagonist or inhibitor or the three dimensional structure of binding site;

(c) the synthetic candidate compound that combines or react with binding site of deriving or active site of predicting; With

(d) whether the described candidate compound of test is real agonist, antagonist or inhibitor.

Can also use gene therapy to realize producing the CASB7439 polypeptide by the intravital cells involved endogenous of curee.The summary of related gene treatment, referring to Human Molecular Genetics, the 20th chapter, gene therapy and other Therapeutic Method (Gene Therapyand other Molecular Genetic-based Therapeutic Approaches) based on molecular genetics, T Strachan and A P Read, BIOS Scientific Publishers Ltd (1996) (with the list of references of wherein quoting).

At Pharmaceutical Biotechnology, the 61st volume, vaccine design one subunit and adjuvant method (Vaccine Design-the subunit and adjuvant approach), Powell and Newman write, Plenurn Press, 1995.New Trends and Developments inVaccines, Voller etc. write, University Park Press, Baltimore, Maryand has described bacterin preparation comprehensively among the U.S.A.1978.With the liposomal encapsulated for example United States Patent (USP) 4,235,877 of Fullerton that is described in.Protein and macromole are puted together the United States Patent (USP) 4,474,757 of the United States Patent (USP) 4,372,945 that is disclosed in Likhite for example and Armor etc.

Albumen quality in every kind of vaccine dose is chosen to be induction of immunity protective response in typical vaccine and does not have the amount of obvious toxic-side effects.Such amount changes with employed specific immunogen.Generally speaking, expect that each dosage comprises 1-1000 μ g albumen, preferred 2-100 μ g albumen, 4-40 μ g albumen most preferably.By comprising that observation curee internal antibody is tired and the research on standard of other reaction, can determine the optimised quantity of specific vaccine.After the first vaccination, the curee can also accept a booster shot in about 4 weeks.

" isolating " is meant and changes from native state " artificially ".If a kind of " isolating " compositions or material exist at occurring in nature, its primal environment has changed or has taken out from its primal environment or both have both at the same time so.As this term used herein, for example naturally occurring polynucleotide or polypeptide are not " isolating " in the animal that lives, but are " isolating " with described identical polynucleotide or polypeptide that the material of its native state coexistence separates.

" polynucleotide " generally are meant any polyribonucleotide or polydeoxyribonucleotide, and they can be RNA or DNA or modified RNA or the DNA that comprises the unmodified of strand district and double stranded region.

" variant " is meant different with reference polynucleotide or polypeptide but keeps the polynucleotide or the polypeptide of fundamental characteristics.Typical case's polynucleotide variant lists different with another reference polynucleotide at nucleotides sequence.The variation of described variant nucleotide sequence may change or not change the amino acid sequence of polypeptide of reference polynucleotide encoding.Such as hereinafter argumentation, the change of nucleotide may cause propylhomoserin replacement, interpolation, disappearance, fusion and the truncate of reference sequence encoded polypeptides.Typical polypeptide variants is different with another reference polypeptide on aminoacid sequence.Generally speaking, difference is limited, causes the sequence of reference polypeptide and variant closely similar on the whole and be identical in many districts.Variant and reference polypeptide may be because one or more replacements of any combination, interpolation, disappearance and aminoacid sequence is different.The amino acid residue that replaces or insert can yes or no by genetic code amino acids coding residue.The variant of polynucleotide or polypeptide can be naturally occurring variant such as allelic variation body, and perhaps described variant can be the variant that known non-natural exists.Can be by induced-mutation technique or by directly synthetic, the variant that the non-natural of preparation polynucleotide and polypeptide exists.

" homogeneity " is meant two or more peptide sequence definite by comparative sequences or the relation between two or more polynucleotide sequence as known in the art.In the art, as the case may be, " homogeneity " also refers to according to the coupling between the character string of polypeptide or polynucleotide sequence and definite polypeptide or the serial correlation degree between the polynucleotide sequence.Adopt known method can easily calculate " homogeneity " and " similarity ", described method includes but not limited to the method described in the following document: Computational MolecularBiology, Lesk, A.M. write, Oxford University Press, New York, 1988; Biocomputing:Informatics and Genome Projects, Smith, D.W. writes, Academic Press, New York, 1993; Computer Analysis of Sequence Data, part i, Griffin, A.M. and Griffin, H.G. writes, Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., AcademicPress, 1987; With Sequence Analysis Primer, Gribskov, M. and Devereux, J. writes, M Stockton Press, New York, 1991; And Carillo, H. and Lipman, D., SIAM J.Applied Math., 48:1073 (1988).The method for optimizing of design mensuration homogeneity is the maximum match between the cycle tests in order to provide.The method of homogeneity and similarity of measuring has been compiled into the available computer program of the public.Be used to measure two between the sequence homogeneity and the preferred computer program technic of similarity include but not limited to GCG program package (Devereux, J. etc., 387 (1984)), BLASTP, BLASTN and FASTA (Atschul Nucleic Acids Research 12 (1):, S.F. etc., J.Molec.Biol.215:403-410 (1990)).The public can obtain from NCBI and other source BLAST X program (BLAST Manual, Altschul, S. etc., NCBINLM NIH Bethesda, MD 20894; Atschul, S. etc., J.Mol.Biol.215:403-410 (1990)).Also can use well-known Smith Waterman algorithm to measure homogeneity.

Used optimization algorithm is FASTA.The preferred parameter that uses this algorithm to carry out polypeptide or polynucleotide sequence comparison comprises following parameter:

Gap Penalty (gap penalty): 12

Gap extension penalty (room expansion point penalty): 4

Word size (word string size): 2, be 6 to the maximum

Preferred parameter with the many peptide sequences of other method comprises following parameter:

1) algorithm: Needleman and Wunsch, J.Mol Biol.48:443-453 (1970)

Comparison matrix (comparator matrix): the BLOSSUM62 of Hentikoff and Hentikoff, Proc.Natl.Acad.Sci.USA.89:10915-10919 (1992)

Gap Penalty：12

Gap Length penalty (room length point penalty): 4

The program that can use these parameters is " gap " program, and the public can be from Genetics ComputerGroup, and Madison WI obtains.The top parameter of mentioning is to carry out polypeptide default parameter (simultaneously terminal room not being had point penalty) relatively.

The preferred parameter that is used for the polynucleotide comparison comprises following parameter:

1) algorithm: Needleman and Wunsch, J.Mol Biol.48:443-453 (1970) Comparison matrix:matches (coupling)=+ 10, mismatch (mispairing)=0Gap Penalty:50

Gap Length penalty：3

The program that can use these parameters is " gap " program, and the public can be from Genetics ComputerGroup, and Madison WI obtains.The top parameter of mentioning is to carry out polynucleotide default parameter relatively.

As an example, polynucleotide sequence of the present invention can be identical with the reference sequence of SEQ ID NO:1, and just 100% is identical, and perhaps it can comprise with described reference sequence and comparing, and the nucleotide of a certain integer of as many as changes.Such change is selected from least one nucleotide deletion, replacement (comprising base conversion and transversion) or inserts, and wherein said change can occur between 5 ' or 3 ' terminal position of described contrast nucleotide sequence or this two terminal positions Anywhere, perhaps intersperse among separately separately in the nucleotide of reference sequence, perhaps intersperse among in one or more continuous group of reference sequence.The number that nucleotide changes is following to be determined: SEQ ID NO:1 nucleotide sum multiply by the percentile numerical value percentage rate of corresponding homogeneity (divided by 100), deducts this product from described SEQ ID NO:1 nucleotide sum subsequently, or

n _n≤x _n-(x _n·y)，

N wherein _nBe the number that nucleotide changes, x _nBe SEQ ID NO:1 nucleotide sum, y for example is 0.70 (70%), 0.80 (80%), 0.85 (85%), 0.90 (90%), 0.95 (95%) etc., and wherein with x _nWith any non-integer product of y from x _nBefore deducting, this product is rounded to nearest integer.The change of the polynucleotide sequence of coding SEQ ID NO:2 polypeptide may produce nonsense, missense or frameshift mutation in this coded sequence, thereby changes the polypeptide by described polynucleotide encoding after such change.

Equally, peptide sequence of the present invention can be identical with the reference sequence of SEQ ID NO:2, and just 100% is identical, and perhaps it can comprise with described reference sequence and comparing, the amino acid change of a certain integer of as many as, so that the homogeneity percentage rate is less than 100%.Such change is selected from least one aminoacid deletion, replacement (comprising conservative the replacement and non-conservative replacement) or inserts, and wherein said change can occur between the amino terminal of described reference peptide sequence or carboxyl terminal position or this two terminal positions Anywhere, perhaps intersperse among separately separately in the aminoacid of reference sequence, perhaps intersperse among in one or more continuous group of reference sequence.Number for the following definite described amino acid change of specific homogeneity percentage rate: SEQ ID NO:2 aminoacid sum multiply by the percentile numerical value percentage rate of corresponding homogeneity (divided by 100), deduct this product from described SEQ IDNO:2 aminoacid sum subsequently, or

n _a≤x _a-(x _a·y)，

N wherein _aBe the number of amino acid change, x _aBe SEQ ID NO:2 aminoacid sum, y for example is 0.70 (70%), 0.80 (80%), 0.85 (85%) etc., and wherein with x _aWith any non-integer product of y from x _aBefore deducting, this product is rounded to nearest integer.

" homologue " is the term of a used classification of this area, is meant the polynucleotide sequence or the peptide sequence that have with subject nucleotide sequence height serial correlation.Such dependency can be by determining homogeneity degree between the aforesaid institute comparative sequences and/or similarity degree quantitatively.Belong in this classification term scope is term " directly to congener " and symbiosis congener "; " directly to congener " is meant the polynucleotide or the polypeptide of the function equivalent in another species as a kind of polynucleotide or polypeptide, and " symbiosis congener " is meant is considered to sequence similar on the function in same species.

Description of drawings

Fig. 1: show the PCR in real time data that adopt the Taqman probe.Described being described as follows: adrenal gland: Ad_Gl; Bladder: Bl; Bone marrow: Bo_Ma; Cervix uteri: Ce; Colon: Co; Fallopian tube: Fa_Tu; Ileum: Il; Liver: Li; Lung: Lu; Lymph node: Ly_No; Esophagus: Oe; Parathyroid gland: Pa_Thy; Placenta Hominis: Pl; Prostate: Pr; Rectum: Re; Skin: Sk; Skeletal muscle: Sk_Mu; Small intestinal: Sm_In; Spleen: Sp; Testis: Te; Thyroid: Thy; Trachea: Tr.

Fig. 2 shows the PCR in real time expression of adopting the Sybr scheme.Described being described as follows: adrenal gland: Ad_Gl; Bladder: Bl; Bone marrow: Bo_Ma; Cervix uteri: Ce; Colon: Co; Lymph node: Ly_No; Esophagus: Oe; Parathyroid gland: Pa_Thy; Placenta Hominis: Pl; Prostate: Pr; Rectum: Re; Skin: Sk; Skeletal muscle: Sk_Mu; Small intestinal: Sm_In; Spleen: Sp; Testis: Te; Thyroid: Thy; Trachea: Yr; Heart: He.

Fig. 3 shows the blue painted SDS PAGE of the filial piety Maas of the cell extract that derives from the bacterial strain of expressing CASB7439.Swimming lane 1 shows molecular weight marker, and swimming lane 2 is shown in 39 ℃ of cell extracts of inducing 5 hours; Swimming lane 3 show the supernatant of inductive cell extract; Swimming lane 4 show the precipitation of inductive cell extract.

Fig. 4 shows the western blot analysis of NS1-CASB7439 expressing protein.With the cell extract application of sample of bacterial strain of expressing CASB7439 to this gel, and with anti-NS1 monoclonal antibody announcement.

Fig. 5 shows the SDS-PAGE of the Coomassie blue stain of CASB7439 behind purification.Swimming lane 1 and swimming lane 5 are represented molecular weight marker; Swimming lane 2,3,4 adds 2 μ l, 4 μ l and 6 μ l purifying proteins respectively.

Fig. 6 shows the Western blotting of CASB7439 behind purification that discloses according to anti-poly histidine monoclonal antibody.

Embodiment

Embodiment 1

Real-time RT-PCR is analyzed

Use real-time RT-PCR (U.Gibson.1996.Genome Research:6,996) compares the abundance from the mRNA transcript of candidate antigens in a plurality of patients' paired tumor colon and the normal colonic tissue.In addition, estimate the mRNA level of candidate gene described in one group of normal structure by this method.

Use TriPure reagent (Boehringer), from the quick-freezing biopsy, extract total RNA of normal colon and tumor colon.Total RNA of normal structure is available from InVitrogen or use TriPure reagent to extract from the quick-freezing biopsy.Use oligodeoxythymidylic acid magnetic bead (Dynal), purification Poly-A from the total RNA after the DNA enzyme is handled ⁺MRNA.Use SybrII dyestuff (Molecular Probes), (VersaFluor BioRad) carries out the quantitative of mRNA by spectrofluorimetry.Adopt the default option of TaqMan amplification condition, be used for the primer of PCR in real time amplification with Perkin-ElmerPrimer Express software design.

The 2ng purified mRNA is used in each reaction, carries out real time reaction according to standard pcr.For real-time detection, add SybrI dyestuff (MolecularProbes) with whole dilution factor 1/75000.Adopt conventional instrument setting value, in Perkin-Elmer Biosystems PE7700 system, increase (40 circulations) and detection in real time.Use PE7700Sequence Detector computed in software Ct value.Obtain several Ct values for each sample: for patient's sample, the tumor Ct on the candidate TAA (CtT) value and paired normal colon C t (CtN) value, and for this group normal structure sample, the CtXY of each normal structure XY.Also calculate another Ct (CtA) of actin gene for all samples, as the internal reference thing of all samples.On the other hand, can adopt the amplification of Taqman probe monitoring PCR in real time.Adopt conventional instrument setting value, in Perkin-Elmer Biosystems PE7700 system, increase (40 circulations) and detection in real time.Use PE7700 Sequence Detector computed in software Ct value.Obtain the Ct value of said target mrna (CtX) and actin mRNA (CtA) from each tissue sample.

Because the pcr amplification efficient under common experiment condition approaches theoretical amplification efficiency, so 2 ^{(CtN/T/XY-CtA)}Value is the estimated value of the relative TAA transcriptional level of described sample, promptly carries out standardized value with respect to the actin transcriptional level.Therefore, numerical value is that the expression of 1 expression candidate antigens and actin is identical.

At first tumor colon and paired normal colon from 12 patients' biopsy are carried out real-time PCR reactions.On 18 patients' altogether more fully data set, react (preceding 12 patient's data collection are included) then.6 patient's data in these 18 patients of this data centralization are made with duplication.Also tested other 6 patients, result and preceding 18 patient's data merge.The results of statistical analysis that final merging value is carried out is shown in Table 3, and is illustrated in Fig. 1.

Also represent a series of 48 normal structure samples (normal structure of being analyzed is shown in Table 3) of 29 kinds of different tissues according to the same procedure test.Calculate the TAA transcriptional level as mentioned above.Also according to this data set calculate the overexpression candidate antigens the patient ratio and with respect to the transcript overexpression meansigma methods of normal structure.The results are shown among Fig. 1.

Table 1:CASB7439 PCR in real time expression of results: 12 patient's data collection

MRNA level higher patient's percentage rate (positive patient) in paired tumor colon	92％
		MRNA level high at least 3 times patient's percentage rate in paired tumor colon	92％
MRNA level high at least 10 times patient's percentage rate in paired tumor colon	92％
		The mRNA level is hanged down patient's percentage rate of 3 times at least in paired tumor colon	8％
Paired normal colon mRNA horizontal average (using the actin standardization)	0.0026
		Paired normal colon mRNA horizontal average (using the actin standardization) in positive patient	0.265
MRNA overexpression multiple meansigma methods	2028
		MRNA overexpression multiple intermediate value	115
Normal structure mRNA horizontal average	0.0079
		The horizontal intermediate value of normal structure mRNA	0.0016
Normal structure mRNA horizontal average	0.0064
		The horizontal intermediate value of normal structure mRNA	0.0017
Patient's percentage rate that the mRNA level is higher than normal structure meansigma methods	92％
		Patient's percentage rate that the mRNA level is higher 10 times than normal structure meansigma methods	75％
Than high essential (non-dispensable) normal structure of the horizontal intermediate value of the mRNA of normal structure	Do not have

Table 2:CASB7439 PCR in real time expression of results: 18 patient's data collection

MRNA level higher patient's percentage rate (positive patient) in paired tumor colon	89％
		MRNA level high at least 3 times patient's percentage rate in paired tumor colon	89％
MRNA level high at least 10 times patient's percentage rate in paired tumor colon	78％
		The mRNA level is hanged down patient's percentage rate of 3 times at least in paired tumor colon	5％
Paired normal colon mRNA horizontal average (using the actin standardization)	0.005
		Paired normal colon mRNA horizontal average (using the actin standardization) in positive patient	0.152
MRNA overexpression multiple meansigma methods	1100
		MRNA overexpression multiple intermediate value	60
Normal structure mRNA horizontal average	0.0065
		The horizontal intermediate value of normal structure mRNA	0.0015
Normal structure mRNA horizontal average	0.005
		The horizontal intermediate value of normal structure mRNA	0.0015
Patient's percentage rate that the mRNA level is higher than normal structure meansigma methods	94％
		Patient's percentage rate that the mRNA level is higher 10 times than normal structure meansigma methods	94％
Than the high essential normal structure of the horizontal intermediate value of the mRNA of normal structure	Do not have

Table 3:CASB7439 PCR in real time expression of results: 24 patient's data collection

CASB7439 transcript level high patient's percentage rate (positive patient) in the tumor colon than in adjacent normal colon	92％
		CASB7439 transcript level high at least 10 times positive patient percentage rate in the tumor colon than in adjacent normal colon	75％
Transcript overexpression multiple meansigma methods in the tumor colon of positive patient	1289
		CASB7439 transcript level patient percentage rate higher in the tumor colon than normal structure meansigma methods	96％
MRNA level patient percentage rate higher at least 10 times in the tumor colon than normal structure meansigma methods	62.5％
		Wherein the CASB7439 transcript is expressed the normal structure that equals the tumor transcript level in the tumor	Do not have

Also adopt Taqman method (as mentioned above), to carrying out real-time PCR reactions from the tumor colon of 6 patient's biopsies and adjacent normal colon.Adopt three duplications to measure for each sample, further calculate with meansigma methods.The results are shown among Fig. 1.In addition, also represent 36 normal structure samples (referring to table 5) of 28 kinds of different tissues according to the same procedure test.The results are shown among Fig. 2.

Table 4: the CASB7439 PCR in real time expression of results that adopts the Taqman probe

Tumor sample number from different patients	6
		CASB7439 transcript level patient percentage rate (positive patient) higher in the tumor colon than adjacent normal colon	100％
CASB7439 transcript level positive patient percentage rate higher at least 10 times in the tumor colon than adjacent normal colon	83％
		Transcript overexpression multiple meansigma methods in the tumor of positive patient	109
CASB7439 transcript level patient percentage rate higher in the tumor colon than normal structure meansigma methods	100％
		MRNA level patient percentage rate higher at least 10 times in the tumor colon than normal structure meansigma methods	100％
Wherein the CASB7439 transcript is expressed the normal structure that equals the tumor transcript level in the tumor	Do not have

The result clearly illustrates that, compares with all above-mentioned normal structures with adjacent normal colon, and the CASB7439 transcript is overexpression in the colorectum tumor.Compare the strong overexpression of CASB7439 transcript in the tumor of the described patient more than 90% with adjacent normal colon.Average overexpression multiple in the described tumor is at least 100.In addition, compare with other normal structure, CASB7439 transcript overexpression in the colon tumor of the described patient more than 90%, wherein the overexpression multiple more than 60% among the described patient of overexpression CASB7439 transcript is at least 10 times.

Table 5: the normal structure catalog that is used for CASB7439 transcript expression analysis

Tissue	Abbreviation
		The adrenal gland	Ad_Gl
Aorta	Ao
		Bladder	Bl
Bone marrow	Bo_Ma
		Brain	Bra
Cervix uteri	Ce
		Colon	Co
Fallopian tube	Fa_Tu
		Heart	He
Ileum	Il
		Kidney	Ki
Liver	Li
		Lung	Lu
Lymph node	Ly_No
		Esophagus	Oe
Parathyroid gland	Pa_Thy
		Rectum	Re
Skin	Sk
		Skeletal muscle	Sk_Mu
Small intestinal	Sm_In
		Spleen	Sp
Stomach	St
		Thyroid	Thy
Trachea	Tra
		Ovary	Ov
Placenta Hominis	Pl
		Prostate	Pr
Testis	Te

Embodiment 2

The differential screening of cDNA array

Finish deducting the evaluation of the tumor-related gene in the cDNA library by differential screening.

From 100 μ l overnight culture, extract bacteria total DNA.With guanidinium isothiocyanate cracking antibacterial, use magnetic glass (Boehringer) that DNA of bacteria is carried out affinity purification.Reclaim plasmid by Advantage pcr amplification (Clontech) from DNA of bacteria and insert fragment.Adopt Biomek 96 HDRT instruments (Beekman), on PCR product point sample to two nylon membrane, produce the High Density cDNA array.Mottled cDNA is through UV irradiation and film covalent bond.With first film with mix the cDNA probe hybridization from the preparation of the tumor of single patient.Second film and equivalent mixed the cDNA probe hybridization from the normal colon preparation of same patient.Prepare probe cDNA by pcr amplification as mentioned above, and adopt AlkPhos Direct System (Amersham) its labelling.Hybridization conditions and strict washing are as described in the AlkPhos Direct test kit.Hybridization probe detects with chemiluminescence.By the segmental intensity for hybridization of every kind of cDNA on film light densitometry or two traces of direct algoscopy (BioRad Fluor-S Max) mensuration.Calculate the ratio (T/N) of tumor intensity for hybridization with the normal intensity for hybridization of each gene, to estimate the overexpression degree in the tumor.Gene to remarkable overexpression in colon tumor carries out follow-up study.Significance at random is defined as a standard deviation of T/N frequency distribution.Employing repeats the differential screening experiment from the RNA of a plurality of patient's donors (＞18), to estimate the frequency of the tumor of overexpression in this patient colony.In addition, with the DNA array with from the normal structure except that colon (referring to catalog above) mix the cDNA probe hybridization, to measure the expression of described candidate gene in these tissues.

Embodiment 3

Dna microarray

Detect the mRNA expression and distribution type of gene big collection thing in a plurality of samples with dna microarray.Replenish the data that obtain by PCR in real time with this information, and be provided at the independent measurement of gene expression dose in tumor tissues and the normal structure.

The example that is used to produce the technology of dna microarray at present comprises 1) Affymetrix " GeneChip " array, wherein adopt photoetching process to synthesize surperficial synthetic oligonucleotide at described chip by solid state chemistry, 2) DNA point sample (spotting) technology, wherein the small size dna solution is deposited to the surface of solid phase (for example glass), being fixed then by robot.In both cases, with described chip with from destination organization (for example normal structure, tumor etc..) extract and hybridize with radioactivity or with the cDNA or the cRNA of fluorescence reporter molecule labelling.Make marker material and described chip hybridization, use special scanners then, the bonded probe amount of each sequence on mensuration and the described chip.Described experiment can be set up with single fluorescence reporter molecule (or radioactivity), perhaps can carry out with two kinds of fluorescence reporter molecules.Under latter event, wherein a kind of reporter molecule labelling of each in described two samples.Then with these two sample of labelling and the sequence competitive hybridizations on the described DNA chip.Determine the ratio of two kinds of fluorescence signals of each sequence on the described chip.Calculate the relative abundance of transcript described in described two samples with this ratio.Detailed protocol can derive from many sources, comprises " dna microarray: a kind of practical approach (DNA Microarrays:A practical approach).Schena M.Oxford UniverstyPress1999 " and WWW (http://cmgm.stanford.edu/pbrown/protocols/index.html), http://arrayit.com/DNA-Microarray-Protocols/) and many professional distributors (for example Affymetrix).

Embodiment 5

The RNA-DNA engram analysis

By Advantage PCR (referring to above) limited amount blended tumor colon cDNA of amplification and paired normal colon cDNA.Also use the messenger RNA of same procedure amplification from a plurality of normal structures.CDNA (1 μ g) electrophoresis on 1.2% agarose gel with being increased is transferred on the nylon membrane then.With described film and the probe hybridization (AlkPhos Direct System) of using candidate TAA cDNA produced in fragments.The RNA-DNA engram analysis provides transcript size in relevant tumor tissues and the normal structure, whether has the information of splicing variants and transcript abundance.

Embodiment 6

Rna blot analysis

Use 1 μ g poly A+mRNA to produce the RNA trace according to standard method.Adopt Ready-to-Go system (Pharmacia) preparation radioactive probe.

Embodiment 7

The experimental identification of full length cDNA sequence

Adopt Lambda ZapII system (Stratagene) to make up colon tumor cDNA library from 5 μ g poly A+mRNA.The scheme that is provided is provided, only is to use SuperscriptII (LifeTechnologies) to carry out reverse transcription step.Make up oligomerization dT primer library and random primer library.For each screening in library, plating about 1.5 * 10 ⁶Individual phagus liber.Plaque is transferred on the nylon leaching film, and adopts the cDNA probe hybridization of using AlkPhos Direct labelling.By the chemiluminescence detection positive bacteriophage.Positive bacteriophage is downcut from agar plate, eluting in 500 μ l SM buffer, PCR confirms by gene specific.Become strand M13 phage by the bacteriophage conversion that removes in the body eluting.By colibacillary infection, described bacteriophage conversion is become double-stranded plasmid DNA then.With infected antibacterial plating, carry out second with described cDNA probe then and take turns screening.Go out plasmid DNA from the positive bacteria clone purification, then to two chain order-checkings.

When full-length gene can not directly obtain from the cDNA library, (Marathon Kit, ClonTech) sequence was lost in separation to adopt the RACE technology.This method depends on the mRNA reverse transcription is become double-stranded cDNA, with two terminal are connected of joint with cDNA, adopts the required end of the primer amplified cDNA of gene-specific primer and joint oligonucleotide.With the MarathonPCR product cloning to plasmid (pCRII-TOPO, InVitrogen) in, then the order-checking.

Use this method to obtain the polynucleotide of SEQ ID NO:1.

Embodiment 8.

The EST profile

A kind of complementarity method that experiment antigen tissue expression characterizes is seeker's est database.EST (" expressed sequence tag ") is the small fragment from the cDNA of the mRNA aggregation preparation of particular organization or cell line extraction.Such data base provides a large amount of people EST (2 10 that organizes library (comprising the tumor tissues from the disease of all kinds and stadium) from thousands of kinds of cDNA at present ⁶).By means of information tool (Blast), carry out the comparison search of CASB7439 sequence, so that more in depth understand tissue expression.

The EST of CASB7439 distributes

EST GenBank registration number	EST cDNA organizes the library
		C00634	Adult (K.Okubo)
AA468668	NCI_CGAP_Co3
		AA565752	NCI_CGAP_Co11
AA565766	NCI_CGAP_Co11
		AA565767	NCI_CGAP_Co11
AI337239	NCI_CGAP_Co16
		AI337448	NCI_CGAP_Co16
AI393930	NCI_CGAP_CLL1
		AI473673	NCI_CGAP_Co14
AI632444	NCI_CGAP_GC6
		AI861937	NCI_CGAP_Co16
AI825214	NCI_CGAP_GC6
		AW080652	NCI_CGAP_Co19
AW083899	NCI_CGAP_Co19
		AW206058	NCI_CGAP_Sub3
AW237006	NCI_CGAP_GC6
		AW364626	DT0036
AW449612	NCI_CGAP_Sub5

These EST and CASB7439 Perfect Matchings.This table comprises 9 EST from 4 different tumor colons libraries, 1 EST from 1 normal colon library, 3 EST from 1 tumor sexual cell library, 1 EST from 1 chronic lymphocytic leukemia cell library, 2 EST from 2 mixed rumour libraries, 2 EST from the UNKNOWN TYPE library.This clearly illustrates that expection is the same together, compares with normal structure, and CASB7439 is overexpression in tumor tissues, especially overexpression in the colorectum tumor tissues.

Embodiment 9:

9.1 the expression of tumor specific antigen and purification

Employing is expressed in microbial hosts or in vitro transcription/translation, generation is used for vaccine purpose antigen of the present invention and produces protein fragments or intact proteins, is used for fast purifying and produces by immunohistochemical method identifying natural expressing protein or the required antibody of purification tracking.

Can be in two kinds of microbial hosts-escherichia coli and yeast (for example saccharomyces cerevisiae (Saccharomyces cerevisiar) or pichia pastoris phaff (Pichia pastoris)) express recombinant protein.The expression system that this allows selection to have best features is for producing this specific antigen.Generally speaking, allow recombinant antigen at expression in escherichia coli, and allow reagent albumen in yeast, express.

Expression strategy at first comprises the primary structure that designs recombinant antigen.Generally will express fusion partner (EFP) and place N-terminal, to improve expression, described expression fusion partner also can comprise zone one an Immune Fusion gametophyte (IFP) that can be used for regulating described antigen immune originality characteristic.In addition, comprise at the C-end and can be used for helping the affinity fusion partner (AFP) that is further purified.

As mentioned above, can compare evaluation to several constructs:

For quick expression and purification and produce antibody at CASB7439, suggestion produces in escherichia coli has NS1 as EFP and the histidine tail total length CASB7439 albumen as AFP.

Therefore, two kinds of constructs are proposed:

Construct 1: with the total length wild type CASB7439 cDNA (SEQ ID NO:8) of NS1 cDNA (as EFP) and histidine tail code cDNA (as AFP) fusion.Coded fusion rotein sequence is SEQ ID NO:10.

Construct 2: with the total length saltant CASB7439 cDNA (SEQ ID NO:9) of NS1 cDNA (as EFP) and histidine tail code cDNA (as AFP) fusion.Suggestion has in this construct by e. coli codon selects specific codon to replace preceding 50 codons of natural CASB7439cDNA, to strengthen the expression potentiality of CASB7439 in its escherichia coli host.Coded fusion rotein sequence is SEQ ID NO:10.

Described CASB7439 albumen design is as follows:

" NS1 " is the N-end fragment (80 aminoacid) of influenza virus protein NS1." HIS " is poly histidine tail.

Used recombinant bacterial strain is AR58: be derived from the disguised λ lysogen of N99 and cI857, N99 is gal E ∷ Tn 10, Δ-8 (chlD-pgl, Δ-H1 (cro-chlA), N ⁺(Proc.Natl.Acad.Sci.USA the 82nd volume, the 88-92 page or leaf, in January, 1985 Biochemistry).

When recombinant bacterial strain can obtain, predict further that by the evaluation expression level and by the behavior of analyzing crude extract described proteic dissolubility characterizes recombinant products.

After growth on the suitable culture medium and inducing expression of recombinant proteins, by SDS-PAGE analyzing total extract.Recombiant protein is manifested on the dyeing gel, and right and use specific antibody is identified by western blot analysis.

Plasmid:

Title: TCM 281 pRIT..15143

Replicon: pMB1

Select: Kan

Promoter: PL long

Insert fragment: NS1-C74-39-His construct 1 express recombinant protein:

Allow antibacterial in LB culture medium+50 μ g/ml Kan in 30 ℃ of growths

When culture reaches OD=0.5 (620nm), culture is heated to 39 ℃ at the most,

After inducing 5 hours, harvesting

The preparation of extract:

Cell concentration: .50X.. is complete at buffer PBS+ ... in

Broken: French press 3X

Centrifugal: in 14000t 30 minutes

Remarks: in the supernatant of cell extract＞90%

With cell extract electrophoresis on 12.5%SDS PAGE, use Coomassie blue stain subsequently.Also use commercially available monoclonal antibody (Quiagen) to carry out western blot analysis at poly histidine tail.Gained gel (Fig. 3 and Fig. 4) shows that this albumen is expressed, and manifests in the cell extract supernatant.

Purification scheme adopts the classical way that exists based on histidine affinity tail in the recombiant protein.In a model experiment, filter broken antibacterial, then with the cell-free extract application of sample to the ionic metal affinity column (IMAC that keeps described recombiant protein specifically; Ni ⁺⁺NTA derives from Qiagen) on.In phosphate buffer, with the albumen of 0-500mM imidazoles gradient (may in the presence of detergent) the described reservation of eluting.

To derive from the supernatant of results culture at 6M carbamide, 100mM NaH ₂PO ₄, degeneration among 10mMTris, the pH8, go up sample then under the following conditions to chromatographic column IMAC Qiagen NTANi ⁺⁺:

Level pad: NaH ₂PO ₄100mM pH8

Tris 10mM

Carbamide 6M

Sample: carbamide 6M, 100mM NaH ₂PO ₄, the supernatant among the 10mM Tris

Lavation buffer solution: 1) NaH ₂PO ₄100mM pH8

Tris 10mM

Carbamide 6M

Imidazoles 25mM

2)NaH ₂PO ₄ 100mM pH8

Tris 10mM

Carbamide 6mM

Imidazoles 50mM

Elution buffer: NaH ₂PO ₄100mM pH5.5

Tris 10mM

Carbamide 6M

Imidazoles 500mM

Eluted protein in 500mM imidazoles+6M carbamide is dialysed under the following conditions:

-PBS PH 7.2+sarkosyl 0.5%+4M carbamide

-the same, in 2M carbamide 2 hours

-the same, in 0M carbamide 2 hours

With the freezing preservation of final material.Protein content adopts the Lowry protein determination to come quantitatively (0.9mg/1.2ml).Estimate purity (Fig. 5) by 12.5%PAGE SDS, check exist (Fig. 6) of recombiant protein by Western blotting, the anti-poly histidine monoclonal antibody of employing with Coomassie blue stain.

Expressed antigenic comparative evaluation to multi-form will make it possible to select the most promising material standed for, use it for then to be further purified and immunological evaluation.

9.2 production of antibodies and immunohistochemistry

Can produce the immunology instrument with the albumen of a small amount of purification relatively, so that

A) in normal or cancerous tissue section, detect described expression by immunohistochemistry;

B) detect described expression, and during purge process, follow the tracks of described albumen (ELISA/ Western blotting); Or

C) evaluation/quantitative described purifying protein (ELISA).

9.2.1 polyclonal antibody:

Immunity

Rabbit is formulated in albumen among the adjuvant 3D-MPL/QS21 with 3 weekly interval intramusculars (I.M.) immunity 3 times with 100 μ g.Each immunity 3 weeks of back, take a blood sample, use described albumen as envelope antigen then, according to standard method,, estimate the antibody titer in the described serum by ELISA.

ELISA

96 hole microtest plates (maxisorb Nunc) are spent the night in 4 ℃ of bags with 5 μ g albumen.In 37 ℃ after saturated 1 hour, reach 1 hour 30 minutes with 1%PBS NCS 1% in 37 ℃ of rabbit anteserums (originating in 1/10) that add serial dilutions.After PBS tween washing 3 times, add anti-rabbit biotinylation antiserum (Amersham) (1/5000).The washing culture plate adds peroxidase coupling Succ-PEG-DSPE (1/5000) in 37 ℃ then and reaches 30 minutes.After the washing, add 50 μ l TMB (BioRad) and reach 7 minutes, use 0.2M H then ₂SO ₄Cessation reaction.Can measure OD at 450nm, and calculate the mid point dilution factor with SoffmaxPro.

9.2.2 monoclonal antibody

Immunity

With 5 μ g purifying proteins to 5 BALB/c mouse with 3 weekly intervals immunity 3 times.Blood-letting was carried out in 1 week in back 14 days of the 2nd immunity and the 3rd immunity back.Make envelope antigen with purifying protein, test described serum by Elisa.According to these results (mid point dilution factor＞10000), select 1 mice to be used for merging.

Fusion/HAT selects

According to standard method, use 40%PEG and 5%DMSO, splenocyte and SP2/0 myeloma cell are merged.Then with 2.5 * 10 ⁴-10 ⁵Cells/well in 96 orifice plates, is selected resistance clone with cell inoculation then in the HAT culture medium.Test the content of specific antibody in these hybridoma supernatant, when the hybridoma supernatant is positive, it is carried out 2 circulation limiting dilutions.After taking turns screening through 2, select 3 hybridomas to be used for ascites production.

9.2.3 immunohistochemistry

When antibody can obtain, to normal tissue slice or cancerous tissue section carrying out immunostaining, so that determine:

◇ for normal structure in the cancerous tissue the antigenic expression of the present invention or

◇ expresses the ratio of described antigenic a certain type cancer

Whether other cancer type is also expressed described antigen to ◇

◇ expresses described antigenic cell proportion in a kind of cancerous tissue

The tissue sample preparation

After the dissection, tissue sample is fixed on the cork dish with the OCT chemical compound, then quick freezing in the supercooled isopentane in liquid nitrogen (160 ℃) formerly.Before using always with described frozen block-70 ℃ of preservations.7-10 μ m section is finished in cryostat chamber (20 ,-30 ℃).

Dyeing

Tissue slice was descended dry 5 minutes in room temperature (RT), fix 10 minutes under the room temperature in acetone, after drying uses PBS 0.5%BSA 5% serum saturated then., directly or indirectly dye after following 30 minutes in room temperature with antigen-specific antibodies.Direct staining produces the better but lower dyeing of intensity of specificity, and dyeing produces higher but the dyeing that specificity is lower of intensity indirectly.

9.3 analysis at the antigenic people's cellullar immunologic response of the present invention

By contacting antigen the external human T-cell of making, it is antigenic immune-related to estimate the present invention.All T cell lymphocyte systems and dendritic cell all derive from the PBMC (peripheral blood lymphocytes) of healthy donors (being preferably the HLA-A2 hypotype).The HLA-A2.1/Kb transgene mouse model also is used for screening the HLA-A2.1 peptide.

By stimulated in vitro weekly, produce and keep newfound antigenic specificity CD8 ⁺T cell line.Adopt standard method, test described CD8 ⁺The lytic activity of described antigen or antigen derived peptide and the generation of γ-IFN are replied by system.

Use two kinds of strategies to produce described CD8 ⁺T cell line: a kind of method and a kind of method based on complete genome based on peptide.Two kinds of methods all require with the full-length cDNA of the correct frame of new discovery antigen or in the proper delivery system clone or be used for predicting the sequence of HLA binding peptide.

Method based on peptide

General introduction ground is said, with the HLA-A2 peptide immune transgenic mice that contains adjuvant, can not induce CD8 ⁺Replying those peptides of (the effective cracking of self splenocyte according to the peptide burst process is determined) further analyzes in robot system.

People's dendritic cell (cultivating according to described methods such as Romani) carry out burst process with peptide, and are used for stimulating CD8 ⁺The T cell (passing through Facs) of classification.After stimulating weekly for several times, at first self BLCL (EBV-B transformation cell lines) in the peptide burst process goes up the described CD8 of test ⁺System.In order to prove conclusively the described peptide of correct in vivo processing, go up the described CD8 of test at the tumor cell (LnCap of HLA-A2 transfection, Skov3 or CAMA tumor cell) of cDNA transfection ⁺System.

Method based on complete genome

Make CD8 ⁺T cell line contact antigen, the dendritic cell of fibroblast, recombinant poxvirus or the adenovirus infection of the B7.1 transfection of the dendritic cell of usefulness particle gun transfection, retrovirus retrovirus transduction stimulate then.The cell of viral infection is the antigen-presenting peptide very effectively, because described antigen is with high level expression, and can only use once, to avoid the undue growth of viral T cell line.

After changing stimulation, as mentioned above, the described CD8 of test on the tumor cell of cDNA transfection ⁺System.Measure peptide specific and homogeneity to confirm immunological test.

CD4 ⁺T cell response

Equally, also can estimate CD4 ⁺The T cellullar immunologic response.Adopt to load and produce specific C D4 in order to the reorganization purifying protein of stimulation T cell or the dendritic cell of peptide ⁺The T cell.

Prediction is in conjunction with the allelic epi-position of HLA (nine aggressiveness and ten aggressiveness):

According to Parker algorithm (Parker, K.C., the independent combination of M.A.Bednarek and the indivedual peptide strands of J.E.Coligan.1994. basis is with graduate scheme J.Immunol.152:163 of potential HLA-A2 binding peptide and http://bimas.dcrt.nih.gov/molbio/hla_bind) or Rammensee method (Rammensee, Friede, Stevanovic, MHC part and peptide motif: first tabulation, Immunogenetics 41,178-228,1995; Rammensee, Bachmann, Stevanovic:MHC part and peptide motif.Landes Bioscience 1997 and http: // 134.2.96.221/scripts/hlaserver.dll/home.htm), prediction HLAI class peptide binding sequence.In HLA-A2.1/Kb transgene mouse model (Vitiello etc.), screen peptide then.

Utilization Tepitope algorithm is with being set to 6 (Stumiolo, Hammer etc., Nature Biotechnology.1999.17 by score; 555-561), prediction HLA II class peptide binding sequence.

Following table has been collected the epitope sequences of I class and the prediction of II class:

0201: ten aggressiveness of HLA-A
					Grade	Original position	The tabulation of subsequence residue	Parker score °	SEQ ID：
1	64	KLVNLGFQAL	142.060	SEQ ID NO：16

°: contain the estimation of the molecular dissociation half-life of described subsequence.

HLA A0201: nine aggressiveness
					Grade	Original position	The tabulation of subsequence residue	Parker score °	SEQ ID：
1	182	ELLDFSSWL	507.976	SEQ ID NO：17
					2	104	RLLAEHDAV	126.098	SEQ ID NO：18
3	64	KLVNLGFQA	100.850	SEQ ID NO：19

°: contain the estimation of the molecular dissociation half-life of described subsequence.

24: nine aggressiveness of HLA-A
					Grade	Original position	The tabulation of subsequence residue	Parker score °	SEQ ID：
1	97	EYIRALQRL	360.000	SEQ ID NO：20

°: contain the estimation of the molecular dissociation half-life of described subsequence.

24: ten aggressiveness of HLA-A
					Grade	Original position	The tabulation of subsequence residue	Parker score °	SEQ ID：
1	97	EYIRALQRLL	360.000	SEQ ID NO：21

°: the molecular dissociation that contains described subsequence is partly shown the estimation of phase.

7: ten aggressiveness of HLA-B
					Grade	Original position	The tabulation of subsequence residue	Parker score °	SEQ ID：
1	111	AVRNALAGGL	600.000	SEQ ID NO：22

°: contain the estimation of the molecular dissociation half-life of described subsequence.

4403: ten aggressiveness of HLA-B
					Grade	Original position	The tabulation of subsequence residue	Parker score °	SEQ ID：
1	156	SEPGSPRSAY	360.000	SEQ ID NO：23
					2	89	VETLRSAVEY	180.000	SEQ ID NO：24

°: contain the estimation of the molecular dissociation half-life of described subsequence.

HLA-DRB1*1501: nine aggressiveness
					Grade	Original position	The tabulation of subsequence residue	The Tepitope score	SEQ ID：
1	99	IRALQRLLA	5.6	SEQ ID NO：25

HLA-DRB1*1502: nine aggressiveness
					Grade	Original position	The tabulation of subsequence residue	The Tepitope score	SEQ ID：
1	99	IRALQRLLA	4.6	SEQ ID NO：25

HLA-DRB1*0402: nine aggressiveness
					Grade	Original position	The tabulation of subsequence residue	The Tepitope score	SEQ ID：
1	120	LRPQAVRPS	5.4	SEQ ID NO：26

HLA-DRB1*1101: nine aggressiveness
					Grade	Original position	The tabulation of subsequence residue	The Tepitope score	SEQ ID：
1	99	IRALQRLLA	4.8	SEQ ID NO：25

HLA-DRB1*1102: nine aggressiveness
					Grade	Original position	The tabulation of subsequence residue	The Tepitope score	SEQ ID：
1	120	LRPQAVRPS	6.2	SEQ ID NO：26

HLA-DRB1*1104: nine aggressiveness
					Grade	Original position	The tabulation of subsequence residue	The Tepitope score	SEQ ID：
1	99	IRALQRLLA	5.8	SEQ ID NO：25

HLA-DRB1*1106: nine aggressiveness
					Grade	Original position	The tabulation of subsequence residue	The Tepitope score	SEQ ID：
1	99	IRALQRLLA	5.8	SEQ ID NO：25

HLA-DRB1*1301: nine aggressiveness
					Grade	Original position	The tabulation of subsequence residue	The Tepitope score	SEQ ID：
1	120	LRPQAVRPS	6.6	SEQ ID NO：26
					2	73	LRQHVPHGG	4.9	SEQ ID NO：27
3	31	LLRCSRRRR	4.4	SEQ ID NO：33

HLA-DRB1*1302: nine aggressiveness
					Grade	Original position	The tabulation of subsequence residue	The Tepitope score	SEQ ID：
1	120	LRPQAVRPS	5.6	SEQ ID NO：26

1304: nine aggressiveness of HLA-DRB1*
					Grade	Original position	The tabulation of subsequence residue	The Tepitope score	SEQ ID：
1	120	LRPQAVRPS	6.2	SEQ ID NO：26
					2	73	LRQHVPHGG	4.8	SEQ ID NO：27
3	31	LGFQALRQH	4.6	SEQ ID NO：28

HLA-DRB1*1305: nine aggressiveness
					Grade	Original position	The tabulation of subsequence residue	The Tepitope score	SEQ ID：
1	99	IRALQRLLA	4.8	SEQ ID NO：25

HLA-DRB1*0703: nine aggressiveness
					Grade	Original position	The tabulation of subsequence residue	The Tepitope score	SEQ ID：
1	112	VRNALAGGL	5.1	SEQ ID NO：29
					2	98	YIRALQRLL	4.8	SEQ ID NO：30
3	65	LVNLGFQAL	4.5	SEQ ID NO：31

HLA-DRB5*0101: nine aggressiveness
					Grade	Original position	The tabulation of subsequence residue	The Tepitope score	SEQ ID：
1	96	VEYIREALQR	4.3	SEQ ID NO：32

Sequence information

SEQ ID NO：1

GTACCTTGCTTTGGGGGCGCACTAAGTACCTGCCGGGAGCAGGGGGCGCACCGGGAACTCGCAGATTTCGCC

AGTTGGGCGCACTGGGGATCTGTGGACTGCGTCCGGGGGATGGGCTAGGGGGACATGCGCACGCTTTGGGCC

TTACAGAATGTGATGGCGCGAGGGGGAGGGCGAAGCGTGGCGGGAGGGCGAGGCGAAGGAAGGAGGGCGTGA

GAAAGGCGACGGCGGCGGCGCGGAGGAGGGTTATCTATACATTTAAAAACCAGCCGCCTGCGCCGCGCCTGC

GGAGACCTGGGAGAGTCCGGCCGCACGCGCGGGACACGAGCGTCCCACGCTCCCTGGCGCGTACGGCCTGCC

ACCACTAGGCCTCCTATCCCCGGGCTCCAGACGACCTAGGACGCGTGCCCTGGGGAGTTGCCTGGCGGCGCC

GTGCCAGAAGCCCCCTTGGGGCGCCACAGTTTTCCCCGTCGCCTCCGGTTCCTCTGCCTGCACCTTCCTGCG

GCGCGCCGGGACCTGGAGCGGGCGGGTGGATGCAGGCGCGatggacggcggcacactgcccaggtccgcgcc

ccctgcgccccccgtccctgtcggctgcgctgcccggcggagacccgcgtccccggaactgttgcgctgcag

ccggcggcggcgaccggccaccgcagagaccggaggcggcgcagcggccgtagcgcggcgcaatgagcgcga

gcgcaaccgcgtgaagctggtgaacttgggcttccaggcgctgcggcagcacgtgccgcacggcggcgccag

caagaagctgagcaaggtggagacgctgcgctcagccgtggagtacatccgcgcgctgcagcgcctgctggc

cgagcacgacgccgtgcgcaacgcgctggcgggagggctgaggccgcaggccgtgcggccgtctgcgccccg

cgggccgccagggaccaccccggtcgccgcctcgccctcccgcgcttcttcgtccccgggccgcgggggcag

ctcggagcccggctccccgcgttccgcctactcgtcggacgacagcggctgcgaaggcgcgctgagtcctgc

ggagcgcgagctactcgacttctccagctggttagggggctactgaGCGCCCTCGACCTATGAGCCTCAGCC

CCGGAAGCCGAGCGAGCGGCCGGCGCGCTCATCGCCGGGGAGCCCGCCAGGTGGACCGGCCCGCGCTCCGCC

CCCAGCGAGCCGGGGACCCACCCACCACCCCCCGCACCGCCGACGCCGCCTCGTTCGTCCGGCCCAGCCTGA

CCAATGCCGCGGTGGAAACGGGCTTGGAGCTGGCCCCATAAGGGCTGGCGGCTTCCTCCGACGCCGCCCCTC

CCCACAGCTTCTCGACTGCAGTGGGGCGGGGGGCACCAACACTTGGAGATTTTTCCGGAGGGGAGAGGATTT

TCTAAGGGCACAGAGAATCCATTTTCTACACATTAACTTGAGCTGCTGGAGGGACACTGCTGGCAAACGGAG

ACCTATTTTTGTACAAAGAACCCTTGACCTGGGGCGTAATAAAGATGACCTGGACCCCTGCCCCCACTATCT

GGAGTTTTCCATGCTGGCCAAGATCTGGACACGAGCAGTCCCTGAGGGGCGGGGTCCCTGGCGTGAGGCCCC

CGTGACAGCCCACCCTGGGGTGGGTTTGTGGGCACTGCTGCTCTGCTAGGGAGAAGCCTGTGTGGGGCACAC

CTCTTCAAGGGAGCGTGAACTTTATAAATAAATCAGTTCTGTTTAAAAAAAAAAAAAAAAAA

SEQ ID NO-2

MDGGTLPRSAPPAPPVPVGCAARRRPASPELLRCSRRRRPATAETGGGAAAVARRNERERNRVKLVNLGFQA

LRQHVPHGGASKKLSKVETLRSAVEYIRALQRLLAEHDAVRNALAGGLRPQAVRPSAPRGPPGTTPVAASPS

RASSSPGRGGSSEPGSPRSAYSSDDSGCEGALSPAERELLDFSSWLGGY

SEQ ID NO：3

MSAPAARSASGAEAHRSRALSSPLTSWRSRVARAPQDSARLRSRCRPTSRRNAGSRAPSCPRGPGTKKRGR

ARRRPGWSLAAGAQTAARPAASALPPARRCARRRARPAGAAARGCTPRLSAASPPCSASCWRRRAARAAAA

PGSPSSPASRGCARAHCAALRPLRRLRSLRWPVAAAGCSATVPGTRVSAGQRSRQGRGAQGARTWAVCRRP

SRLHPPARRSRRAAGRCRQRNRRRRGKLWRPKGASGTAPPGNSPGHAS

SEQ ID NO：4

GTACCTTGCTTTGGGGGCGCACTAAGTACCTGCCGGGAGCAGGGGGCGCACCGGGAACTCGCAGATTTCGCC

AGTTGGGCGCACTGGGGATCTGTGGACTGCGTCCGGGGGATGGGCTAGGGGGACATGCGCACGCTTTGGGCC

TTACAGAATGTGATCGCGCCGAGGGGGAGGGCCGAAGCGTGGCGGGAGGGCGAGGCGAAGGAAGGAGGGCGT

GAGAAAGGCGACGGCGGCGGCGCGGAGGAGGGTTATCTATACATTTAAAAACCAGCCGCCTGCGCCGCGCCT

GCGGAGACCTGGGAGAGTCCGGCCGCACGCGCGGGACACGAGCGTCCCACGCTCCCTGGCGCGTACGGCCTG

CCACCACTAGGCCTCCTATCCCCGGGCTCCAGACGACCTAGGACGCGTGCCCTGGGGAGTTGCCTGGCGGCG

CCGTGCCAGAAGCCCCCTTGGGGCGCCACAGTTTTCCCCGTCGCCTCCGGTTCCTCTGCCTGCACCTTCCTG

CGGCGCGCCGGGACCTGGAGCGGGCGGGTGGATGCAGGCGCGatggacggcggcacactgcccaggtccgcg

ccccctgcgccccccgtccctgtcggctgcgctgcccggcggagacccgcgtccccggaactgttgcgctgc

agccggcggcggcgaccggccaccgcagagaccggaggcggcgcagcggccgtagcgcggcgcaatgagcgc

gagcgcaaccgcgtgaagctggtgaacttgggcttccaggcgctgcggcagcacgtgccgcacggcggcgcc

agcaagaagctgagcaaggtggagacgctgcgctcagccgtggagtacatccgcgcgctgcagcgcctgctg

gccgagcacgacgccgtgcgcaacgcgctggcgggagggctgaggccgcaggccgtgcggccgtctgcgccc

cgcgggccgccagggaccaccccggtcgccgcctcgccctcccgcgcttcttcgtccccgggccgcgggggc

agctcggagcccggctccccgcgttccgcctactcgtcggacgacagcggctgcgaaggcgcgctgagtcct

gcggagcgcgagctactcgacttctccagctggttagggggctactgaGCGCCCTCGACCTAATAAGCCTCA

AGCCCCGGAAACCCGAGCGAACGGGCCGGCGCGCTTCATCGCCGGGGAAGCCCGCCAAGGTGGACCGGGCCC

GCGCTCCGCCCCCAGCGAGCCGGGGACCCACCCACCACCCCCCGCACCGCCGACGCCGCCTCGTTCGTCCGG

CCCAGCCTGACCAATGCCGCGGTGGAAACGGGCTTGGAGCTGGCCCCATAAGGGCTGGCGGCTTCCTCCGAC

GCCGCCCCTCCCCACAGCTTCTCGACTGCAGTGGGGCGGGGGGCACCAACACTTGGAGATTTTTCCGGAGGG

GAGAGGATTTTCTAAGGGCACAGAGAATCCATTTTCTACACATTAACTTGAGCTGCTGGAGGGACACTGCTG

GCAAACGGAGACCTATTTTTGTACAAAGAACCCTTGACCTGGGGCGTAATAAAGATGACCTGGACCCCTGCC

CCCACTATCTGGAGTTTTCCATGCTGGCCAAGATCTGGACACGAGCAGTCCCTGAGGGGCGGGGTCCCTGGC

GTGAGGCCCCCGTGACAGCCCACCCTGGGGTGGGTTTGTGGGCACTGCTGCTCTGCTAGGGAGAAGCCTGTG

TGGGGCACACCTCTTCAAGGGAGCGTGAACTTTATAAATAAATCAGTTCTGTTTAAAAAAAAAAAAAAAAAA

AAAACCGAGGGGGGGCCCGGAGCCAACAAA

SEQ ID NO：5

GGTAAACAGAACTGATTTATTTATAAAGTTCACGCTCCCTTGAAGAGGTGTGCCCCACACAGGCTTCTCCC

TAGCAGAGCAGCAGTGCCCACAAACCCACCCCAGGGTGGGCTGTCACGGGGGCCTCACGCCAGGGACCCCG

CCCCTCAGGGACTGCTCGTGTCCAGATCTTGGCCAGCATGGAAAACTCCAGATAGTGGGGGCAGGGGTCCA

GGTCATCTTTATTACGCCCCAGGTCAAGGGTTCTTTGTACAAAAATAGGTCTCCGTTTGCCAGCAGTGTCC

CTCCAGCAGCTCAAGTTAATGTGTAGAAAATGGATTCTCTGTGCCCTTAGAAAATCCTCTCCCCTCCGGAA

AAATCTCCAAGTGTTGGTGCCCCCCGCCCCACTGCAGTCGAGAAGCTGTGGGGAGGGGCGGCGTCGGAGGA

AGCCGCAGCCCATTATGGGGCCAGCTCCAAGCCCGTTTCCACCGCGGCATTGGTCAGGCTGGGCGGACGAA

CGAGGCGGCGTCGGCGGTGCGGGGGGTGGTGGGTGGGTCCCCGGCTCGCTGGGGGCGGAGCAGCGGGCCGG

TCCACCTGGCGGGCTCCCC

SEQ ID NO：6

TTTTTTTTTTTTTTTTTTTAAACAGAACTGATTTATTTATAAAGTTCACGCTCCCTTGAAGAGGTGTGCCCC

ACACAGGCTTCTCCCTAGCAGAGCAGCAGTGCCCACAAACCCACCCCAGGGTGGGCTGTCACGGGGGCCTCA

CGCCAGGGACCCCGCCCCTCAGGGACTGCTCGTGTCCAGATCTTGGCCAGCATGGAAAACTCCAGATAGTGG

GGGCAGGGGTCCAGGTCATCTTTATTACGCCCCAGGTCAAGGGTTCTTTGTACAAAAATAGGTCTCCGTTTG

CCAGCAGTGTCCCTCCAGCAGCTCAAGTTAATGTGTAGAAAATGGATTCTCTGTGCCCTTAGAAAATCCTCT

CCCCTCCGGAAAAATCTCCAAGTGTTGGTGCCCCCCGCCCCACTGCAGTCGAGAAGCTGTGGGGAGGGGCGG

CGTCGGAGGAAGCCGCCAGCCCTTATGGGGCCAGCTCCAAGCCCGTTTCCACCGCGGCATTGGTCAGGCTGG

GCCGGACGAACGAGGCGGCGTCGGCGGTGCGGGGGGTGGTGGGTGGGTCCCCGGCTCGCTGGGGGCGGAGCG

CGGGCCGGTCCACCTGGCGGGCTCCCCGGCGATGAGCGCGCCGGCCGCTCGCTCGGCTTCCGGGGCTGAGGC

TCATAGGTCGAGGGCGCTCAGTAGCCCCCTAACCAGCTGGACAAGTCGAGTAGCTCGCGCTCCGCAGGACTC

AGCGCGCCTTCGCAGCCGCTGTCGTCCGACGAGTAGGCGGAACGCGGGGAGCCGGGCTCCGAGCTGCCCCCG

CGGCCCGGGGACGAAGAAGCGCGGGAGGGCGAGGCGGCGACCGGGGTGGTCCCTGGCGGCCCGCGGGGCGCA

GACGGCCGCACGGCCTGCGGCCTCAGCCCTCCCGCCAGCGCGTTGCGCACGGCGTCGTGCTCGGCCAGCAGG

CGCTGCAGCGCGCGGATGTACTCCACGGCTGAGCGCAGCGTCTCCACCTTGCTCAGCTTCTTGCTGGCGCCG

CCGTGCGGCACGTGCTGCCGCAGCGCCTGGAAGCCCAAGTTCACCAGCTTCACGCGGTTGCGCTCGCGCTCA

TTGCGCCGCGCTACGGCCGCTGCGCCGCCTCCGGTCTCTGCGGTGGCCGGTCGCCGCCGCCGGCTGCAGCGC

AACAGTTCCGGGGACGCGGGTCTCCGCCGGGCAGCGCAGCCGACAGGGACGGGGGGCGCAGGGGGCGCGGAC

CTGGGCAGTGTGCCGCCGTCCATCGCGCCTGCATCCACCCGCCCGCTCCAGGTCCCGGCGCGCCGCAGGAAG

GTGCAGGCAGAGGAACCGGAGGCGACGGGGAAAACTGTGGCGCCCCAAGGGGGCTTCTGGCACGGCGCCGCC

AGGCAACTCCCCAGGGCACGCGTCCTAGGTCGTCTGGAGCCCGGGGATAGGAGGCCTAGTGGTGGCAGGCCG

TACGCGCCAGGGAGCGTGGGACGCTCGTGTCCCGCGCGTGCGGCCGGACTCTCCCAGGTCTCCGCAGGCGCG

GCGCAGGCGGCTGGTTTTTAAATGTATAGATAACCCTCCTCCGCGCCGCCGCCGTCGCCTTTCTCACGCCCT

CCTTCCTTCGCCTCGCCCTCCCGCCACGCTTCGCCCTCCCCCTCGCGCGATCACATTCTGTAAGGCCCAAAG

CGTGCGCATGTCCCCCTAGCCCATCCCCCGGACGCAGTCCACAGATCCCCAGTGCGCCCAACTGGCGAAATC

TGCGAGTTCCCGGTGCGCCCCCTGCTCCCGGCAGGTACTTAGTGCGCCCCCAAAGCAAGGTAC

SEQ ID NO：7

MCRKWILCALRKSSPLRKNLQVLVPPAPLQSRSCGEGRRRRKPPALMGPAPSPFPPPHWSGWAGRTRRRRR

CGGWWVGPRLAGGGARARSTLAGFPGDEARRPVRSGFRGLRLIRSRALSSPLTSWRSRVARAPQDSARLRS

RCRPTSRRNAGSRAPSCPRGPGTKKRGRARRRPGWSLAARGACTAARPAASALPPARCARRRARPAGAAAR

GCTPRLSAASPPCSASCWRPRAARAAAAPGSPSSPASRGCARAHCAALRPLRRLRSLRWPVAAAGCSATVP

GTRVSAGQRSRQGRGAQGARTWAVCRRPSRLHPPARSRSRRAAGRCRQRNRRRRGKLWRPKGASGTAPPGN

SPGHAS

SEQ ID NO：8

ATGGATCCAAACACTGTGTCAAGCTTTCAGGTAGATTGCTTTCTTTGGCATGTCCGCAAACGAGTTGCAGAC

CAAGAACTAGGTGATGCCCCATTCCTTGATCGGCTTCGCCGAGATCAGAAATCCCTAAGAGGAAGGGGCAGC

ACcCTcGGTCTGGACATCGAGACAGCCACACGTGCTGGAAAGCAGATAGtGGAGCGGAttctGAAAGAAGAA

TCCGATGAGGCACTTAAAATGACCATGGACGGCGGCACACTGCCCAGGTCCGCGCCCCCTGCGCCCCCCGTC

CCTGTCGGCTGCGCTGCCCGGCGGAGACCCGCGTCCCCGGAACTGTTGCGCTGCAGCCGGCGGCGGCGACCG

GCCACCGCAGAGACCGGAGGCGGCGCAGCGGCCGTAGCGCGGCGCAATGAGCGCGAGCGCAACCGCGTGAAG

CTGGTGAACTTGGGCTTCCAGGCGCTGCGGCAGCACGTGCCGCACGGCGGCGCCAGCAAGAAGCTGAGCAAG

GTGGAGACGCTGCGCTCAGCCGTGGAGTACATCCGCGCGCTGCAGCGCCTGCTGGCCGAGCACGACGCCGTG

CGCAACGCGCTGGCGGGAGGGCTGAGGCCGCAGGCCGTGCGGCCGTCTGCGCCCCGCGGGCCGCCAGGGACC

ACCCCGGTCGCCGCCTCGCCCTCCCGCGCTTCTTCGTCCCCGGGCCGCGGGGGCAGCTCGGAGCCCGGCTCC

CCGCGTTCCGCCTACTCGTCGGCGACAGCGGCTGCGAAGGCGCGCTGAGTCCTGCGGAGCGCGAGCTACTC

GACTTCTCCAGCTGGTTAGGGGGCTACactagtggccaccatcaccatcaccattaa

SEQ ID NO：9

TTGGATCCAAACACTGTGTCAAGCTTTCAGGTAGATTGCTTTCTTTGGCATGTCCGCAAACGAGTTGCAGA

CCAAGAACTAGGTGATGCCCCATTCCTTGATCGGCTTCGCCGAGATCAGAAATCCCTAAGAGGAAGGGGCA

GCACCCTCGGTCTGGACATCGAGACAGCCACACGTGCTGGAAAGCAGATAGTGGAGCGGATTCTGAAAGAA

GAATCCGATGAGGCACTTAAAATGACCATGGACGGCGGCACCCTGCCGCGTTCCGCGCCGCCGGCGCCGCC

AGTTCCGGTTGGCTGCGCTGCCCGTCGCCGTCCCGCGTCCCCGGAACTGCTGCGCTGCAGCCGTCGCCGTC

GCCCGGCCACCGCAGAGACCGGAGGCGGCGCAGCGGCCGTAGCGCGGCGCAATGAGCGCGAGCGCAACCGC

GTGAAGCTGGTGAACTTGGGCTTCCAGGCGCTGCGGCAGCACGTGCCGCACGGCGGCGCCAGCAAGAAGCT

GAGCAAGGTGGAGACGCTGCGCTCAGCCGTGGAGTACATCCGCGCGCTGCAGCGCCTGCTGGCCGAGCACG

ACGCCGTGCGCAACGCGCTGGCGGGAGGGCTGAGGCCGCAGGCCGTGCGGCCGTCTGCGCCCCGCGGGCCG

CCAGGGACCACCCCGGTCGCCGCCTCGCCCTCCCGCGCTTCTTCGTCCCCGGGCCGCGGGGGCAGCTCGGA

GCCCGGCTCCCCGCGTTCCGCCTACTCGTCGGACGACAGCGGCTGCGAAGGCGCCCTGAGTCCTGCGGAGC

GCGAGCTACTCGACTTCTCCAGCTGGTTAGGGGGCTACACTAGTGGCCACCATCACCATCACCATTAA

SEQ ID NO：10

MDPNTVSSFQVDCFLWHVRKRVADQELGDAPFLDRLRRDQKSLRGRGSTLGLDIETATRAGKQIVERILKEE

SDEALKMTMDGGTLPRSAPPAPPVPVGCAARRRPASPELLRSSRRRRPATAETGGGAAAVARRNERERNRVK

LVNLGFQALRQHVPHGGASKKLSKVETLRSAVEYIRALQRLLAEHDAVRNALAGGLRPQAVRPSAPRGPPGT

TPVAASPSRASSSPGRGGSSEPGSPRSAYSSDDSGCEGALSPAERELLDFSSWLGGYTSGHHHHHH

SEQ ID NO：11

MYSTAERSVSTLLSFLLAPPCGTCCRSAWKPKFTSFTRLRSRSLRRATAAAPPPVSAVAGRRRRLQRNSSG

DAGLRRAAQPTGTGGAGGADLGSVPPSIAPASTRPLQVPARRRKVQAEEPEATGKTVAPQGGFWHGAARQL

PRARVLGRLEPGDRRPSGGRPYAPGSVGRSCPARAAGLSQVSAGAAQAAGF

SEQ ID NO：12

MEAHLDWYGVPGLQEASDACPRESCSSALPEAREGANVHFPPHPVPREHFSCAAPELVAGAQGLNASLMDG

GALPRLMPTSSGVAGACAARRRQASPELLRCSRRRRSGATEASSSSAAVARRNERERNRVKLVNLGFQALR

QHVPHGGANKKLSKVETLRSAVEYIRALQRLLAEHDAVRAALAGGLLTPATPPSDECAQPSASPASASLSC

ASTSPSPDRLGCSEPTSPRSAYSSEESSCEGELSPMEQELLDFSSWLGGY

SEQ ID NO：13

GCCCGGAGCATGGAAGCACGTCAGCTAGGCCATGAACTGCACCCGGGAGGGGTGGGGGTGGAAGCGCACGG

TGTCAGCTTTGCAGAATGTGTACACCAAGGGGAGGGCGAGGCGAAGGAAGGAGGGCGTAAGAAAGGAGGCG

GTGGCGGGGCGGAGGAGATTATCTATACTTTTTAAAAAAAAGGAGCCTCTTAGCCGCGTAAAGGAGACTTG

GGGAGCGCCTGACAGCACGCGCGGGACACGAGAGTACCACGCTTCCCTACTCTTTTCAGACCTTGACTGGT

ACGGGGTCCCAGGACTGCAGGAGGCCAGCGACGCSTGCCCTAGGGAGTCCTGCAGCAGTGCCCTGCCTGAG

GCCCGTGAAGGTGCAAACGTCCACTTCCCACCGCACCCGGTTCCTCGCGAGCACTTTTCCTSTGCCGCACC

AGAACTCGTAGCAGGGGCCCAGGGGCTGAATGCAAGCTTGATGGACGGCGGCGCGCTGCCCAGACTCATGC

CCACCTCGTCTGGAGTCGCTGGAGCCTGCGCTGTCCGGCGGAGACAAGCGTCTCCGGAATTGCTGCGCTGC

AGCCGGCGGCGGCGATCTGGAGCAACCGAGGCCAGCAGCAGCTCGGCGTCCGTGGCACGCCGCAATGAGCG

CGAGCGCAACCGCGTAAAGCTGGTAAACTTGGGCTTCCAGGCGCTGCGGCAGCACGTGCCGCACGGCGGCG

CCAACAAGAAGCTGAGTAAGGTGGAGACGCTGCGCTCCGCGGTAGAGTACATTCGTGCGCTGCAGCGGCTG

CTCGCAGAGCACGACACGGTGCGGCCGGNGCTCGCTGGGGGGCTGTTAACACCCGCTACTCCGCCGTCCGA

TGAGTGCACGCAGCCCTCTGCCTCCCCTGCCAGCGGGTCTCTGTCCTGCGCCTCTACGTCTCCGTCCCGGA

CCCTGGGCTGCTCTGAGCCTACCTCCCCGCGCTCCGCCTACTCGTCGGAGGAAAGCAGCTGCGAGGGAGAG

CTAAGCCCGATGGAGCAGGAGCTGCTTGACTTTTCCAGTTGGTTAGGGGGCTACTGA

SEQ ID NO：14

MESHFNWYGVPRLQKASDACPRESCSSALPEAREGANVHFPPHPVPREHFSCGAPKPVAGAPALNASLMDG

GALPRLVPTSSGVAGACTARRRPPSPELLRCSRRRRSGATEASSSSAAVARRNERERNRVKLVNLGFQALR

QRVPHGGANKKLSKVETLRSAVEYIRALQRLLAEHDAVRAALSGGLLTPATRPSDVCTQPSASPASASLSC

TSTSPDRLGCSEPASPRSAYSSEDSSCEGETYPMGQMFDFSNWLGGY

SEQ ID NO：15

TTCACCCGGCTGCAAGCGCTAGGTGTACGGAGACCTGGCAGCTCTTGGGGCTTAAGGACTGAGCRCCAGAG

CCGGTGGAGGTTCCTGTGGAGTACATTCGGACCCTCTCACAGCCCCCGAGAGTGCGGGACGTGCGGAGCGC

AGTTCGGGATCTGCACTCGAGGACTTGTCGAGGACGCATTAAGCTAAGCATCTGCTCGGAGCATGGAATCG

CACTTTAACTGGTACGGGGTCCCAAGGCTCCAGAAGGCTAGCGACGCGTGCCCTAGGGAATCCTGCAGCAG

TGCCCTGCCTGAGGCCCGTGGAAGGTGCGAACGTCCACTTCCCACCGCACCCGGTTCCTCGCGAGCCTTTT

CCTGTGGCGCACCGAAACCCGTAGCGGGGGCCCCGGCGCTGAATGCAAGCTTGATGGACGGCGGCGCGCTG

CCCAGACTCGTGCCCACCTCGTCTGGAGTCGCTGGAGCCTGCACTGCTCGGCGGAGACCCCCGTCCCCGGA

ACTGCTTCGCTGCAGCCGACGGCGGCGATCGGGAGCAACCGAGGCCAGCAGCAGCTCGGCGGCCGTGGCAC

GCCGCAATGAGCGTGAGCGCAACCGCGTAAAGCTGGTAAACTTGGGCTTCCAGGCGCTGCGGCAGCACGTG

CCGCACGGCGGCGCCAACAAGAAGCTGAGTAAGGTGGAGACGCTGCGCTCCGCGGTAGAGTACATCCGTGC

GCTGCAGCGGCTGCTAGCAGAGCACGACGCGGTGCGTGCTGCGCTCTCTGGGGGTCTATTAACACCCGCTA

CTCGGCCGTCCGATGTGTGCACGCAGCCCTCCGCCTCCCCTGCCAGCGCGTCTCTGTCCTGCACCTCTACA

TCCCCAGACCGCCTAGGCTGCTCCGAGCCHCCTCTCCGCGCTCCGCCTTACTCGTCGGAGGACAGCAGCTG

CGAGGGAGAGACTTACCCGATGGGGCAGATGTTTHACTTTTCCAATTGGTTAGGGGGCTACTGAGCACCCC

ACACCCCTAAGCTGCGTCCCTGGGTGTCCCCTGGTGGACCTACCTGCGTTTCTTGCCCAGGAAACCTGGGC

CCATGCCTTACCCATGCTGTCTAGTGCAGCCTGACCAAATGCCAAGTACTGACCTCTGCTCGGCCTCCACG

CCGCGGAATGACATCTTCCATCTCCCAGTCCTTGCCGAACCAGGACTTGGAAATTTCTCAGGAGAAAGAAT

TTTACAATGACAATCTGCTTTTTATCAATTAACTTGAACTGCTGGAGGACTCTGCTGAAAATATGAAGAAT

TATTTTTATACAAAGGATCCTTAAGCTTGGAGCACAATAAAGATGACCTCTGTCTCTCACCCCCACTGTCT

AGAACTTTCCAACCTGGCCAAAGTGTGGACGGGTCGGGCCCTGAGGGCAAGATGCCTGGCTGCACCCTTCT

TCCTCTTCCGAAGCCTATCCTGACGCTGATGTTTGGCCAGTGTGGGAACCCTGCTATTGCAAAGTGTACTA

TTCTATAAAAGTTGTTTTTCATTGGAAAGGAATTC

SEQ ID NO：16

KLVN1GFQAL

SEQ ID NO：17

ELLDFSSWL

SEQ ID NO：18

RLLAEHDAV

SEQ ID NO：19

KLVNLGFQA

SEQ ID NO：20

EYIRALQRL

SEQ ID NO：21

EYIRALQRLL

SEQ ID NO：22

AVRNALAGGL

SEQ ID NO：23

SEPGSPRSAY

SEQ ID NO：24

VETLRSAVEY

SEQ ID NO：25

IRALQRLLA

SEQ ID NO：26

LRPQAVRPS

SEQ ID NO：27

LRQHVPHGG

SEQ ID NO：28

LGFQALRQH

SEQ ID NO：29

VRNALAGGL

SEQ ID NO：30

YIRALQRLL

SEQ ID NO：31

LVNLGFQAL

SEQ ID NO：32

VEYIRALQR

SEQ ID NO：33

LLRCSRRRR

＜110〉Smithkline Beecham Biologicals

(SmithKline Beecham Biologicals s.a.)

＜120〉noval chemical compound

<130>BC45300

<160>33

<170>FastSEQ for Windows Version 3.0

<210>1

<211>1791

<212>DNA

＜213〉mankind

<400>1

gtaccttgct ttgggggcgc actaagtacc tgccgggagc agggggcgca ccgggaactc 60

gcagatttcg ccagttgggc gcactgggga tctgtggact gcgtccgggg gatgggctag 120

ggggacatgc gcacgctttg ggccttacag aatgtgatcg cgcgaggggg agggcgaagc 180

gtggcgggag ggcgaggcga aggaaggagg gcgtgagaaa ggcgacggcg gcggcgcgga 240

ggagggttat ctatacattt aaaaaccagc cgcctgcgcc gcgcctgcgg agacctggga 300

gagtccggcc gcacgcgcgg gacacgagcg tcccacgctc octggcgcgt acggcctgcc 360

accactaggc ctcctatccc cgggctccag acgacctagg acgcgtgccc tggggagttg 420

cctggcggcg ccgtgccaga agcccccttg gggcgccaca gttttccccg tcgcctccgg 480

ttcctctgcc tgcaccttcc tgcggcgcgc cgggacctgg agcgggcggg tggatgcagg 540

cgcgatggac ggcggcacac tgcccaggtc cgcgccccct gcgccccccg tccctgtcgg 600

ctgcgctgcc cggcggagac ccgcgtcccc ggaactgttg cgctgcagcc ggcggcggcg 660

accggccacc gcagagaccg gaggcggcgc agcggccgta gcgcggcgca atgagcgcga 720

gcgcaaccgc gtgaagctgg tgaacttggg cttccaggcg ctgcggcagc acgtgccgca 780

cggcggcgcc agcaagaagc tgagcaaggt ggagacgctg cgctcagccg tggagtacat 840

ccgcgcgctg cagcgcctgc tggccgagca cgacgccgtg cgcaacgcgc tggcgggagg 900

gctgaggccg caggccgtgc ggccgtctgc gccccgcggg ccgccaggga ccaccccggt 960

cgccgcctcg ccctcccgcg cttcttcgtc cccgggccgc gggggcagct cggagcccgg 1020

ctccccgcgt tccgcctact cgtcggacga cagcggctgc gaaggcgcgc tgagtcctgc 1080

ggagcgcgag ctactcgact tctccagctg gttagggggc tactgagcgc cctcgaccta 1140

tgagcctcag ccccggaagc cgagcgagcg gccggcgcgc tcatcgccgg ggagcccgcc 1200

aggtggaccg gcccgcgctc cgcccccagc gagccgggga cccacccacc accccccgca 1260

ccgccgacgc cgcctcgttc gtccggccca gcctgaccaa tgccgcggtg gaaacgggct 1320

tggagctggc cccataaggg ctggcggctt cctccgacgc cgcccctccc cacagcttct 1380

cgactgcagt ggggcggggg gcaccaacac ttggagattt ttccggaggg gagaggattt 1440

tctaagggca cagagaatcc attttctaca cattaacttg agctgctgga gggacactgc 1500

tggcaaacgg agacctattt ttgtacaaag aacccttgac ctggggcgta ataaagatga 1560

cctggacccc tgcccccact atctggagtt ttccatgctg gccaagatct ggacacgagc 1620

agtccctgag gggcggggtc cctggcgtga ggcccccgtg acagcccacc ctggggtggg 1680

tttgtgggca ctgctgctct gctagggaga agcctgtgtg gggcacacct cttcaaggga 1740

gcgtgaactt tataaataaa tcagttctgt ttaaaaaaaa aaaaaaaaaa a 1791

<210>2

<211>193

<212>PRT

＜213〉mankind

<400>2

Met Asp Gly Gly Thr Leu Pro Arg Ser Ala Pro Pro Ala Pro Pro Val

1 5 10 15

Pro Val Gly Cys Ala Ala Arg Arg Arg Pro Ala Ser Pro Glu Leu Leu

20 25 30

Arg Cys Ser Arg Arg Arg Arg Pro Ala Thr Ala Glu Thr Gly Gly Gly

35 40 45

Ala Ala Ala Val Ala Arg Arg Asn Glu Arg Glu Arg Asn Arg Val Lys

50 55 60

Leu Val Asn Leu Gly Phe Gln Ala Leu Arg Gln His Val Pro His Gly

65 70 75 80

Gly Ala Ser Lys Lys Leu Ser Lys Val Glu Thr Leu Arg Ser Ala Val

85 90 95

Glu Tyr Ile Arg Ala Leu Gln Arg Leu Leu Ala Glu His Asp Ala Val

100 105 110

Arg Asn Ala Leu Ala Gly Gly Leu Arg Pro Gln Ala Val Arg Pro Ser

115 120 125

Ala Pro Arg Gly Pro Pro Gly Thr Thr Pro Val Ala Ala Ser Pro Ser

130 135 140

Arg Ala Ser Ser Ser Pro Gly Arg Gly Gly Ser Ser Glu Pro Gly Ser

145 150 155 160

Pro Arg Ser Ala Tyr Ser Ser Asp Asp Ser Gly Cys Glu Gly Ala Leu

165 170 175

Ser Pro Ala Glu Arg Glu Leu Leu Asp Phe Ser Ser Trp Leu Gly Gly

180 185 190

Tyr

<210>3

<211>262

<212>PRT

＜213〉mankind

<400>3

Met Ser Ala Pro Ala Ala Arg Ser Ala Ser Gly Ala Glu Ala His Arg

1 5 10 15

Ser Arg Ala Leu Ser Ser Pro Leu Thr Ser Trp Arg Ser Arg Val Ala

20 25 30

Arg Ala Pro Gln Asp Ser Ala Arg Leu Arg Ser Arg Cys Arg Pro Thr

35 40 45

Ser Arg Arg Asn Ala Gly Ser Arg Ala Pro Ser Cys Pro Arg Gly Pro

50 55 60

Gly Thr Lys Lys Arg Gly Arg Ala Arg Arg Arg Pro Gly Trp Ser Leu

65 70 75 80

Ala Ala Arg Gly Ala Gln Thr Ala Ala Arg Pro Ala Ala Ser Ala Leu

85 90 95

Pro Pro Ala Arg Cys Ala Arg Arg Arg Ala Arg Pro Ala Gly Ala Ala

100 105 110

Ala Arg Gly Cys Thr Pro Arg Leu Ser Ala Ala Ser Pro Pro Cys Ser

115 120 125

Ala Ser Cys Trp Arg Arg Arg Ala Ala Arg Ala Ala Ala Ala Pro Gly

130 135 140

Ser Pro Ser Ser Pro Ala Ser Arg Gly Cys Ala Arg Ala His Cys Ala

145 150 155 160

Ala Leu Arg Pro Leu Arg Arg Leu Arg Ser Leu Arg Trp Pro Val Ala

165 170 175

Ala Ala Gly Cys Ser Ala Thr Val Pro Gly Thr Arg Val Ser Ala Gly

180 185 190

Gln Arg Ser Arg Gln Gly Arg Gly Ala Gln Gly Ala Arg Thr Trp Ala

195 200 205

Val Cys Arg Arg Pro Ser Arg Leu His Pro Pro Ala Arg Ser Arg Ser

210 215 220

Arg Arg Ala Ala Gly Arg Cys Arg Gln Arg Asn Arg Arg Arg Arg Gly

225 230 235 240

Lys Leu Trp Arg Pro Lys Gly Ala Ser Gly Thr Ala Pro Pro Gly Asn

245 250 255

Ser Pro Gly His Ala Ser

260

<210>4

<211>1830

<212>DNA

＜213〉mankind

<400>4

gtaccttgct ttgggggcgc actaagtacc tgccgggagc agggggcgca ccgggaactc 60

gcagatttcg ccagttgggc gcactgggga tctgtggact gcgtccgggg gatgggctag 120

ggggacatgc gcacgctttg ggccttacag aatgtgatcg cgccgagggg gagggccgaa 180

gcgtggcggg agggcgaggc gaaggaagga gggcgtgaga aaggcgacgg cggcggcgcg 240

gaggagggtt atctatacat ttaaaaacca gccgcctgcg ccgcgcctgc ggagacctgg 300

gagagtccgg ccgcacgcgc gggacacgag cgtcccacgc tccctggcgc gtacggcctg 360

ccaccactag gcctcctatc cccgggctcc agacgaccta ggacgcgtgc cctggggagt 420

tgcctggcgg cgccgtgcca gaagccccct tggggcgcca cagttttccc cgtcgcctcc 480

ggttcctctg cctgcacctt cctgcggcgc gccgggacct ggagcgggcg ggtggatgca 540

ggcgcgatgg acggcggcac actgcccagg tccgcgcccc ctgcgccccc cgtccctgtc 600

ggctgcgctg cccggcggag acccgcgtcc ccggaactgt tgcgctgcag ccggcggcgg 660

cgaccggcca ccgcagagac cggaggcggc gcagcggccg tagcgcggcg caatgagcgc 720

gagcgcaacc gcgtgaagct ggtgaacttg ggcttccagg cgctgcggca gcacgtgccg 780

cacggcggcg ccagcaagaa gctgagcaag gtggagacgc tgcgctcagc cgtggagtac 840

atccgcgcgc tgcagcgcct gctggccgag cacgacgccg tgcgcaacgc gctggcggga 900

gggctgaggc cgcaggccgt gcggccgtct gcgccccgcg ggccgccagg gaccaccccg 960

gtcgccgcct cgccctcccg cgcttcttcg tccccgggcc gcgggggcag ctcggagccc 1020

ggctccccgc gttccgccta ctcgtcggac gacagcggct gcgaaggcgc gctgagtcct 1080

gcggagcgcg agctactcga cttctccagc tggttagggg gctactgagc gccctcgacc 1140

taataagcct caagccccgg aaacccgagc gaacgggccg gcgcgcttca tcgccgggga 1200

agcccgccaa ggtggaccgg gcccgcgctc cgcccccagc gagccgggga cccacccacc 1260

accccccgca ccgccgacgc cgcctcgttc gtccggccca gcctgaccaa tgccgcggtg 1320

gaaacgggct tggagctggc cccataaggg ctggcggctt cctccgacgc cgcccctccc 1380

cacagcttct cgactgcagt ggggcggggg gcaccaacac ttggagattt ttccggaggg 1440

gagaggattt tctaagggca cagagaatcc attttctaca cattaacttg agctgctgga 1500

gggacactgc tggcaaacgg agacctattt ttgtacaaag aacccttgac ctggggcgta 1560

ataaagatga cctggacccc tgcccccact atctggagtt ttccatgctg gccaagatct 1620

ggacacgagc agtccctgag gggcggggtc cctggcgtga ggcccccgtg acagcccacc 1680

ctggggtggg tttgtgggca ctgctgctct gctagggaga agcctgtgtg gggcacacct 1740

cttcaaggga gcgtgaactt tataaataaa tcagttctgt ttaaaaaaaa aaaaaaaaaa 1800

aaaaccgagg gggggcccgg agccaacaaa 1830

<210>5

<211>587

<212>DNA

＜213〉mankind

<400>5

ggtaaacaga actgatttat ttataaagtt cacgctccct tgaagaggtg tgccccacac 60

aggcttctcc ctagcagagc agcagtgccc acaaacccac cccagggtgg gctgtcacgg 120

gggcctcacg ccagggaccc cgcccctcag ggactgctcg tgtccagatc ttggccagca 180

tggaaaactc cagatagtgg gggcaggggt ccaggtcatc tttattacgc cccaggtcaa 240

gggttctttg tacaaaaata ggtctccgtt tgccagcagt gtccctccag cagctcaagt 300

taatgtgtag aaaatggatt ctctgtgccc ttagaaaatc ctctcccctc cggaaaaatc 360

tccaagtgtt ggtgcccccc gccccactgc agtcgagaag ctgtggggag gggcggcgtc 420

ggaggaagcc gcagcccatt atggggccag ctccaagccc gtttccaccg cggcattggt 480

caggctgggc ggacgaacga ggcggcgtcg gcggtgcggg gggtggtggg tgggtccccg 540

gctcgctggg ggcggagcag cgggccggtc cacctggcgg gctcccc 587

<210>6

<211>1791

<212>DNA

＜213〉mankind

<400>6

tttttttttt ttttttttta aacagaactg atttatttat aaagttcacg ctcccttgaa 60

gaggtgtgcc ccacacaggc ttctccctag cagagcagca gtgcccacaa acccacccca 120

gggtgggctg tcacgggggc ctcacgccag ggaccccgcc cctcagggac tgctcgtgtc 180

cagatcttgg ccagcatgga aaactccaga tagtgggggc aggggtccag gtcatcttta 240

ttacgcccca ggtcaagggt tctttgtaca aaaataggtc tccgtttgcc agcagtgtcc 300

ctccagcagc tcaagttaat gtgtagaaaa tggattctct gtgcccttag aaaatcctct 360

cccctccgga aaaatctcca agtgttggtg ccccccgccc cactgcagtc gagaagctgt 420

ggggaggggc ggcgtcggag gaagccgcca gcccttatgg ggccagctcc aagcccgttt 480

ccaccgcggc attggtcagg ctgggccgga cgaacgaggc ggcgtcggcg gtgcgggggg 540

tggtgggtgg gtccccggct cgctgggggc ggagcgcggg ccggtccacc tggcgggctc 600

cccggcgatg agcgcgccgg ccgctcgctc ggcttccggg gctgaggctc ataggtcgag 660

ggcgctcagt agccccctaa ccagctggag aagtcgagta gctcgcgctc cgcaggactc 720

agcgcgcctt cgcagccgct gtcgtccgac gagtaggcgg aacgcgggga gccgggctcc 780

gagctgcccc cgcggcccgg ggacgaagaa gcgcgggagg gcgaggcggc gaccggggtg 840

gtccctggcg gcccgcgggg cgcagacggc cgcacggcct gcggcctcag ccctcccgcc 900

agcgcgttgc gcacggcgtc gtgctcggcc agcaggcgct gcagcgcgcg gatgtactcc 960

acggctgagc gcagcgtctc caccttgctc agcttcttgc tggcgccgcc gtgcggcacg 1020

tgctgccgca gcgcctggaa gcccaagttc accagcttca cgcggttgcg ctcgcgctca 1080

ttgcgccgcg ctacggccgc tgcgccgcct ccggtctctg cggtggccgg tcgccgccgc 1140

cggctgcagc gcaacagttc cggggacgcg ggtctccgcc gggcagcgca gccgacaggg 1200

acggggggcg cagggggcgc ggacctgggc agtgtgccgc cgtccatcgc gcctgcatcc 1260

acccgcccgc tccaggtccc ggcgcgccgc aggaaggtgc aggcagagga accggaggcg 1320

acggggaaaa ctgtggcgcc ccaagggggc ttctggcacg gcgccgccag gcaactcccc 1380

agggcacgcg tcctaggtcg tctggagccc ggggatagga ggcctagtgg tggcaggccg 1440

tacgcgccag ggagcgtggg acgctcgtgt cccgcgcgtg cggccggact ctcccaggtc 1500

tccgcaggcg cggcgcaggc ggctggtttt taaatgtata gataaccctc ctccgcgccg 1560

ccgccgtcgc ctttctcacg ccctccttcc ttcgcctcgc cctcccgcca cgcttcgccc 1620

tccccctcgc gcgatcacat tctgtaaggc ccaaagcgtg cgcatgtccc cctagcccat 1680

cccccggacg cagtccacag atccccagtg cgcccaactg gcgaaatctg cgagttcccg 1740

gtgcgccccc tgctcccggc aggtacttag tgcgccccca aagcaaggta c 1791

<210>7

<211>361

<212>PRT

＜213〉mankind

<400>7

Met Cys Arg Lys Trp Ile Leu Cys Ala Leu Arg Lys Ser Ser Pro Leu

1 5 10 15

Arg Lys Asn Leu Gln Val Leu Val Pro Pro Ala Pro Leu Gln Ser Arg

20 25 30

Ser Cys Gly Glu Gly Arg Arg Arg Arg Lys Pro Pro Ala Leu Met Gly

35 40 45

Pro Ala Pro Ser Pro Phe Pro Pro Arg His Trp Ser Gly Trp Ala Gly

50 55 60

Arg Thr Arg Arg Arg Arg Arg Cys Gly Gly Trp Trp Val Gly Pro Arg

65 70 75 80

Leu Ala Gly Gly Gly Ala Arg Ala Arg Ser Thr Leu Ala Gly Phe Pro

85 90 95

Gly Asp Glu Ala Arg Arg Pro Val Arg Ser Gly Phe Arg Gly Leu Arg

100 105 110

Leu Ile Arg Ser Arg Ala Leu Ser Ser Pro Leu Thr Ser Trp Arg Ser

115 120 125

Arg Val Ala Arg Ala Pro Gln Asp Ser Ala Arg Leu Arg Ser Arg Cys

130 135 140

Arg Pro Thr Ser Arg Arg Asn Ala Gly Ser Arg Ala Pro Ser Cys Pro

145 150 155 160

Arg Gly Pro Gly Thr Lys Lys Arg Gly Arg Ala Arg Arg Arg Pro Gly

165 170 175

Trp Ser Leu Ala Ala Arg Gly Ala Gln Thr Ala Ala Arg Pro Ala Ala

180 185 190

Ser Ala Leu Pro Pro Ala Arg Cys Ala Arg Arg Arg Ala Arg Pro Ala

195 200 205

Gly Ala Ala Ala Arg Gly Cys Thr Pro Arg Leu Ser Ala Ala Ser Pro

210 215 220

Pro Cys Ser Ala Ser Cys Trp Arg Arg Arg Ala Ala Arg Ala Ala Ala

225 230 235 240

Ala Pro Gly Ser Pro Ser Ser Pro Ala Ser Arg Gly Cys Ala Arg Ala

245 250 255

His Cys Ala Ala Leu Arg Pro Leu Arg Arg Leu Arg Ser Leu Arg Trp

260 265 270

Pro Val Ala Ala Ala Gly Cys Ser Ala Thr Val Pro Gly Thr Arg Val

275 280 285

Ser Ala Gly Gln Arg Ser Arg Gln Gly Arg Gly Ala Gln Gly Ala Arg

290 295 300

Thr Trp Ala Val Cys Arg Arg Pro Ser Arg Leu His Pro Pro Ala Arg

305 310 315 320

Ser Arg Ser Arg Arg Ala Ala Gly Arg Cys Arg Gln Arg Asn Arg Arg

325 330 335

Arg Arg Gly Lys Leu Trp Arg Pro Lys Gly Ala Ser Gly Thr Ala Pro

340 345 350

Pro Gly Asn Ser Pro Gly His Ala Ser

355 360

<210>8

<211>849

<212>DNA

＜213〉influenza virus and the mankind

<400>8

atggatccaa acactgtgtc aagctttcag gtagattgct ttctttggca tgtccgcaaa 60

cgagttgcag accaagaact aggtgatgcc ccattccttg atcggcttcg ccgagatcag 120

aaatccctaa gaggaagggg cagcaccctc ggtctggaca tcgagacagc cacacgtgct 180

ggaaagcaga tagtggagcg gattctgaaa gaagaatccg atgaggcact taaaatgacc 240

atggacggcg gcacactgcc caggtccgcg ccccctgcgc cccccgtccc tgtcggctgc 300

gctgcccggc ggagacccgc gtccccggaa ctgttgcgct gcagccggcg gcggcgaccg 360

gccaccgcag agaccggagg cggcgcagcg gccgtagcgc ggcgcaatga gcgcgagcgc 420

aaccgcgtga agctggtgaa cttgggcttc caggcgctgc ggcagcacgt gccgcacggc 480

ggcgccagca agaagctgag caaggtggag acgctgcgct cagccgtgga gtacatccgc 540

gcgctgcagc gcctgctggc cgagcacgac gccgtgcgca acgcgctggc gggagggctg 600

aggccgcagg ccgtgcggcc gtctgcgccc cgcgggccgc cagggaccac cccggtcgcc 660

gcctcgccct cccgcgcttc ttcgtccccg ggccgcgggg gcagctcgga gcccggctcc 720

ccgcgttccg cctactcgtc ggacgacagc ggctgcgaag gcgcgctgag tcctgcggag 780

cgcgagctac tcgacttctc cagctggtta gggggctaca ctagtggcca ccatcaccat 840

caccattaa 849

<210>9

<211>849

<212>DNA

＜213〉influenza virus and the mankind

<400>9

atggatccaa acactgtgtc aagctttcag gtagattgct ttctttggca tgtccgcaaa 60

cgagttgcag accaagaact aggtgatgcc ccattccttg atcggcttcg ccgagatcag 120

aaatccctaa gaggaagggg cagcaccctc ggtctggaca tcgagacagc cacacgtgct 180

ggaaagcaga tagtggagcg gattctgaaa gaagaatccg atgaggcact taaaatgacc 240

atggacggcg gcaccctgcc gcgttccgcg ccgccggcgc cgccagttcc ggttggctgc 300

gctgcccgtc gccgtcccgc gtccccggaa ctgctgcgct gcagccgtcg ccgtcgcccg 360

gccaccgcag agaccggagg cggcgcagcg gccgtagcgc ggcgcaatga gcgcgagcgc 420

aaccgcgtga agctggtgaa cttgggcttc caggcgctgc ggcagcacgt gccgcacggc 480

ggcgccagca agaagctgag caaggtggag acgctgcgct cagccgtgga gtacatccgc 540

gcgctgcagc gcctgctggc cgagcacgac gccgtgcgca acgcgctggc gggagggctg 600

aggccgcagg ccgtgcggcc gtctgcgccc cgcgggccgc cagggaccac cccggtcgcc 660

gcctcgccct cccgcgcttc ttcgtccccg ggccgcgggg gcagctcgga gcccggctcc 720

ccgcgttccg cctactcgtc ggacgacagc ggctgcgaag gcgcgctgag tcctgcggag 780

cgcgagctac tcgacttctc cagctggtta gggggctaca ctagtggcca ccatcaccat 840

caccattaa 849

<210>10

<211>282

<212>PRT

＜213〉influenza virus and the mankind

<400>10

Met Asp Pro Asn Thr Val Ser Ser Phe Gln Val Asp Cys Phe Leu Trp

1 5 10 15

His Val Arg Lys Arg Val Ala Asp Gln Glu Leu Gly Asp Ala Pro Phe

20 25 30

Leu Asp Arg Leu Arg Arg Asp Gln Lys Ser Leu Arg Gly Arg Gly Ser

35 40 45

Thr Leu Gly Leu Asp Ile Glu Thr Ala Thr Arg Ala Gly Lys Gln Ile

50 55 60

Val Glu Arg Ile Leu Lys Glu Glu Ser Asp Glu Ala Leu Lys Met Thr

65 70 75 80

Met Asp Gly Gly Thr Leu Pro Arg Ser Ala Pro Pro Ala Pro Pro Val

85 90 95

Pro Val Gly Cys Ala Ala Arg Arg Arg Pro Ala Ser Pro Glu Leu Leu

100 105 110

Arg Cys Ser Arg Arg Arg Arg Pro Ala Thr Ala Glu Thr Gly Gly Gly

115 120 125

Ala Ala Ala Val Ala Arg Arg Asn Glu Arg Glu Arg Asn Arg Val Lys

130 135 140

Leu Val Asn Leu Gly Phe Gln Ala Leu Arg Gln His Val Pro His Gly

145 150 155 160

Gly Ala Ser Lys Lys Leu Ser Lys Val Glu Thr Leu Arg Ser Ala Val

165 170 175

Glu Tyr Ile Arg Ala Leu Gln Arg Leu Leu Ala Glu His Asp Ala Val

180 185 190

Arg Asn Ala Leu Ala Gly Gly Leu Arg Pro Gln Ala Val Arg Pro Ser

195 200 205

Ala Pro Arg Gly Pro Pro Gly Thr Thr Pro Val Ala Ala Ser Pro Ser

210 215 220

Arg Ala Ser Ser Ser Pro Gly Arg Gly Gly Ser Ser Glu Pro Gly Ser

225 230 235 240

Pro Arg Ser Ala Tyr Ser Ser Asp Asp Ser Gly Cys Glu Gly Ala Leu

245 250 255

Ser Pro Ala Glu Arg Glu Leu Leu Asp Phe Ser Ser Trp Leu Gly Gly

260 265 270

Tyr Thr Ser Gly His His His His His His

275 280

<210>11

<211>193

<212>PRT

＜213〉mankind

<400>11

Met Tyr Ser Thr Ala Glu Arg Ser Val Ser Thr Leu Leu Ser Phe Leu

1 5 10 15

Leu Ala Pro Pro Cys Gly Thr Cys Cys Arg Ser Ala Trp Lys Pro Lys

20 25 30

Phe Thr Ser Phe Thr Arg Leu Arg Ser Arg Ser Leu Arg Arg Ala Thr

35 40 45

Ala Ala Ala Pro Pro Pro Val Ser Ala Val Ala Gly Arg Arg Arg Arg

50 55 60

Leu Gln Arg Asn Ser Ser Gly Asp Ala Gly Leu Arg Arg Ala Ala Gln

65 70 75 80

Pro Thr Gly Thr Gly Gly Ala Gly Gly Ala Asp Leu Gly Ser Val Pro

85 90 95

Pro Ser Ile Ala Pro Ala Ser Thr Arg Pro Leu Gln Val Pro Ala Arg

100 105 110

Arg Arg Lys Val Gln Ala Glu Glu Pro Glu Ala Thr Gly Lys Thr Val

115 120 125

Ala Pro Gln Gly Gly Phe Trp His Gly Ala Ala Arg Gln Leu Pro Arg

130 135 140

Ala Arg Val Leu Gly Arg Leu Glu Pro Gly Asp Arg Arg Pro Ser Gly

145 150 155 160

Gly Arg Pro Tyr Ala Pro Gly Ser Val Gly Arg Ser Cys Pro Ala Arg

165 170 175

Ala Ala Gly Leu Ser Gln Val Ser Ala Gly Ala Ala Gln Ala Ala Gly

180 185 190

Phe

<210>12

<211>263

<212>PRT

＜213〉mice

<400>12

Met Glu Ala His Leu Asp Trp Tyr Gly Val Pro Gly Leu Gln Glu Ala

1 5 10 15

Ser Asp Ala Cys Pro Arg Glu Ser Cys Ser Ser Ala Leu Pro Glu Ala

20 25 30

Arg Glu Gly Ala Asn Val His Phe Pro Pro His Pro Val Pro Arg Glu

35 40 45

His Phe Ser Cys Ala Ala Pro Glu Leu Val Ala Gly Ala Gln Gly Leu

50 55 60

Asn Ala Ser Leu Met Asp Gly Gly Ala Leu Pro Arg Leu Met Pro Thr

65 70 75 80

Ser Ser Gly Val Ala Gly Ala Cys Ala Ala Arg Arg Arg Gln Ala Ser

85 90 95

Pro Glu Leu Leu Arg Cys Ser Arg Arg Arg Arg Ser Gly Ala Thr Glu

100 105 110

Ala Ser Ser Ser Ser Ala Ala Val Ala Arg Arg Asn Glu Arg Glu Arg

115 120 125

Asn Arg Val Lys Leu Val Asn Leu Gly Phe Gln Ala Leu Arg Gln His

130 135 140

Val Pro His Gly Gly Ala Asn Lys Lys Leu Ser Lys Val Glu Thr Leu

145 150 155 160

Arg Ser Ala Val Glu Tyr Ile Arg Ala Leu Gln Arg Leu Leu Ala Glu

165 170 175

His Asp Ala Val Arg Ala Ala Leu Ala Gly Gly Leu Leu Thr Pro Ala

180 185 190

Thr Pro Pro Ser Asp Glu Cys Ala Gln Pro Ser Ala Ser Pro Ala Ser

195 200 205

Ala Ser Leu Ser Cys Ala Ser Thr Ser Pro Ser Pro Asp Arg Leu Gly

210 215 220

Cys Ser Glu Pro Thr Ser Pro Arg Ser Ala Tyr Ser Ser Glu Glu Ser

225 230 235 240

Ser Cys Glu Gly Glu Leu Ser Pro Met Glu Gln Glu Leu Leu Asp Phe

245 250 255

Ser Ser Trp Leu Gly Gly Tyr

260

<210>13

<211>1051

<212>DNA

＜213〉mice

<400>13

gcccggagca tggaagcacg tcagctaggc catgaactgc acccgggagg ggtgggggtg 60

gaagcgcacg gtgtcagctt tgcagaatgt gtacaccaag gggagggcga ggcgaaggaa 120

ggagggcgta agaaaggagg cggtggcggg gcggaggaga ttatctatac tttttaaaaa 180

aaaggagcct cttagccgcg taaaggagac ttggggagcg cctgacagca cgcgcgggac 240

acgagagtac cacgcttccc tactcttttc agaccttgac tggtacgggg tcccaggact 300

gcaggaggcc agcgacgcgt gccctaggga gtcctgcagc agtgccctgc ctgaggcccg 360

tgaaggtgca aacgtccact tcccaccgca cccggttcct cgcgagcact tttcctgtgc 420

cgcaccagaa ctcgtagcag gggcccaggg gctgaatgca agcttgatgg acggcggcgc 480

gctgcccaga ctcatgccca cctcgtctgg agtcgctgga gcctgcgctg ctcggcggag 540

acaagcgtct ccggaattgc tgcgctgcag ccggcggcgg cgatctggag caaccgaggc 600

cagcagcagc tcggcgtccg tggcacgccg caatgagcgc gagcgcaacc gcgtaaagct 660

ggtaaacttg ggcttccagg cgctgcggca gcacgtgccg cacggcggcg ccaacaagaa 720

gctgagtaag gtggagacgc tgcgctccgc ggtagagtac attcgtgcgc tgcagcggct 780

gctcgcagag cacgacacgg tgcggccggn gctcgctggg gggctgttaa cacccgctac 840

tccgccgtcc gatgagtgca cgcagccctc tgcctcccct gccagcgggt ctctgtcctg 900

cgcctctacg tctccgtccc ggaccctggg ctgctctgag cctacctccc cgcgctccgc 960

ctactcgtcg gaggaaagca gctgcgaggg agagctaagc ccgatggagc aggagctgct 1020

tgacttttcc agttggttag ggggctactg a 1051

<210>14

<211>260

<212>PRT

＜213〉rat

<400>14

Met Glu Ser His Phe Asn Trp Tyr Gly Val Pro Arg Leu Gln Lys Ala

1 5 10 15

Ser Asp Ala Cys Pro Arg Glu Ser Cys Ser Ser Ala Leu Pro Glu Ala

20 25 30

Arg Glu Gly Ala Asn Val His Phe Pro Pro His Pro Val Pro Arg Glu

35 40 45

His Phe Ser Cys Gly Ala Pro Lys Pro Val Ala Gly Ala Pro Ala Leu

50 55 60

Asn Ala Ser Leu Met Asp Gly Gly Ala Leu Pro Arg Leu Val Pro Thr

65 70 75 80

Ser Ser Gly Val Ala Gly Ala Cys Thr Ala Arg Arg Arg Pro Pro Ser

85 90 95

Pro Glu Leu Leu Arg Cys Ser Arg Arg Arg Arg Ser Gly Ala Thr Glu

100 105 110

Ala Ser Ser Ser Ser Ala Ala Val Ala Arg Arg Asn Glu Arg Glu Arg

115 120 125

Asn Arg Val Lys Leu Val Asn Leu Gly Phe Gln Ala Leu Arg Gln His

130 135 140

Val Pro His Gly Gly Ala Asn Lys Lys Leu Ser Lys Val Glu Thr Leu

145 150 155 160

Arg Ser Ala Val Glu Tyr Ile Arg Ala Leu Gln Arg Leu Leu Ala Glu

165 170 175

His Asp Ala Val Arg Ala Ala Leu Ser Gly Gly Leu Leu Thr Pro Ala

180 185 190

Thr Arg Pro Ser Asp Val Cys Thr Gln Pro Ser Ala Ser Pro Ala Ser

195 200 205

Ala Ser Leu Ser Cys Thr Ser Thr Ser Pro Asp Arg Leu Gly Cys Ser

210 215 220

Glu Pro Ala Ser Pro Arg Ser Ala Tyr Ser Ser Glu Asp Ser Ser Cys

225 230 235 240

Glu Gly Glu Thr Tyr Pro Met Gly Gln Met Phe Asp Phe Ser Asn Trp

245 250 255

Leu Gly Gly Tyr

260

<210>15

<211>1526

<212>DNA

＜213〉rat

<400>15

ttcacccggc tgcaagcgct aggtgtacgg agacctggca gctcttgggg cttaaggact 60

gagcrccaga gccggtggag gttcctgtgg agtacattcg gaccctctca cagcccccga 120

gagtgcggga cgtgcggagc gcagttcggg atctgcactc gaggacttgt cgaggacgca 180

ttaagctaag catctgctcg gagcatggaa tcgcacttta actggtacgg ggtcccaagg 240

ctccagaagg ctagcgacgc gtgccctagg gaatcctgca gcagtgccct gcctgaggcc 300

cgtgaaggtg cgaacgtcca cttcccaccg cacccggttc ctcgcgagca cttttcctgt 360

ggcgcaccga aacccgtagc gggggccccg gcgctgaatg caagcttgat ggacggcggc 420

gcgctgccca gactcgtgcc cacctcgtct ggagtcgctg gagcctgcac tgctcggcgg 480

agacccccgt ccccggaact gcttcgctgc agccgacggc ggcgatcggg agcaaccgag 540

gccagcagca gctcggcggc cgtggcacgc cgcaatgagc gtgagcgcaa ccgcgtaaag 600

ctggtaaact tgggcttcca ggcgctgcgg cagcacgtgc cgcacggcgg cgccaacaag 660

aagctgagta aggtggagac gctgcgctcc gcggtagagt acatccgtgc gctgcagcgg 720

ctgctagcag agcacgacgc ggtgcgtgct gcgctctctg ggggtctatt aacacccgct 780

actcggccgt ccgatgtgtg cacgcagccc tccgcctccc ctgccagcgc gtctctgtcc 840

tgcacctcta catccccaga ccgcctaggc tgctccgagc ctgcctctcc gcgctccgcc 900

tactcgtcgg aggacagcag ctgcgaggga gagacttacc cgatggggca gatgtttgac 960

ttttccaatt ggttaggggg ctactgagca ccccacaccc ctaagctgcg tccctgggtg 1020

tcccctggtg gacctacctg cgtttcttgc ccaggaaacc tgggcccatg ccttacccat 1080

gctgtctagt gcagcctgac caaatgccaa gtactgacct ctgctcggcc tcaacgccgc 1140

ggaatgacat cttccatctc ccagtccttg ccgaaccagg acttggaaat ttctcaggag 1200

aaagaatttt acaatgacaa tctgcttttt atcaattaac ttgaactgct ggaggactct 1260

gctgaaaata tgaagaatta tttttataca aaggatcctt aagcttggag cacaataaag 1320

atgacctctg tctctcaccc ccactgtcta gaactttcca acctggccaa agtgtggacg 1380

ggtcgggccc tgagggcaag atgcctggct gcacccttct tcctcttccg aagcctatcc 1440

tgacgctgat gtttggccag tgtgggaacc ctgctattgc aaagtgtact attctataaa 1500

agttgttttt cattggaaag gaattc 1526

<210>16

<211>10

<212>PRT

＜213〉mankind

<400>16

Lys Leu Val Asn Leu Gly Phe Gln Ala Leu

1 5 10

<210>17

<211>9

<212>PRT

＜213〉mankind

<400>17

Glu Leu Leu Asp Phe Ser Ser Trp Leu

1 5

<210>18

<211>9

<212>PRT

＜213〉mankind

<400>18

Arg Leu Leu Ala Glu His Asp Ala Val

1 5

<210>19

<211>9

<212>PRT

＜213〉mankind

<400>19

Lys Leu Val Asn Leu Gly Phe Gln Ala

1 5

<210>20

<211>9

<212>PRT

＜213〉mankind

<400>20

Glu Tyr Ile Arg Ala Leu Gln Arg Leu

1 5

<210>21

<211>10

<212>PRT

＜213〉mankind

<400>21

Glu Tyr Ile Arg Ala Leu Gln Arg Leu Leu

1 5 10

<210>22

<211>10

<212>PRT

＜213〉mankind

<400>22

Ala Val Arg Asn Ala Leu Ala Gly Gly Leu

1 5 10

<210>23

<211>10

<212>PRT

＜213〉mankind

<400>23

Ser Glu Pro Gly Ser Pro Arg Ser Ala Tyr

1 5 10

<210>24

<211>10

<212>PRT

＜213〉mankind

<400>24

Val Glu Thr Leu Arg Ser Ala Val Glu Tyr

1 5 10

<210>25

<211>9

<212>PRT

＜213〉mankind

<400>25

Ile Arg Ala Leu Gln Arg Leu Leu Ala

1 5

<210>26

<211>9

<212>PRT

＜213〉mankind

<400>26

Leu Arg Pro Gln Ala Val Arg Pro Ser

1 5

<210>27

<211>9

<212>PRT

＜213〉mankind

<400>27

Leu Arg Gln His Val Pro His Gly Gly

1 5

<210>28

<211>9

<212>PRT

＜213〉mankind

<400>28

Leu Gly Phe Gln Ala Leu Arg Gln His

1 5

<210>29

<211>9

<212>PRT

<213>Human

<400>29

Val Arg Asn Ala Leu Ala Gly Gly Leu

1 5

<210>30

<211>9

<212>PRT

＜213〉mankind

<400>30

Tyr Ile Arg Ala Leu Gln Arg Leu Leu

1 5

<210>31

<211>9

<212>PRT

＜213〉mankind

<400>31

Leu Val Asn Leu Gly Phe Gln Ala Leu

1 5

<210>32

<211>9

<212>PRT

＜213〉mankind

<400>32

Val Glu Tyr Ile Arg Ala Leu Gln Arg

1 5

<210>33

<211>9

<212>PRT

＜213〉mankind

<400>33

Leu Leu Arg Cys Ser Arg Arg Arg Arg

1 5

Claims (32)

1. immunogenic composition, described compositions comprises CASB7439 polypeptide or its immunogenic fragments and the pharmaceutically acceptable carrier of safe and effective amount, and wherein said CASB7439 polypeptide is SEQ ID NO:2.

2. immunogenic composition, described compositions comprises polynucleotide or its fragment and the pharmaceutically acceptable carrier of the coding CASB7439 of safe and effective amount, and the polynucleotide of wherein said coding CASB7439 are the polypeptid coding sequence of the nucleotide 545-1126 of SEQ ID NO:1.

3. claim 1 or 2 immunogenic composition, described compositions also comprises TH-1 induction type adjuvant.

4. the immunogenic composition of a claim 3, wherein said TH-1 induction type adjuvant is selected from the mixture of mixture, CpG oligonucleotide or two or more described adjuvant of following adjuvant: 3D-MPL, QS21, QS21 and cholesterol.

5. immunogenic composition, described compositions comprises the antigen-presenting cell of effective dose and effective carrier pharmaceutically, described antigen-presenting cell is by being modified at external loading CASB7439 polypeptide, perhaps external genetically modified to express the CASB7439 polypeptide.

6. isolating polypeptide, one section aminoacid sequence that described polypeptide comprises has at least 70% homogeneity with aminoacid sequence shown in the SEQ ID NO:2 on the total length of SEQ IDNO:2.

7. the isolating polypeptide of a claim 6, wherein said aminoacid sequence and SEQ IDNO:2 have at least 95% homogeneity.

8. the polypeptide of claim 7, described polypeptide comprises the aminoacid sequence of SEQ ID NO:2.

9.SEQ the isolating polypeptide of ID NO:2.

10. polypeptide that comprises the immunogenic fragments of each polypeptide among the claim 6-9, the immunogenicity activity of the active polypeptide with SEQ ID NO:2 of the immunogenicity of wherein said immunogenic fragments is substantially the same.

11.SEQ the immunogenic fragments of ID NO:2, wherein said fragment comprise the one or more sequence among SEQ IDNO:16 to the SEQ ID NO:33.

12. each polypeptide among the claim 6-11, wherein said polypeptide is an a kind of part than larger fusion protein.

13. each polypeptide among the claim 6-11, described polypeptide and a kind of carrier protein are chemically conjugated.

14. isolating polynucleotide, each polypeptide among the described polynucleotide encoding claim 6-12.

15. the isolating polynucleotide of claim 14, described polynucleotide comprise the sequence of the nucleotide 545-1126 of SEQ IDNO:1.

16. isolating polynucleotide that comprise the nucleotide sequence of the peptide species of encoding, described polypeptide have at least 70% homogeneity with the aminoacid sequence of SEQ ID NO:2 on the total length of SEQ ID NO:2.

17. each isolating polynucleotide among the claim 14-16, wherein said homogeneity is at least 95%.

18. isolating polynucleotide, described polynucleotide are selected from:

(a) comprise the polynucleotide of nucleotide sequence of the polypeptide of coding SEQ ID NO:2;

(b) polypeptid coding sequence of the nucleotide 545-1126 of SEQ ID NO:1.

19. the recombinant microorganism of an expression vector or a kind of work, described carrier or microorganism comprise among the claim 14-18 each isolating polynucleotide.

20. a host cell, described host cell comprise each isolating polynucleotide of the expression vector of claim 19 or claim 14-18.

21. a method of producing each immunogenic composition among the claim 1-5, described method comprise the polynucleotide of CASB7439 polypeptide or coding CASB7439 polypeptide are mixed with suitable adjuvant, diluent or other pharmaceutically acceptable carrier.

22. a method of producing each a peptide species among the claim 6-12, described method are included in the host cell of cultivating claim 20 under the condition that is enough to produce described polypeptide, reclaim described polypeptide then from culture medium.

23. each the polypeptide or the purposes of polynucleotide among claim 6-13 and the 14-18, described polypeptide or polynucleotide are used to produce, and the immunotherapeutical treatment suffers from or cancer-prone patient's vaccine.

24. each the polypeptide or the purposes of polynucleotide among claim 6-13 and the 14-18, described polypeptide or polynucleotide are used to produce the vaccine that the immunotherapeutical treatment suffers from or easily suffer from the patient of colon cancer or other colon related neoplasms or disease.

25. an immune specificity antibody, described antibody has immune specificity for each claimed polypeptide or immunology fragment among the claim 6-13.

26. a screening technique, described method is in order to identify the chemical compound that stimulates or suppress the function of each polypeptide among the claim 6-13, and described method comprises the following a kind of method that is selected from:

(a) utilize directly or indirectly in conjunction with the labelling of candidate compound, measure described candidate compound and described polypeptide (or with cell that carries described polypeptide or cell membrane) or with the combining of described polypeptide amalgamation protein;

(b) in the presence of labelling competition thing, measure candidate compound and described polypeptide (or with cell that carries described polypeptide or cell membrane) or with the combining of described polypeptide amalgamation protein;

(c) use the detection system of cell or the cell membrane be suitable for carrying described polypeptide, test the signal whether described candidate compound causes that activation or inhibition owing to described polypeptide produce;

(d) require the solution of each polypeptide among the 6-13 to mix with containing right candidate compound, form mixture, measure the activity of polypeptide described in the described mixture then, and the activity of described mixture and the activity of standard substance are compared; Or

(e) for example adopt ELISA to measure, detect the influence of candidate compound the generation of the mRNA of coding said polypeptide in cell and described polypeptide.

27. agonist or antagonist at the polypeptide of claim 6-13.

28. a chemical compound that is used for the treatment of, described chemical compound is:

(a) a kind of agonist or antagonist of the polypeptide at claim 6-13;

(b) the isolating polynucleotide of claim 14-18; Or

(c) a kind of nucleic acid molecules of regulating the expression of the nucleotide sequence of each polypeptide among the coding claim 6-13.

29. diagnostic method, described method be used for diagnosing experimenter and claim 6-13 each polypeptide expression or active diseases associated or to the susceptibility of described disease, described method comprises existence or the content of analyzing the described polypeptide in the sample that derives from described experimenter.

30. diagnostic method, described method be used for diagnosing experimenter and claim 14-18 each the expression of polynucleotide or active diseases associated or to the susceptibility of described disease, described method comprises existence or the content of analyzing the described polynucleotide in the sample that derives from described experimenter.

31. diagnostic method, described method be used for diagnosing experimenter and claim 6-13 each the polypeptide expression or the existence of active relevant colorectal carcinoma or to the susceptibility of described colorectal carcinoma, described method comprises existence or the content of analyzing the described polypeptide in the sample that derives from described experimenter.

32. diagnostic method, described method be used for diagnosing experimenter and claim 14-18 each the expression of polynucleotide or the existence of active relevant colorectal carcinoma or to the susceptibility of described colorectal carcinoma, described method comprises existence or the content of analyzing the described polynucleotide in the sample that derives from described experimenter.

Images